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1
4 Introduction
Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of
cancer death among men in the Netherlands. Due to the shortcomings of the current diag-
nostic pathway for prostate cancer, especially with respect to assessing cancer aggressiveness,
alternative strategies are being investigated. Magnetic resonance imaging (MRI) has emerged
as an important modality to assist and potentially replace (part o) the current diagnostic path-
way. e high complexity of prostate MRI and the lack of suﬃcient expertise among the ra-
diological community at large has opened the door for (semi-)automated analysis of prostate
MRI by computer systems, with or without human intervention. is thesis will cover the
development and evaluation of such a system in a clinical seing.
1.1 Prostate cancer
1.1.1 Prostate anatomy
e prostate is a walnut-sized organ in the male pelvis, located between the pelvic bones. e
apex (caudal part) of the prostate is supported by the pelvic ﬂoor muscles. e base (cranial
part) of the prostate borders the bladder. e urethra, originating in the bladder, and two
ejaculatory ducts, originating at the seminal vesicles, pass through the prostate. is is de-
picted schematically in Figure 1.1. e prostate plays a role in the male reproductive system;
it secretes an alkaline ﬂuid, which is added to the spermatozoa and the seminal vesicle ﬂuid,
increasing the motility and lifespan of the spermatozoa. Furthermore, smooth muscle cells
within the prostate help expel the semen during ejaculation. Structurally, the prostate is oen
Figure 1.1: Anatomy of the male pelvis with the prostate circled.
divided into three distinct zones (Figure 1.2)1. e central zone surrounds the ejaculatory ducts
at the base of the prostate and encompasses around 25% of the glandular tissue in a healthy
prostate. However, only 2.5% of prostate cancers originate in this zone2. e transition zone
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surrounds the proximal urethra and contains around 5% of the glandular tissue. Between 10
and 20% of cancers originate here2. As individuals age, the transition zone oen undergoes
hyperplasia, causing it to grow substantially in size. Lastly, the peripheral zone encompasses
up to 70% of all glandular tissue in a healthy prostate and it occupies the posterior and lateral
parts of the gland. Approximately 70% of all prostate cancers are found in this zone2. In addi-
tion to these glandular zones, the prostate usually contains an area of ﬁbromuscular stroma,
typically located at the ventral side of the prostate.
Figure 1.2: Schematic overview of the zonal anatomy of the prostate. Based on a ﬁgure by De Marzo et al. 3
1.1.2 Epidemiology
Around 11000 men were diagnosed with prostate cancer in 2011 in the Netherlands and this
incidence is rising (IKNL, http://www.cijfersoverkanker.nl/). Annually, approximately
2400 - 2500 men will die because of prostate cancer. Globally, the estimates are around 900000
new cases and 250000 deaths per year4. From these numbers it can be observed that prostate
cancer has a high incidence-to-mortality ratio. e main reason for the high incidence-to-
mortality ratio is that most of the diagnosed prostate cancers are indolent, i.e. will not kill the
patient in their lifetime. is is evidenced by the high 10-year survival rate (77%) but also by
the large number of prostate cancers discovered on autopsy inmenwho died of other causes5,6.
Almost 75% of all prostate cancer cases are diagnosed in developed countries. e twomain
reasons are the higher average age of the general populace in developed countries compared
to developing countries (70% of all new prostate cancer patients in the Netherlands are older
than 65 years) and secondly, the advent of prostate speciﬁc antigen (PSA) based testing in the
1990s7.
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1.1.3 Current diagnostic pathway
e current diagnostic pathway for prostate cancer consists of a combination of PSA blood
tests, digital rectal examinations (DRE) and trans-rectal ultrasound-guided (TRUS) biopsies
(IKNL, Guidelines on Prostate Cancer). PSA tests measure the concentration of PSA in the
blood in nanograms per milliliter (ng/mL). In individuals with healthy prostates, the PSA level
will be low, as the PSA will be contained in the prostate glands. In individuals with prostate
cancer or other prostate disorders (e.g. benign prostatic hyperplasia or prostatitis) the PSA
level can increase because the integrity of the prostate glands is compromised. e American
Cancer Society suggest a threshold of four ng/mL to refer patients for further examination. In
the Netherlands current guidelines suggest using a threshold of three ng/mL, although PSA
testing itself is discouraged.
In digital rectal examinations urologists will use a lubricated, gloved ﬁnger to inspect the
surface of the prostate. Prostate cancer tends to feel as a stony, asymmetrical lump compared
to so, smooth healthy prostate tissue. However, DREs have a very limited area of coverage
(ventrally located tumors are missed) and tend to miss smaller tumors. As such DRE has a
limited sensitivity and speciﬁcity8.
Aer initial suspicion has arisen due to either PSA or DRE usually a TRUS biopsy is per-
formed. As most prostate cancers are invisible on ultrasound9, TRUS biopsies are performed
in a systematic way, usually with between six and twelve cores covering part of the prostate.
Biopsy specimens are subsequently evaluated by a pathologist using the Gleason Scoring Sys-
tem.
e Gleason Scoring System is named aer Donald Gleason, who developed it with other
colleagues at the Minneapolis Veterans Aﬀairs Hospital during the 1960s10. e system was
subsequently updated in 2005 by International Society of Urological Pathology11. A Gleason
score is assigned by the pathologist by summing two numbers; the ﬁrst number indicates the
grade of the most common tumor paern in the specimen, the second number indicates the
secondmost common paern. If there are more than two paerns present in the specimen, the
second number should refer to the remaining paern with the highest grade (which contains
at least 5% of the total tumor volume). Gleason grades range from 1 - 5, where 5 is considered
the most aggressive paern. e descriptions of the diﬀerent paerns are:
1. Very well diﬀerentiated, small, closely packed, uniform, glands in essentially circum-
scribed masses.
2. Similar (to paern 1) but with moderate variation in size and shape of glands and more
atypia in the individual cells; cribriform paerns may be present, still essentially cir-
cumscribed, but more loosely arranged.
3. Similar to paern 2 but marked irregularity in size and shape of glands, with tiny glands
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Figure 1.3: Schematic representation of the diﬀerent Gleason grades. Image adapted from 12
or individual cells invading stroma away from circumscribed masses, or solid cords and
masses with easily identiﬁable glandular diﬀerentiation within most of them. May be
papillary or cribriform, which vary in size and may be quite large, but the essential
feature is the smooth and usually rounded edge around all the circumscribed masses of
tumor.
4. Large clear cells growing in a diﬀuse paern resembling hypernephroma; may show
gland formation. Raggedly inﬁltrating, fused-glandular tumor; glands are not single
and separate, but coalesce and branch.
5. Very poorly diﬀerentiated tumors; usually solid masses or diﬀuse growth with lile or
no diﬀerentiation into glands. Can resemble comedocarcinoma of the breast; almost
absent gland paern with few tiny glands or signet cells.
ese descriptions are illustrated in Figure 1.3. Gleason scores 2 (1+1), 3 (2+1 or 1+2) and 4
(2+2) are generally discouraged aer the Gleason Scoring System revision in 200511. As such,
in clinical practice, only Gleason score of 3+2 or higher are encountered, of which 3+3 is by
far the most common paern.
e aending physician will use the biopsy Gleason score and other clinical parameters
(e.g. PSA level, number of positive biopsy cores) to decide on the best management of the
disease.
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1.1.4 Management and treatment
Severalmanagement and treatment options exist for prostate cancer, themost common choices
are active surveillance, radical prostatectomy, radiotherapy, or focal therapy.
Active surveillance is an ideal option for men with low grade, localized, well-diﬀerentiated
prostate cancer. Several studies have shown that in men with untreated, low-risk prostate
cancer the 10- to 20-year survival rates are similar to an age-matched group of men without
prostate cancer13–15. Based on these results several groups have implemented active surveil-
lance protocols using PSA tests and TRUS biopsies for follow-up. Initial results are diﬃcult to
compare, as inclusion criteria diﬀer between studies. e study by Klotz et al.16, including 450
patients, has the longest median follow-up (6.8 years) and has shown promising results with
a cancer speciﬁc survival of 97%.
Radical prostatectomy, external beam radiotherapy (EBRT) or brachytherapy are all treat-
ment options with intent to cure. In the United States the use of these three treatment modal-
ities is approximately equal. Cancer recurrence and survival rates are relatively similar, and
as such other factors like disease stage (lymph node involvement), expected side-eﬀects and
patient opinion are important factors in which treatment is chosen17. One advantage of rad-
ical prostatectomy over the other two modalities is the potential to completely stage the
prostate cancer (complete Gleason grading, extra-capsular extension) and the easier biochem-
ical follow-up using PSA (PSA level should reduce to near zero aer removal of the prostate).
Research interest into focal therapy has risen over the past decade, with several options
available, e.g. laser interstitial thermotherapy (LITT), cryo-ablation or high-intensity focused
ultrasound (HIFU). Although initial results with these therapy options are promising, espe-
cially for localized, low-grade prostate cancer, they are currently not yet widely available
clinically. All treatment options for prostate cancer with intent to cure have the potential
to cause side-eﬀects among which incontinence and sexual dysfunction are the most com-
mon18–20. Two studies reported that between around 40 - 45% of all patients have issues with
erectile dysfunction aer prostatectomy18,20. Urinary problems are reported less consistently,
with the percentage of patients aﬀected ranging from 7 - 49%. Reported side-eﬀects for both
EBRT and brachytherapy are lower with around 13 - 22% of patients suﬀering from erectile
dysfunction and 11 - 18% of patients having urinary problems. However, patients who under-
went brachytherapy or EBRT had more issues with diarrhea or blood in their stool (10%). Due
to the impact of these side eﬀects it is important to only diagnose and treat prostate cancer
that will cause premature death.
1.1.5 Drawbas of the current diagnostic pathway
e relative simplicity of PSA testing and subsequent TRUS biopsies has lead to trials investi-
gating the potential role of these two techniques in a screening seing for prostate cancer. In
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2009 Schröder et al. published the results of a large European screening trial using PSA test-
ing and TRUS biopsies to detect prostate cancer21. An update was published in 201222. eir
results showed that there is potential for prostate cancer screening, with a reduction in the
relative risk of death due to prostate cancer of around 29%. However, the poor sensitivity and
speciﬁcity of PSA testing and TRUS biopsies would cause large amounts of over-diagnosis and
over-treatment. To save one life, 1055 men had to be screened and 37 men had to be treated
for prostate cancer.
In this screening setup, PSA testing is essentially used as a triage test for the more invasive
procedure of TRUS biopsies. As such the cut-oﬀ value selected for this test limits the overall
maximum sensitivity of the screening program. A large study byompson et al. investigated
the sensitivity and speciﬁcity of PSA at diﬀerent cut-oﬀ values in over 8500 patients with an
initial PSA of 3.0 ng/mL or lower with 7 year follow-up. Aer 7 years all patients received a
end-of-study prostate biopsy. ey found that at thresholds of 1.1, 2.1, 3.1 and 4.1 the sensi-
tivities of the PSA test for predicting any cancer were 83.4, 52.6, 32.2 and 20.5% with 38.9, 72.5,
86.7 and 93.8% as the respective speciﬁcities. is is visualized in an receiver-operating char-
acteristic curve in Figure 1.4. A review study by the American Cancer Society showed similar
results23. is indicates that the maximum sensitivity for the screening program is between
32.2 and 20.5 depending on the cut-oﬀ value used. Lower cut-oﬀ values as they would result
in a very large amount of unnecessary TRUS biopsies in healthy men, as the prevalence of
prostate cancer in the screening group of men aged between 55 and 74 years is only 8.2%21.
For cancer with a Gleason score larger than or equal to 7 the sensitivities were 92.8, 75.6, 57.6
and 40.4 with 37.0, 67.3, 82.3 and 90.0 as the respective speciﬁcities. ese numbers are arbi-
trarily more relevant, as these are the cancers that need to be detected as they have a relatively
poor prognosis.
e subsequent TRUS biopsies and pathological analysis of the biopsy specimens are the
end-result of the screening program. Patient handling is based on these results. However, the
reported detection rates of TRUS are relatively poor. e most common sextant biopsy strat-
egy typically misses 15 - 34% of prostate cancers at the ﬁrst biopsy24–26. Furthermore, TRUS
biopsies oen under- or over-estimate cancer grade. Underestimation occurs in around 46%
of the cases and overestimation in 18% of the cases when compared to pathological analysis
of radical prostatectomy specimens27,28.
Combining the results for PSA testing and TRUS it becomes apparent that the current tools
are inadequate for prostate cancer screening. e high threshold of 4 ng/mL on the initial PSA
test causes almost 80% of cancers to be missed at a relatively low screening speciﬁcity of 93.8%.
For the high-grade cancers, which are clinically most relevant, 59.6% at a speciﬁcity of 90.0%
would be missed. To put this into perspective: if 100000 men are screened, 2307 men would
have a high-grade cancer and require biopsy. Of these cancers 1375 would be missed due to the
poor sensitivity of PSA at this cut-oﬀ. Furthermore, an additional 232 cancers would be missed
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Figure 1.4: Receiver operating characteristic curve for prostate speciﬁc antigen blood tests in identifying prostate
cancer.
due to the poor detection rate of the TRUS biopsies and 322 of the cancers would be under-
graded. Of the 100000men 10000would receive an unnecessary biopsy, whowould have either
no cancer (9170 men) or a low-grade cancer (830 men). e men with low-grade cancer will
most likely receive some sort of (unnecessary) treatment and the associated side-eﬀects. e
9170 men with no cancer will have to undergo an unpleasant procedure, suﬀer from anxiety of
potentially having prostate cancer and the associated morbidity of the biopsy. Furthermore,
even aer a negative result, they will be unsure whether they are actually cancer-free due to
the poor sensitivity of TRUS biopsies and thus will most likely undergo repeat biopsies in the
future.
Summarizing, although there is potential for prostate cancer screening, the currently ac-
cepted clinical tools for diagnosis are inadequate. If an alternative technology can improve the
overall sensitivity, and especially the speciﬁcity of the diagnostic pathway, and thus reduce
over-diagnosis and over-treatment, screening might become feasible. One technology which
has shown potential is magnetic resonance imaging (MRI).
1.2 MRI for prostate cancer
1.2.1 General concepts
e ﬁrst magnetic resonance image (MRI) was created by Paul Lauterbur in 197329. He ex-
panded on the pioneering work by Herman Carr in 1952. Since then MRI has become a main-
stay imaging modality in hospitals worldwide. Magnetic resonance imaging uses the quantum
mechanical concept of spin (intrinsic angular moment of particles) to create images. Unpaired
protons, neutrons and electrons all possess a spin quantiﬁed as 1/2. Combinations of particles
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have diﬀerent amounts of spin, depending on their interactions, the so called net spin. MRI
can only visualize particles with a net spin which is non-zero. e rest of this section will
speciﬁcally be on hydrogen MRI (hydrogen atoms have a net spin of 1/2).
Particles with a net spin possess a magnetic moment. When a external magnetic ﬁeld is
applied the magnetic moment starts precessing about the direction of the magnetic ﬁeld with
a spin-dependent angle. e rate of precession is governed by the gyromagnetic ratio (, an
intrinsic property of the particle) and the magnetic ﬁeld strength (B0), resulting in a precession
at the so called Lamor frequency (!):
! = B0 (1.1)
For particles with a net spin of 1/2 this precession can occur in a low- (parallel to the magnetic
ﬁeld) or a high-energy (anti-parallel to the magnetic ﬁeld) state. Transitions between the two
states are possible by absorbing a photon with the exact same energy as the energy diﬀerence
between the states. is energy diﬀerence is determined by the strength of the magnetic ﬁeld;
with a higher magnetic ﬁeld strength a higher energy diﬀerence between states exists. When
grouping a set of particles with certain spin at room temperature their will be slightly more
spins in the lower energy state than in the higher energy state. As the signal inMRI is acquired
using the diﬀerence in energy absorbed by the spins making the transition from the lower to
the higher energy state and the energy released by the spins moving from the higher to the
lower energy state, the amount of signal is proportional to the distribution of the spins in the
high- and low-energy states.
Because of the diﬀerence between the distribution of the spins over the diﬀerent energy
levels a net magnetization vector is present along the direction of the magnetic ﬁeld. By ap-
plying an electromagnetic wave of photons (a radiofrequency pulse) with energy equal to the
energy diﬀerence between the two states the orientation of the net magnetization vector can
be changed and pushed in the transverse plane. When a long enough pulse is given the dif-
ference in particles in the energy states can become zero and the net magnetization vector is
fully in the transverse plane (a so-called 90-degree pulse). Over time the spin states will re-
turn to their original distribution with a time constant T1. is recovery is called spin-laice
relaxation and is governed by the equation:
Mz(t) =M0

1- e-tT1

(1.2)
A second relaxation eﬀect occurs in the transverse plane and is called spin-spin relaxation.
Immediately aer the 90-degree radiofrequency pulse the magnetic moment of the spins will
be in phase and the net magnetization vector will start precessing along the transverse plane.
As the spin magnetic moments will dephase over time, the net magnetization vector will decay
with a time constant T2 governed by the equation:
Mxy(t) =Mxy0

e
-t
T2

(1.3)
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Dephasing of the spins is caused by magnetic dipole-dipole interactions. Another eﬀect which
causes the dephasing is inhomogeneities in the B0 ﬁeld. e combination of the dipole inter-
actions and the inhomogeneity eﬀects leads to a time constant T2.
By using diﬀerent sequences of radiofrequent pulses signals can be measured which are
either weighted relative to T1, T2 or spin density at a spatial location. Spatial localization
of the signals can be performed by using gradients, which give each spatial location either a
slightly diﬀerent frequency or a slightly diﬀerent phase. By encoding spatial locations using
phase and frequency a Fourier transformation can be used to obtain images.
Tissue usually has distinctly diﬀerent MRI properties (e.g. T1 or T2 times), which allows
for high so tissue contrast in MR images. Depending on the organ or disease of interest one
might have a preference for T1-weighted, T2-weighted or more advanced types of imaging.
1.2.2 Prostate MRI
MRI for prostate cancer diagnosis has been around since the 1980s. Initially only focused on
T2-weighted imaging30 due to the high tissue contrast and spatial resolution, it has since ex-
panded to include multiple MR parameters. Modern prostate MRI can consist of T2-weighted
imaging, dynamic contrast-enhanced imaging (T1-weighted), diﬀusion-weighted imaging and
spectroscopic imaging31–33. Prostate MRI is usually acquired using 1.5 or 3 tesla MRI with ei-
ther a pelvic phased-array coil or an endo-rectal coil. e decision whether an endo-rectal coil
is required depends on the required resolution and signal-to-noise ratio (SNR) of the images.
T2-weighted imaging is considered the standard for anatomical assessment of the prostate,
as it has the highest resolution and best tissue contrast of all the modalities. Usually, three
orthogonal directions are acquired: sagial, axial and coronal with a high in-plane resolution
(around 0.2 - 0.6mm) and a relatively large slice thickness (2 - 4 mm). On T2-weighted imaging
the peripheral zone of the prostate usually appears as a bright, relatively homogenous region.
e central zone, transition zone and ﬁbromuscular stroma are usually hardly discernible ra-
diologically and are thus oen grouped together as a single zone: the central gland34. e
central gland is usually of a much darker appearance with a chaotic texture (caused by benign
disease like benign prostatic hyperplasia). An example of T2-weighted imaging is shown in
Figure 1.5.
Dynamic contrast-enhanced (DCE) imaging is a combination of several T1-weighted image
acquisitions over time following contrast agent injection. MRI has several types of contrast
agents, one of which are T1-shortening agents, usually containing paramagnetic metals. e
most common type of these agents are the gadolinium chelates. Administering a gadolinium
contrast agent will result in a T1 shortening proportional to the concentration of agent at the
speciﬁc location. A shortening of T1 will result in a higher signal intensity on T1-weighted
imaging and as such higher contrast between areas with a high concentration of contrast agent
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Central gland
(d)
Figure 1.5: Example of T2-weighted prostate MRI in three orthogonal directions. Figure (a), (b) and (c) show the
transversal, sagial and coronal view respectively. Figure (d) shows the transversal view with several anatomical
structures annotated. ese images were acquired on a 3T MRI scanner using a pelvic phased array coil.
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Figure 1.6: Example of dynamic contrast-enhanced MRI. Figure (a) shows a pre-contrast image, Figure (b) a post-
contrast image. In Figure (c) a Ktrans parameter map is overlayed on a pre-contrast image. ese images were
acquired on a 3T MRI scanner using a pelvic phased array coil.
and areas with low concentrations. An example of a T1-weighted prostate image before and af-
ter administration of contrast is visualized in Figures 1.6a and 1.6b. Cancer tends to be rapidly
growing tissue needing lots of nutrients and oxygen. is causes cancer cells to stimulate
blood vessel growth, however, due to the fast growth vessel integrity is usually sub-optimal,
resulting in ’leaky’ vessels. e increased vascularity and permeability of the blood vessels
causes contrast agent to diﬀuse out into cancerous tissue more easily than into normal tissue,
resulting in higher concentrations and thus higher signal intensity on T1-weighted imaging.
By inspecting the signal-intensity-over-time curves diagnostic information can be obtained.
For example, the increase of signal intensity over time is related to the rate of uptake of con-
trast agent. To accurately describe the dynamic behavior of tissue with respect to contrast
agent uptake over time a high temporal resolution is typically needed, usually in the order of
seconds. High temporal resolution data also allows quantitative extraction of tissue parame-
ters using pharmacokinetic modeling. Pharmacokinetic modeling tries to capture quantitative
physiological parameters from DCE MRI signal-intensity-over-time curves by compartmental
modeling of tissue. e original models proposed by Tos35 and Brix36 assume that any tis-
sue voxel consists of two compartments that have exchange of contrast agent. As gadolinium
chelates cannot enter the interior of the cells, there is only exchange between the blood plasma
and the extra-vascular, extra-cellular space or ’leakage’ space (EES) through the vessel wall.
is can be described using the following equation:
Ct(t) = vpCp(t) + K
trans
Z
Cp()e
-kep(t-)d (1.4)
kep =
Ktrans
ve
(1.5)
here Ct(t) is the concentration of contrast agent in the tissue at time t, vp is the fraction of
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plasma within the tissue, Cp(t) is the concentration of contrast agent in the blood plasma at
time t, Ktrans is the volume transfer constant between blood plasma and EES, kep is the rate
constant between EES and blood plasma and ve is the fraction of EES within the tissue. In
most practical implementations of this model vp is neglected because it is usually assumed
to be close to zero. Furthermore, it requires very high temporal resolution data to correctly
estimate37. Ktrans and ve are of interest because they describe inherent tissue properties where
Ktrans is related to vessel permeability and ve is related to microscopic tissue structure.
Diﬀusion-weighted imaging is the newest parameter in prostate cancer MRI and tries to
capture information on the Brownian motion of protons38,39. Diﬀusion-weighted MRI is based
on the pioneering work of Stejskal and Tanner40. It has has been related to cellular density in
tissue (higher cell density means restricted diﬀusion)41. Cellular density is usually increased in
cancer due to rapid proliferation of cells. MRI is made sensitive to diﬀusion eﬀects by applying
a spatially varying gradient pulse and then aer a certain time  applying the exact same pulse
in the opposite direction. If there was no diﬀusion, the net eﬀect on the spins would be zero.
However, due to diﬀusion the spins are aﬀected diﬀerently by the gradient pulses, resulting
in signal loss. As signal loss is also related to T1 and T2 relaxation eﬀects, multiple diﬀusion-
weighted acquisitions are made with varying gradient pulse parameters (for example strength,
or duration). e amount of signal loss over the diﬀerent diﬀusion-weighted acquisitions can
then be calculated using:
S(b) = S(0) exp-bADC (1.6)
where b is a parameter which summarizes the gradient pulse acquisition seings (strength,
duration and time between pulses), S(b) is the signal intensity at a certain value of b, and
ADC the apparent diﬀusion coeﬃcient, which is a tissue property. Given at least two diﬀerent
b-value acquisitions, the ADC at a certain location (x,y, z) can be calculated using:
ADC(x,y, z) =
ln S(b2,x,y,z)
S(b1,x,y,z)
b1 - b2
(1.7)
Subscripts 1 and 2 indicate the acquisition number. Using least squares optimization this
equation can be extended to an arbitrary number of acquisitions and b-values. e ADC is
in principle sensitive to the gradient pulse direction and as such usually multiple acquisition
in orthogonal directions are made and averaged to obtain a direction-independent ADC. An
example of two diﬀerent b-value images and an ADC map are shown in Figure 1.7.
Finally, MR spectroscopic imaging uses the principle of chemical shi (hydrogen protons
aached to diﬀerent molecules exhibit a slightly diﬀerent resonance frequency due to their
environment) to measure the concentration of diﬀerent metabolites in vivo. Voxel sizes tend
to be much larger than in the other MR parameters (5x5x5mm for example), however, at each
voxel a complete resonance spectrum is obtained. Visualization usually happens by overlaying
a voxel grid over the T2-weighted imaging, which allows clinicians to correlate the spectrum
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Figure 1.7: Example of diﬀusion-weighted MRI. Figure a and b show a transversal slice with low (a) and high (b)
b-value diﬀusion-weighting. Image c shows an example of an apparent diﬀusion coeﬃcient map calculated from
multiple b-value images. ese images were acquired on a 3T MRI scanner using a pelvic phased array coil.
to a spatial location. An example is shown in Figure 1.8. In prostate MR, spectroscopy allows
us to measure concentrations of for example choline, creatine and citrate. MR spectroscopic
imaging is currently not as widely used in clinical practice as the other modalities due to the
complexity of the acquisition and post-processing, which results in reduced reproducibility.
1.2.3 Prostate cancer diagnosis on MRI
A large body of literature exists describing the use of individual and combinations of diﬀerent
MR parameters for prostate cancer detection. For T2-weighted imaging alone only a moderate
sensitivity (57 - 84%) and speciﬁcity (50 - 94%) are reported42–44. Dynamic contrast-enhanced
imaging is able to achieve 59 - 73% sensitivity and 74 - 94% speciﬁcity45,46. Additionally, in a
recent study Vos et al. investigated the use of DCE MRI to assess cancer aggressiveness and
reported an area under the receiver operating characteristic (ROC) curve of 0.72 in discriminat-
ing low-grade cancer from intermediate-to-high-grade cancer47. Diﬀusion-weighted imaging
has a reported sensitivity of 84- 90% and a corresponding speciﬁcity of 81-84% for the detec-
tion of prostate cancer48–50. However, stand-alone performance of diﬀusion-weighted imaging
was only evaluated in a limited amount of patients. Additionally, several studies have shown
a clear relation between the value of the apparent diﬀusion coeﬃcient and Gleason grade51,52.
However, this holds mostly for the peripheral zone as in the central gland the diagnosis is more
diﬃcult due to overlapping imaging characteristics of BPH and prostate cancer with respect
to diﬀusion-weighted imaging. Finally, one study also included the stand-alone performance
of spectroscopic imaging for the detection of prostate cancer with an area under the ROC of
0.81 versus 0.80 for T2-weighted imaging42.
Several groups have evaluated the added value of the functional imaging techniques in
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Figure 1.8: Example of visualization of spectroscopic imaging in prostate MRI. Figure (a) shows the spectroscopy
grid overlayed on a transversal T2-weighted image. Figure (b) shows the obtained spectrum for the selected voxel
(indicated in red in Figure (a)). ese images were acquired with an endo-rectal coil.
Figure 1.9: A dark, homogenous region with indistinct boundaries (erased charcoal sign) can be identiﬁed in the
the top-right part of the image. is lesionwas scored a 5 on T2-weighted imaging following the ESUR guidelines.
addition to T2-weighted imaging. In32 an area under the ROC curve (AUC) of 0.84was reported
for T2-weighted imaging alone. e addition of DWI resulted in an AUC of 0.89 and the
addition of DCE in an AUC of 0.88. Combining all three parameters resulted in an AUC of
0.90. Similar results were obtained by31 with an AUC for T2-weighted imaging alone of 0.77.
e addition of only DWI resulted in an AUC of 0.90, a combination of all parameters resulted
in an AUC of 0.97. e combination of MR spectroscopy with T2-weighted imaging resulted
in an AUC of 0.85 versus 0.80 for T2-weighted imaging alone42.
Although these results show that MRI for prostate cancer has potential, a major issue with
broad adaptation was the professional disagreement on what MR parameters to use, how to
interpret them and when to use MRI53,54 (as evidenced by the large variation in reported sen-
sitivities and speciﬁcities). Recently, an eﬀort has been made by the European Society for
Urogential Radiology (ESUR) to standardize prostate MRI33. Currently, this is being formal-
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Figure 1.10: Schematic visualization of the three diﬀerent curve types that can be classiﬁed in DCE MRI of the
prostate. Curve type 3 (red curve) is a sign of malignancy.
(a) (b)
Figure 1.11: A focal lesion with high Ktrans is visualized in Figure a. e corresponding curve (type 3) is shown
in Figure b. is lesion was assigned a score of 5 according to the DCE reporting guidelines of the ESUR.
ized in a Prostate Imaging Reporting and Data Standard (PIRADS) by the American College of
Radiology. Table 1.1 gives a summary of the scoring criteria presented by ESUR.
For T2-weighted imaging there are separate instructions for the detection of cancer in the
peripheral zone and the central gland. As mentioned in section 1.2.2, the appearance of both
zones is markedly diﬀerent and the co-occurence of benign disease like BPH in the central
gland make special guidelines for this zone a necessity. In the peripheral zone prostate cancer
typically manifests as a round or ill-deﬁned, low-signal-intensity focus. In the CG tumor oen
shows a homogeneous signal mass with indistinct margins (the so called “erased charcoal
sign”). An example of a tumor which was scored a 5 on T2-weighted imaging according to the
ESUR guidelines is shown in Figure 1.9.
For DCE imaging the basic analysis described in the ESUR guidelines uses curve types.
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Score Criteria
T2-weighted imaging for the peripheral zone
1 Uniform high signal intensity
2 Linear, wedge shaped, or geographic areas of lower SI, usually not well demarcated
3 Intermediate appearances not in categories 1/2 or 4/5
4 Discrete, homogeneous low signal focus/mass conﬁned to the prostate
5 Discrete, homogeneous low signal intensity focus with extra-capsular extension/invasive behavior
or mass eﬀect on the capsule (bulging), or broad (>1.5 cm) contact with the surface
T2-weighted imaging for the transition zone
1 Heterogeneous TZ adenoma with well-deﬁned margins: “organised chaos”
2 Areas of more homogeneous low SI, however well marginated, originating from the TZ/BPH
3 Intermediate appearances not in categories 1/2 or 4/5
4 Areas of more homogeneous low SI, ill deﬁned: “erased charcoal sign”
5 Same as 4, but involving the anterior ﬁbromuscular stroma or the anterior horn of the PZ, usually
lenticular or water-drop shaped.
Diﬀusion-weighted imaging
1 No reduction in ADC compared with normal glandular tissue. No increase in SI on any
high b-value image (> b800)
2 Diﬀuse, hyper SI on ≥b800 image with low ADC; no focal features, however, linear, triangular or
geographical features are allowed
3 Intermediate appearances not in categories 1/2 or 4/5
4 Focal area(s) of reduced ADC but iso-intense SI on high b-value images (> b800)
5 Focal area/mass of hyper SI on the high b-value images (> b800) with reduced ADC
Dynamic contrast-enhanced imaging
1 Type 1 enhancement curve
2 Type 2 enhancement curve
3 Type 3 enhancement curve
+1 For focal enhancing lesion with curve type 2–3
+1 For asymmetric lesion or lesion at an unusual place with curve type 2–3
Magnetic resonance spectroscopic imaging
1 Citrate peak height exceeds choline peak height >2 times
2 Citrate peak height exceeds choline peak height times > 1, < 2 times
3 Choline peak height equals citrate peak height
4 Choline peak height exceeds citrate peak height > 1, < 2 times
5 Choline peak height exceeds citrate peak height >2 times
Table 1.1: ESUR guidelines for scoring multi-parametric prostate MRI per modality.
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Figure 1.12: A lesion with restricted diﬀusion, evidenced by the high signal intensity on the high b-value image
(a) and low apparent diﬀusion coeﬃcient (b). is lesion was assigned a score of 5 in concordance with the ESUR
guidelines for diﬀusion-weighted imaging.
e three diﬀerent curve types are visualized schematically in Figure 1.10. Curve type 1 rep-
resents slow-to-moderate initial enhancement and persistent enhancement in the laer part of
the curve. Curve type 2 is slow-to-moderate initial enhancement with a subsequent enhance-
ment plateau. Curve type 3 is fast initial enhancement with a subsequent drop in enhance-
ment (wash-out). Curve type 3 is considered a sign of malignancy. At the Radboud University
Medical Center pharmacokinetic analysis has been used since 200155–57 to provide additional
analysis tools. As explained in section 1.2.2, pharmacokinetic modelling allows us to calculate
tissue parameters related to the local vasculature. ese parameters can be presented as image
overlays to the radiologist. In addition to their quantitative value (high values of Ktrans corre-
spond to higher permeability, thus higher risk of cancer) they also make it easier to assess the
focality or symmetry of lesions. An example of a lesion which was scored a 5 on DCE MRI is
presented in Figure 1.11.
For DWI imaging the scoring of the lesion is performed using a high b-value image and the
apparent diﬀusion coeﬃcient map. A high b-value image (>800) is needed to minimize the T2
shine-through eﬀect. Prostate cancer usually has a high signal intensity on the high b-value
image and a low ADC value combined with a focal appearance on both images. An example
of a 5-scored lesion is presented in Figure 1.12.
Last, spectroscopic imaging gives information about the metabolites citrate, choline and
creatine. In prostate cancer choline concentrations tend to be higher than in normal tissue
due to increased cell proliferation. e ESUR guidelines for spectroscopy specify the relative
heights of the peaks for these metabolites with respect to the scores. Typically, the individual
peaks are extracted using post-processing soware and visualized as ratio parameter maps
(similar to visualization of pharmacokinetic modeling in DCE MRI). An example is the CC-
over-C ratio (choline and creatine over citrate), which is presented in Figure 1.13, with the
corresponding post-processed spectrum.
e ESUR guideline specify that at least two functional modalities (DWI, DCE or spec-
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Figure 1.13: Overlay of the choline + creatine over citrate ratio on the T2-weighted imaging, including the spec-
troscopy grid. e selected voxel (dark blue outline) shows a high ratio of choline over citrate (a) and the corre-
sponding spectrum shows a slightly higher peak for choline (pink) than for citrate (blue). As such a score of 4
was assigned for this lesion, in concordance with the ESUR guidelines.
troscopy) should be used in conjunction with T2-weighted imaging. ey also indicate that a
total score between 1 - 5 should be given for each lesion33. However, in the initial paper by
Barentsz et al. no rules are speciﬁed for turning the per-parameter scores into a ﬁnal lesion
score. Some research papers have investigated using the sum of the parameter scores linearly
(e.g. sum of 13 - 15 corresponds to 5, 10 - 12 corresponds to 4, etc.)58,59. However, in per-
sonal communication with Dr. Barentsz, he has expressed the preference assigning either the
DWI score or the T2W score as the overall lesion score depending on the zone (DWI for the
peripheral zone, T2W for the central gland).
Aer the guidelines were published several groups evaluated their performance58–61. Por-
talez et al.58 showed that using the ESUR guidelines a AUC of 0.87 was obtainable in diﬀer-
entiating normal/benign and prostate cancer regions. Using a cut-oﬀ of 9 for the sum-of-
parameter-scores the obtained sensitivity and speciﬁcity were 69.1 and 92.2%. Schimmöller et
al. investigated the inter-reader agreement among three readers using Cohens’ kappa in ad-
dition to reader performance in 67 consecutive patients. ey found moderate-to-good inter-
reader agreement between radiologists (T2W, =0.55; DWI, =0.64; DCE, =0.65). ey found
a sensitivity and speciﬁcity of 85.7 and 67.6% for a sum score cut-oﬀ of 10 and 92.2 and 47.1%
for a cut-oﬀ of 9. Rosenkrantz et al.59,60 also investigated both the inter-reader agreement and
the overall performance of the guidelines. ey found similar performance characteristics,
however they also found that agreement between experienced and inexperienced reader was
much less than between experienced readers (Concordance Correlation Coeﬃcient of 0.609
versus 0.340 - 0.471).
1.2.4 MRI as a screening tool for prostate cancer
Currently, MRI is mostly used as a tool to diagnose patients with persistently high PSA lev-
els and negative TRUS biopsies. However, given the much improved performance of MRI
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over TRUS biopsies, it could also supplant them in a screening seing. Some studies have
investigated the use of PSA and MRI as a screening tool. ompson et al.62 found a sensi-
tivity of 97% for the detection of clinically signiﬁcant prostate cancer (Gleason score >3+4)
with a speciﬁcity of 0.50. Furthermore, Pokorny et al.63 found that using multi-parametric
MRI and MR-guided biopsy in biopsy-naïve men results in a large reduction of over-diagnosis
of low-grade cancer (82%) while detecting 17% more intermediate/high-grade cancers than
TRUS-guided biopsy.
One oen mentioned argument is that MRI is too expensive for screening. Recently, de
Rooij et al.64 published a cost-eﬀectiveness study comparing the current diagnostic pathway
to one where TRUS biopsies are replaced with MRI and MR-guided biopsies. ey showed
that the overall cost is almost similar (2423 euro for MRI compared to 2392) and that the cost
per quality-adjusted life year was reduced by 323 euros. e main reason for the lower cost
per quality-adjusted life year is the substantially reduced amount of unnecessary biopsies and
treatment. Moreover, markedly lower patient morbidity is expected.
As such, MRI is not only the best performing option for prostate cancer screening (poten-
tially aer initial PSA testing at the appropriate cut-o), but also of similar cost as PSA/TRUS.
However, there are still challenges beforeMRI-based screening can become a reality. One issue
is the availability of experienced radiologists to read the subsequent ﬂood of MRIs, especially
if one wants to implement double reading like in mammography screening. A potential solu-
tion for this issue is the implementation of computer-aided detection algorithms to function
as a ﬁrst or second reader.
1.3 Computer-aided detection and diagnosis
Computer-aided detection and diagnosis (CAD) in medical imaging (oen named CADe and
CADx to diﬀerentiate the two) is a ﬁeld at the cross-roads of image analysis, medicine and
machine learning. A very general description of CAD research is: “the use of computer al-
gorithms to aid the image interpretation process”65. e very ﬁrst publication on the use of
computer algorithms to aid image interpretation was published in 1963 and focused on the
analysis of pulmonary lesions in chest radiographs66. Since then, availability of computers,
increase in computing power and the digitization of radiological images has led to an increase
in publications in the ﬁeld of CAD. e main subject of this thesis is the research and devel-
opment of fully automated computer programs to detect and characterize prostate cancer on
multi-parametric MRI.
1.3.1 General concepts
A complete CAD program is usually referred to as a “CAD system”. is naming is apt, as a
CAD system is not a single algorithm, but a pipeline involving multiple, distinct algorithms
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which can individually be replaced without changing the rest of the system (algorithmically).
Typically, CAD systems share many similar steps (or modules); the most common ones are:
pre-processing, segmentation, feature calculation and classiﬁcation. ese are set up in a
pipeline fashion with the result of one module feeding into the next. However, more com-
plex pipelines with feedback loops are also used. Each of these modules is designed to tackle
a speciﬁc problem.
Pre-processing steps are usually designed to make the original medical images suitable for
the subsequent modules. Typical examples are noise reduction, contrast improvement, or edge
enhancement. In the analysis of MRI images intensity diﬀerences between diﬀerent scanner
vendors or protocols are an issue as computers usually interpret image values absolutely, in-
stead as relative as humans usually do. A pre-processing step could involve removing scanner
and protocol dependencies from the signal intensities. An example of such a strategy is used
in chapters 3 and 6. Another type of pre-processing is assessing whether the CAD system can
actually perform subsequent steps given the input image. For example, if the image is of too
poor quality it might be beer to save computation time and ﬂag the image as unusable. is
prevents meaningless output, which in the end might reduce the conﬁdence of the end-user
in the system.
Segmentation is commonly meant to reduce the complexity of the classiﬁcation task for
the rest of the CAD system. As an example, forcing a CAD system to detect cancer in the
entire abdomen is much more diﬃcult than detecting cancer in just the prostate, not only be-
cause the search area is increased substantially, but also because some structures might exhibit
similar characteristics as prostate cancer. For example, muscle appears dark on T2-weighted
imaging, as does prostate cancer. Segmentation of the prostate is covered in chapter 2. How-
ever, segmentation is not only performed on an organ-basis. Lesions are also segmented with
the goal of extracting features from the lesion area, or from the segmentation itself. Finally,
segmentations do not have to be binary, they can also be probabilistic, giving a likelihood per
pixel/voxel of belonging to a certain anatomical structure. In this way it can for example be
used as a feature. is concept will be used in chapters 3 and 6.
Features are imaging characteristics which separate diﬀerent classes, in this thesis prostate
cancer from normal prostate tissue and benign prostate disease. Feature design for CAD sys-
tems is usually based on some inherent knowledge of the task. Extensive use was made of the
features described by the ESUR guidelines. However, it is oen diﬃcult for humans to de-
scribe the features they subconsciously use. For example, it is hard to teach a computer what
an “erased charcoal sign” is. As such feature design sometimes also depends on more general
descriptors of image structure, an example of which are Gaussian derivatives67,68. is type of
feature is less intuitive by itself, but a subsequent classiﬁer can use the combination of features
to obtain a meaningful class separation. Additionally, the recently renewed interest in “deep
learning” has made sparse auto-encoders a popular way to discover features from images.
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Sparse auto-encoders can use unlabeled images to automatically extract relevant features69.
Both intuitive features and basic image descriptors for classiﬁcation are used throughout this
thesis. In addition to the features themselves, several dimensionality reduction and feature
selection schemes are typically used in CAD system development to circumvent the so called
curse of dimensionality. e curse of dimensionality refers to the exponential increase in the
size of feature space and as such the required amount of training samples to cover this space.
Dimensionality reduction or feature selection help reduce the size of the feature space and
thus make a subsequent classiﬁcation problem more manageable. Examples of dimensionality
reduction are principle component analysis and sparse coding. Maximum relevance minimum
redundancy (mRMR) feature selection70, correlation feature selection71 (CFS) and sequential
forward ﬂoating feature selection (SFFS) are example of feature selection strategies, of which
the laer is used in Chapter 4.
Classiﬁcation is the task of assigning labels to unlabeled samples, in which each sample has
one or more feature values. Classiﬁers do this by constructing a decision boundary, a hyper-
plane through feature space which separates diﬀerent classes. Classiﬁers can be supervised
or unsupervised, in this thesis we focus on supervised classiﬁcation. Supervised classiﬁca-
tion requires a training step in which the classiﬁers learns the decision boundary from labeled
data. ere are roughly two types of supervised classiﬁers: parametric and non-parametric.
Parametric classiﬁers impose a distribution on the data, usually a Gaussian distribution. Two
examples of such classiﬁers are the linear discriminant classiﬁer (LDC) and the quadratic dis-
criminant classiﬁer72. Non-parametric classiﬁers do not assume a speciﬁc data distribution,
examples of such classiﬁers are the k-Nearest Neighbor (kNN) classiﬁer72, the GentleBoost
classiﬁer (GBC)73 and the random forest classiﬁer (RFC)74. Classiﬁers also diﬀer in complexity,
the linear discriminant classiﬁer is a relatively simple classiﬁer with a linear decision bound-
ary whereas a GentleBoost or random forest classiﬁer can learn much more complex decision
boundaries. A general rule of thumb is that the more complex the classiﬁer, the more training
data is needed is to obtain an accurate decision boundary. An example of a decision boundary
constructed by both an LDC and GBC is shown in Figure 1.14.
Aer classiﬁcation usually a label or likelihood is obtained. In the ﬁrst case the classiﬁer
will simply predict the most likely class label for a sample, in the laer case it will give a
likelihood per class. is output can then be used as is, or presented to a human interpreter
to aid in the decision making process.
1.3.2 CAD in clinical practice
eﬁrst computer-aided detection systemwas approved by the Food and Drug Administration
(FDA) for commercial use in 1998. is CAD system indicated location of potential breast
cancer in mammograms aer an initial read by a radiologist. As such it was designed to
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Figure 1.14: Example of classiﬁer decision boundaries for artiﬁcially generated data. Figure (a) shows the decision
boundary of a linear discriminant classiﬁer (LDC) and Figure (b) of a GentleBoost classiﬁer (GBC). One can
observe that the linear nature of the LDC decision boundary is not adequate for correctly classifying this type of
data.
reduce the number of missed cancers. Since then several CAD systems have made their way
to the clinic for a wide variety of applications ranging from analysis of hand radiographs for
bone age reading75 to detection of lung nodules in chest radiographs76,77.
e added value of computer-aided detection has been evaluated in several clinical trials,
with mixed results78–82. Most trials focus on the use of computer-aided detection in mammog-
raphy, where it is historically most widely used due to the implementation of breast cancer
screening programs. In the study by Gilbert et al. it was found that single reading with CAD
was as eﬀective as double reading by two radiologist78. However, Fenton et al. found that
reading with CAD resulted in increased recall rates without any signiﬁcant eﬀect on early-
detected breast cancer82.
Due to the inconclusive results on the usefulness of the current implementation of CAD
algorithms, several research groups have investigated alternative approaches to CAD. One
such approach is the use of CAD systems as an independent ﬁrst reader or second reader83–85.
Another option is the interactive use of CAD, which advocates the idea that missed lesions are
the result of a wrong characterization instead of the lesion being overlooked86,87. In chapter 7
the use of CAD as an independent ﬁrst/second reader was investigated.
1.3.3 CAD for prostate cancer on MRI
Computer-aided detection of prostate cancer on multi-parametric MRI is a relatively young
ﬁeld, with the ﬁrst papers appearing in 2003. Since then several research groups have shown
interest, which has lead to a number of publications. Chan et al. were the ﬁrst to implement a
multi-parametric CAD system for the detection of prostate cancer88 . In their approach they
used line-scan diﬀusion, T2 and T2-weighted images in combination with a support vector
machine (SVM) classiﬁer to classify predeﬁned areas of the peripheral zone of the prostate
for the presence of prostate cancer. Langer et al.89 included dynamic-contrast enhanced im-
ages and pharmacokinetic parameter maps as extra features to a CAD system for prostate
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peripheral zone cancer. Puech et al.90 implemented a computer-aided diagnosis system for
both the peripheral and transition zones based on the dynamic contrast enhanced images. Ar-
tan et al.91 used cost-sensitive conditional random ﬁelds to assess the detection performance
of a multi-parametric CAD system compared to a CAD system based on the individual MR
images. Liu et al.92 presented a CAD system for peripheral zone prostate cancer which does
not need an explicit segmentation of the peripheral zone by including anatomical position
features. Tiwari et al.93,94 investigated the use of magnetic resonance spectroscopy in com-
bination with T2-weighted imaging to identify the spectroscopy voxels that are aﬀected by
prostate cancer. ey also introduced the use of wavelet embedding to map MRS and T2-W
texture features into a common space. is work was further expanded and evaluated in94.
Viswanath et al.95 showed that cancer in diﬀerent zones has quantiﬁable diﬀerences in appear-
ance. Lastly, Vos et al.96 recently implemented a two-stage computer-aided detection system
for prostate cancer using an initial blob detection approach combined with a candidate seg-
mentation and classiﬁcation using statistical region features. Hambrock et al. assessed the po-
tential of computer-aided diagnosis in improving reader performance in prostate MRI97. ey
showed that both inexperienced readers and experienced readers could increase their area un-
der the receiver operating characteristic curve when assessing whether pre-deﬁned regions
were prostate cancer or not. Overall, inexperienced readers were able to achieve near-expert
performance (AUC=0.91 versus 0.93) when using CAD.
However, what all these methods lack is fully automated analysis of prostate MRI images
for all prostate zones at a performance level close to the radiologist. e only fully automated
system that takes a multi-parametric MRI as input and outputs a number of regions with
associated cancer likelihoods was the system presented by Vos et al, however, at a performance
which was yet too low for clinical implementation. A fully automated system is needed before
eﬃciency and the lack of experienced radiologists can be addressed. Such a system could be
used independently of the radiologist to characterize prostate MRI at a high sensitivity level,
thus reducing the workload for the experienced radiologists. Furthermore, using a diﬀerent
operating point, it could potentially replace the role of a second observer in a double reading
seing. Last, it could also be used as an aid to the radiologist reading prostateMRI by providing
a ’second opinion’ for radiologist-indicated regions. By operating in these three seings the
CAD system could solve the problem of the lack of experienced radiologists.
1.4 Performance evaluation and statistical tests
1.4.1 General concepts
To investigate whether research ﬁndings are meaningful and not caused by chance, statistical
signiﬁcance testing is used. In this thesis one of two strategies was employed: logistic re-
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gression analysis or receiver operating characteristic analysis. e former was used to assess
the added value of features and clinical parameters in the diagnosis of prostate cancer and
the laer to compare the diagnostic performance of humans and computer-aided detection
systems.
Logistic regression
Logistic regression measures the relationship between a categorical dependent variable (for
example prostate cancer/not prostate cancer) and one or more independent variables98. Bi-
nomial logistic regression uses the logistic function to map any combination of continuous
descriptors (with any possible value between -1 and +1) to an output between 0 and 1,
which can be interpreted as a likelihood. e logistic function is deﬁned as:
F(t) =
et
et + 1 =
1
1+ e-t (1.8)
t = 0 + 1x1 + . . . (1.9)
where t can be any linear combination of explanatory descriptors. Given a set of samples,
maximum likelihood estimation is used to ﬁt the logistic regression model, usually using op-
timization based on Newton’s method. In general, when enough samples are used relative to
the amount of descriptors, the optimization procedure will converge and result in estimates for
the regression coeﬃcients n. Using the likelihood ratio test one can assess whether a model
is a signiﬁcant improvement over a model with less descriptors. To perform the likelihood
ratio test the deviance needs to be calculated:
D = -2 ln likelihood of the ﬁed modellikelihood of the saturated model (1.10)
here the likelihood of the saturated model is the likelihood of a model with perfect ﬁt to the
data. e diﬀerence in the deviances of the two models one wants to compare can then be
tested using a chi-square distribution with degrees of freedom equal to diﬀerence in the num-
ber of descriptors estimated.
e value of the regression coeﬃcient can be used to interpret the size of the eﬀect a
descriptor has on the overall output. Assuming that the descriptors are similarly scaled, the
further the corresponding regression coeﬃcient deviates from zero, the bigger the impact of
the predictor on the output.
Sensitivity, speciﬁcity and the receiver operating characteristic curve
Any classiﬁcation task will lead to errors, whether it is performed by humans or by a computer
system. In a two-class classiﬁcation problem there are four outcomes: a sample is correctly
classiﬁed as class 1, a sample is incorrectly classiﬁed as class 1, a sample is correctly classiﬁed
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Figure 1.15: An example of a receiver operating characteristic curve. In this ﬁgure the mean bootstrap curve
(dashed line) and the 95% conﬁdence intervals (transparent area) are also ploed.
as class 0 or sample is incorrectly classiﬁed as class 0. Assuming class 1 is the target class (in
this thesis prostate cancer) these outcomes are a true positive (TP), false positive (FP), true
negative (TN) or false negative (FN) respectively. Given the total number of TP, FP, TN and
FNs across a set of data the sensitivity and speciﬁcity of the classiﬁer can be calculated. e
sensitivity and speciﬁcity are deﬁned as:
Sensitivity = TPTP+FN (1.11)
Speciﬁcity = TNTN+FP (1.12)
Sensitivity can be interpreted as the percentage of samples in class 1 which were correctly
classiﬁed as class 1, or in clinical terms, the cases having a disease correctly identiﬁed as having
the disease. Speciﬁcity is the percentage of samples in class 0 which are correctly identiﬁed
as class 0, or again in clinical terms, the cases which are healthy correctly identiﬁed as being
healthy. Usually there is a direct trade-oﬀ between sensitivity and speciﬁcity, increasing one
will decrease the other.
When a classiﬁcation task doesn’t give a binary prediction, but an ordinal one (e.g. the
ESUR lesion score, or likelihood obtained from a logistic regression model) multiple pairs of
sensitivity and speciﬁcity can be generated by changing the threshold at which a sample is
classiﬁed as class 1. Using these pairs a receiver operating characteristic (ROC) curve can
be generated (Figure 1.15). e area under this curve (AUC) can be calculated, which is the
probability that, given a random positive and negative sample, the positive sample will have
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the higher score. e minimum value of the AUC is 0 and the maximum value 1, although
typically 0.5 is considered the worst value as it corresponds to straight-out guessing. e
maximum value of 1 corresponds to perfect classiﬁcation. e AUC is not always the most ap-
propriate measure to evaluate a diagnostic test, sometimes single pair of sensitivity/speciﬁcity
or a partial area under the curve can be more informative, depending on the task. For example,
in a screening seing, where the vast majority of patients is healthy, high sensitivity is only
relevant within the part of the curve with high speciﬁcity.
Sometimes it can be informative to explicitly include the prevalence of the classes in the
performance measure to get a beer understanding what it means in a practical scenario.
In those cases a positive predictive value (PPV) and negative predictive value (NPV) can be
calculated, which are deﬁned as:
PPV = TPTP+FP (1.13)
NPV = TNTN+FN (1.14)
In addition to ROC analysis, which assumes one outcome per case, free-response receiver
operating characteristic (FROC) is oen used. In FROC instead of speciﬁcity, the number of
false positives per case are used, as multiple false detection per scan can typically occur. From
FROC results a ROC can be calculated by converting the multiple detections per case into a
single likelihood.
Statistically evaluating the performance of diﬀerent diagnostic tests or CAD systems in
thesis is usually performed using bootstrapping99,100. Bootstrapping is a non-parametric way
to statistically evaluate diﬀerences in performance. In bootstrapping the output data is re-
sampled with replacement. Each re-sample is one bootstrap sample and from this sample
the performance metric can be calculated, e.g. the AUC. When two methods are statistically
compared they are re-sampled in exactly the same way so a paired test can be performed. e
p-value can then be calculated by counting the amount of bootstrap samples of one method
which give a higher result than the other method.
In addition to bootstrapping in chapter 5 the ROCKIT soware package was used to sta-
tistically compare ROC curves101. is package ﬁrst ﬁts a bi-normal model to diagnostic test
outputs for each class and can then subsequently calculate the ROC curve, AUC and the 95%
conﬁdence intervals.
1.5 esis outline
e main objective of this thesis was to design a computer-aided detection system to detect
cancer in prostate MRI which could be used in clinical practice. Although several papers
already describe these types of systems numerous challenges remain: the system needs be
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fully automated, it needs to work both in the peripheral zone and the central gland and it
should approach the performance of a human expert. Meeting these requirements will allow
us to solve one of the issues currently prohibiting MRI-based prostate cancer screening: the
lack and cost of experienced radiologists. Furthermore, a computer-aided detection system
could help improve the performance of individual radiologists. is thesis tries to meet and
solve the presented challenges and our results are presented in the subsequent chapters.
In chapter 2 the preparation, organization and results of a prostate MRI segmentation chal-
lenge (PROMISE12) are discussed. e goal of the challenge was to identify the performance
of diﬀerent categories and implementations of algorithms that segment the prostate. Multi-
center, multi-protocol and multi-vendor data was used to evaluate the methods to ensure that
algorithms which showed good performance would generalize well to diﬀerent centers.
Chapter 3 subsequently focuses on the use of paern recognition methods to segment the
peripheral zone and central gland, both probabilistically and binary. It also includes a method
to reduce inter-scanner and inter-protocol variation on T2-weighted imaging. Segmentation
results were compared to those of three diﬀerent observers.
In chapter 4 and 5 the design of discriminative features for assessing cancer aggressiveness
and separating cancer from benign confounding classes like BPH is presented. Prostatectomy
specimens were mapped to the MRI to accurately delineate speciﬁc lesions. e use of logistic
regression and SFFS feature selection to identify useful features from a large initial feature set
was investigated.
Chapter 6 is concernedwith the development of the CAD pipeline, including segmentation,
features, classiﬁcation and initial evaluation on a large retrospective data set. A two-stage
classiﬁcation pipeline is built using initial voxel classiﬁcation and subsequent false positive
reduction.
Chapter 7 details the evaluation of the CAD system on a prospective set of data and the
usefulness of the system in a clinical seing where it could function as an independent second
reader. e focus is on the improvement in reader performance and the correlation of the CAD
system likelihoods with cancer aggression.
Segmentation
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2.1 Introduction
Prostate MRI image segmentation has been an area of intense research due to the increased
use of MRI as a modality for the clinical workup of prostate cancer, e.g. diagnosis and treat-
ment planning28,31,32,102,103. Segmentation is useful for various tasks: to accurately localize
prostate boundaries for radiotherapy104, perform volume estimation to track disease progres-
sion105, to initialize multi-modal registration algorithms106 or to obtain the region of interest
for computer-aided detection of prostate cancer94,96, among others. As manual delineation of
the prostate boundaries is time consuming and subject to inter- and intra-observer variation,
several groups have researched (semi-)automatic methods for prostate segmentation104,107–112.
However, as most algorithms are evaluated on proprietary datasets a meaningful comparison
is diﬃcult to make.
is problem is aggravated by the fact that most papers cannot include a comparison
against the state-of-the-art due to previous algorithms being either closed source or very dif-
ﬁcult to implement without help of the original author. Especially in MRI, where signal in-
tensity is not standardized and image appearance is for a large part determined by acquisition
protocol, ﬁeld strength, coil proﬁle and scanner type, these issues present a major obstacle in
further development and improvement of prostate segmentation algorithms.
In recent years several successful ’Grand Challenges in Medical Imaging’ have been or-
ganized to solve similar issues in the ﬁelds of liver segmentation on CT113, coronary image
analysis114, brain segmentation on MR115, retinal image analysis116 and lung registration on
CT117. e general design of these challenges is that a large set of representative training data
is publicly released, including a reference standard for the task at hand (e.g. liver segmen-
tations). A second set is released to the public without a reference standard, the test data.
e reference standard for the test data is used by the challenge organizers to evaluate the
algorithms. Contestants are then allowed to tune their algorithms to the training data aer
which their results on the test data are submied to the organizers who calculate predeﬁned
evaluation measures on these test results. e objective of most challenges is to provide inde-
pendent evaluation criteria and subsequently rank the algorithms based on these criteria. is
approach overcomes the usual disadvantages of algorithm comparison, in particular, bias.
e Prostate MR Image Segmentation (PROMISE12) challenge presented in this paper tries
to standardize evaluation and objectively compare algorithm performance for the segmenta-
tion of prostate MR images. To achieve this goal a large, representative set of 100 MR images
was made available through the challenge website: http://promise12.grand-challenge.
org/. is set was subdivided into training (50), test (30) and live challenge (20) datasets (for
further details on the data, see section 2.2). Participants could download the data and ap-
ply their own algorithms. e goal of the challenge was to accurately segment the prostate
capsule. e calculated segmentations on the test set were then submied to the challenge
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(a) (b) (c) (d)
Figure 2.1: Slice of a data set from diﬀerent centers to show appearance diﬀerences. Figure (a) is from Haukeland
University Hospital, Norway and was acquired at 1.5T with an endorectal coil. Figure (b) is from Beth Israel
Deaconess Medical Center, USA and was acquired at 3.0T with an endorectal coil. Figure (c) if from University
College London, United Kingdom acquired at 1.5T and 3.0T without an endorectal coil. Figure (d) is from the
Radboud University Medical Centre, e Netherlands and was acquired at 3.0T without an endorectal coil.
organizers through the website for independent evaluation. Evaluation of the results included
both boundary and volume based metrics to allow a rigorous assessment of segmentation ac-
curacy. To calculate an algorithm score based on these metrics, they were compared against
human readers. Further details about generation of the algorithm score can be found in section
2.3.2.
is paper will describe the setup of the challenge and the initial results obtained prior to
and at the workshop hosted by the MICCAI2012 conference in Nice, where a live challenge
was held between all participants. New results, which can still be submied through the
PROMISE12 website, can be viewed online.
2.2 Materials
2.2.1 MRI images
In MRI images, the pixel/voxel intensities and therefore appearance characteristics of the
prostate can greatly diﬀer between acquisition protocols, ﬁeld strengths and scanners33,54. Ex-
ample causes of appearance diﬀerences include the bias ﬁeld118,119, signal-to-noise ratio120,121
and resolution31,32, especially through-plane. Additionally, signal intensity values are not stan-
dardized122,123. erefore a segmentation algorithm designed for use in clinical practice needs
to deal with these issues124,125. Consequently, we decided to include data from four diﬀerent
centers: Haukeland University Hospital (HK) in Norway, the Beth Israel Deaconess Medi-
cal Center (BIDMC) in the US, University College London (UCL) in the United Kingdom and
the Radboud University Nijmegen Medical Centre (RUNMC) in the Netherlands. Each of the
centers provided 25 transverse T2-weighted MR images. is resulted in a total of 100 MR
images. Details pertaining to the acquisition can be found in Table 2.1. Additionally, a cen-
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Center Field Strength Endorectal coil Resolution (in-/through-plane in mm) Manufacturer
HK 1.5T Yes 0.625 / 3.6 Siemens
BIDMC 3T Yes 0.25 / 2.2 - 3 GE
UCL 1.5 and 3T No 0.325 - 0.625 / 3 - 3.6 Siemens
RUNMC 3T No 0.5 - 0.75 / 3.6 - 4.0 Siemens
Table 2.1: Details of the acquisition protocols for the diﬀerent centers. Each center supplied 25 T2-weighted MR
images of the prostate.
(a) (b) (c)
Figure 2.2: Example T2-weighted transverse prostate MRI images displaying an apical, central and basal slice.
e reference standard segmentation is shown in yellow and the second observer segmentation in red. Figures
(a), (b) and (c) are at the apex, center and base of the prostate respectively.
tral slice of a data set for each of the centers is shown in Figure 2.1 to show the appearance
diﬀerences. ese scans where acquired either for prostate cancer detection or staging pur-
poses. However, the clinical stage of the patients and the presence and location of prostate
cancer is unknown to the organizers. Transverse T2-weighted MR was used because these
contain most anatomical detail33, are used clinically for prostate volume measurements103,105
and because most current research papers focus on segmentation on T2-weighted MRI. e
data were then split randomly into 50 training cases, 30 test cases and 20 live challenge cases.
Although the selection process was random, it was stratiﬁed according to the diﬀerent centers
to make sure no training bias towards a certain center could occur.
2.2.2 Segmentation Reference Standard
Each center provided a reference segmentation of the prostate capsule performed by an experi-
enced reader. All annotations were performed on a slice-by-slice basis using a contouring tool.
e contouring tool itself was diﬀerent for the diﬀerent institutions, but the way cases were
contoured was similar. Contouring was performed by annotating spline-connected points in
either 3DSlicer (www.slicer.org) or MeVisLab (www.mevislab.de). e reference segmen-
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tations were checked by a second expert, C.H., who has read more than 1000 prostate MRIs,
to make sure they were consistent. is expert had no part in the initial segmentation of the
cases and was asked to correct the segmentation if inconsistencies were found. e resulting
corrected segmentations were used as the reference standard segmentation for the challenge.
An example of a reference segmentation at the base, center and apex of the prostate is shown
in Figure 2.2.
2.2.3 Second Observer
For both the testing and the live challenge data a relatively inexperienced nonclinical observer
(W.v.d.V, two years of experience with prostate MR research) was asked to manually segment
the prostate capsule using a contouring tool. e second observer was blinded to the reference
standard to make sure both segmentations were independent. e second observer segmen-
tations were used to transform the evaluation metrics into a case score, as will be explained
in section 2.3.2. An example of a second observer segmentation is shown in Figure 2.2.
2.3 Evaluation
2.3.1 Metrics
e metrics used in this study are widely used for the evaluation of segmentation algorithms:
1. the Dice coeﬃcient (DSC)108,113
2. the absolute relative volume diﬀerence, the percentage of the absolute diﬀerence be-
tween the volumes (aRVD)113
3. the average boundary distance, the average over the shortest distances between the
boundary points of the volumes (ABD)113
4. the 95% Haussdorf distance (95HD)111
All evaluation metrics were calculated in 3D. We chose both boundary and volume metrics
to give a more complete view of segmentation accuracy, i.e. in radiotherapy boundary based
metrics would be more important, whereas in volumetry the volume metrics would be more
important. In addition to evaluating these metrics over the entire prostate segmentation, we
also calculated them speciﬁcally for the apex and base parts of the prostate, because these
parts are very important to segment correctly, for example in radiotherapy and TRUS/MR fu-
sion. Moreover, these are the most diﬃcult parts to segment due the large variability and slice
thickness. To determine the apex and base the prostate was divided into three approximately
equal parts in the slice dimension (the caudal 1/3 of the prostate volume was considered apex,
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the cranial 1/3 was considered base). If a prostate had a number of slices not dividable by 3
(e.g. 14), the prostate would be divided as 4-6-4 for the base, midgland and apex respectively.
e DSC was calculated using:
D(X,Y) = 2jX \ Yj
jXj+ jYj
(2.1)
where jXj is the number of voxels in the reference segmentation and jYj is the number of voxels
in the algorithm segmentation.
e relative volume diﬀerence was calculated as:
RVD(X,Y) = 100

jXj
jYj
- 1

(2.2)
and thus the absolute relative volume diﬀerence is
aRVD(X,Y) = jRVD(X, Y)j (2.3)
Note that although we use the aRVD to measure algorithm performance (both under- and
over-segmentation are equally bad), in the results we will present the RVD, which makes it
possible to identify if algorithms on average tend to over- or under-segment the prostate.
For both the 95th percentile Hausdorﬀ distance and the average boundary distance we
ﬁrst extract the surfaces of the reference segmentation and the algorithm segmentation. e
regular Hausdorﬀ distance is then deﬁned as:
HDasym(Xs,Ys) = max
x2Xs

min
y2Ys
d(x,y)

(2.4)
HD(Xs,Ys) = max
 HDasym(Xs,Ys), HDasym(Ys,Xs) (2.5)
where Xs and Ys are the sets of surface points of the reference and algorithm segmentations
respectively. e operator d is the Euclidean distance operator. As the normal Hausdorﬀ
distance is very sensitive to outliers we use the 95th percentile of the asymmetric Hausdorﬀ
distances instead of the maximum.
Finally, the average boundary distance (ABD) is deﬁned as:
ABD(Xs,Ys) = 1
NXs +NYs
 X
x2Xs
min
y2Ys
d(x,y) +
X
y2Ys
min
x2Xs
d(y, x)
!
(2.6)
2.3.2 Score
Algorithms were ranked by comparing the resulting evaluation measures to the second ob-
server and the reference segmentation in a way similar to Heimann et al. 113 . First, the metrics
of the second observer segmentations are calculated with respect to the reference segmenta-
tion. en we average each metric over all cases and deﬁne a mapping function:
score(x) = max (ax+ b, 0) (2.7)
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is function maps a metric value x to a score between 0 and 100. e equation is solved for a
and b by seing a score of 100 to a perfect metric result, e.g. a DSC of 1.0 and seing a score
of 85 to a metric result equal to the average metric value of the second observer. is will give
us two equations to solve the two unknowns, a and b. Additionally, a score of zero was set as
the minimum because otherwise cases with a very poor or missing segmentation could bias
the ﬁnal score of an algorithm too much. As an example, if the second observer segmentations
have an average DSC of 0.83, a and b are 88.24 and 11.76 respectively. As such, if an algorithm
obtains a DSC of 0.87 on a case the score will be 88.53. is approach is applied to all metrics.
e scores for all metrics were averaged to obtain a score per case. en the average over all
cases was used to rank the algorithms.
A relatively high reference score of 85 was chosen for the second observer because her
segmentations were in excellent correspondence with the reference standard. An even higher
score than 85 would not be warranted, as the segmentations still contain errors experienced
observers would not make. e average metric scores for the second observer are presented
in Tables 2.6 and 2.7. Comparing these metric scores to scores reported in literature for inter-
observer variability we can see that they are at approximately at the same level104,107–112.
e main reason to use this approach is that it allows us to incorporate completely diﬀer-
ent, but equally important metrics like average boundary distance and the Dice coeﬃcient.
Furthermore, in addition to allowing us to rank algorithms, the scores themselves are also
meaningful, i.e. higher scores actually correspond to beer segmentations. An alternative ap-
proach could have been to rank algorithms per metric and average the ranks over all metrics.
However, such an average rank is not necessarily related to a segmentation performance: the
best ranking algorithm could still show poor segmentation results that are much worse than
the second observer.
2.4 Methods
is section gives an overview of all the segmentation methods that participated in the chal-
lenge. A short description for each algorithm is given. More detailed descriptions of the algo-
rithms can be found in peer-reviewed papers submied to the PROMISE12 challenge, available
at: http://promise12.grand-challenge.org/Results. Algorithms were categorized as
either automatic (no user interaction at all), semi-automatic (lile user interaction, e.g. set-
ting a single seed point) or interactive (much user interaction, e.g. painting large parts of the
prostate). e algorithm categories and additional details can be found in Tables 2.3 and 2.8.
e names in subsection titles are the team names chosen by the participants and are as such
not related to the method themselves. Most names are either abbreviations of group names
or company names. Links to the websites of the individual groups can also be found on the
PROMISE12-website.
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2.4.1 Fully automatic segmentation of the prostate using active appearance models
- Imorphics
Vincent et al. 126 of Imorphics Ltd. have developed a generic statistical modeling system de-
signed to minimize any bespoke development needed for diﬀerent anatomical structures and
image modalities.
e Imorphics system generates a set of dense anatomical landmarks from manually seg-
mented surfaces using a variant of the Minimum Description Length approach to Groupwise
Image Registration127. e correspondence points and associated images are used to build
an Appearance Model. e Appearance Model is matched to an unseen image using an Ac-
tive Appearance Model (AAM) which optimizes the model parameters to generate an instance
which matches the image as closely as possible128.
Active Appearance Models require an initial estimate of the model parameters including
position, rotation and scale. e system uses a multi-resolution gridded search method. is
is started at a low image and model resolution with a small number of measured residuals
to make it reasonably fast. e results of these searches are ranked according to the sum of
squares of the residual, and a proportion removed from consideration. e remaining search
results are used to initialize models at a higher resolution, and so on. Finally, the single best
result at the highest resolution gives the segmentation result.
2.4.2 Region-speciﬁc hierarical segmentation ofMR prostate using discriminative
learning - ScrAutoProstate
e segmentation pipeline developed by Birkbeck et al. 129 addresses the challenges of MR
prostate segmentation through the use of region-speciﬁc hierarchical segmentation with dis-
criminative learning.
First, an intensity normalization is used to adjust for global contrast changes across the
images. Images with an endorectal coil are then further enhanced by ﬂaening the intensity
proﬁle on the bright regions near the coil using an automatic application of Poisson image
editing130.
In the next phase of the pipeline, a statistical model of mesh surface variation learned from
training data is aligned to the normalized image. e pose parameters of the shape model are
extracted through the use of marginal space learning131, which decomposes the estimation of
pose into sequential estimates of the position, orientation, scale, and then the ﬁrst few modes
of variation. e estimation of each set of pose parameters relies on a probabilistic boost-
ing tree classiﬁer to discriminatively model the relationship between the image data and the
unknown parameters being estimated. During training, each classiﬁer automatically selects
the most salient features from a large feature pool of Haar and steerable features. Aer the
statistical mesh model has been aligned to the input image using marginal space learning, the
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segmentation is reﬁned through a coarse-to-ﬁne boundary reﬁnement that uses surface vary-
ing classiﬁers to discriminate the boundary of the prostate from adjacent so tissue. e mesh
from this ﬁnal reﬁnement stage is constrained by the statistical shape model.
2.4.3 Smart paint - CBA
Malmberg et al. 132 have developed an interactive segmentation tool called Smart Paint. e
user segments the organ of interest by sweeping the mouse cursor in the object or background,
similar to how an airbrush is used. Areas are paintedwith a semi-transparent colorwhich gives
immediate feedback in the chosen interaction plane. As the paint is applied in 3D, when the
user moves to another plane using the mouse thumbwheel the eﬀect of the painting is seen
also there.
e algorithmworks by taking both the spatial distance to the cursor and the image content
(intensity values) into account. e image I and the segmentation function f are mappings
from elements of a three dimensional voxel set to the interval [0,1]. A voxel x belongs to the
foreground if f(x) > 0.5, and to the background otherwise. Initially, f = 0. e brush tool has
a value v that is either 1 (to increase the foreground) or 0 (to increase the background). A single
brush stroke centered at voxel x aﬀects the segmentation at all nearby voxels y according to
f(y) (1- (x,y))f(y) + (x,y)v (2.8)
(x,y) = (1- jI(y) - I(x)j)kmax((r- d(x,y))
r
, 0) (2.9)
where d(x,y) is the Euclidean distance between the voxel centers of x and y, r is the brush
radius speciﬁed by the user and  and k are constants.
Additionally, the user can smooth the current segmentation using aweighted average ﬁlter.
e algorithm is not very sensitive to the values selected for the  and k constants. Values
for  were in the range 0.01 - 0.1 and for k in the range 1-5 and inﬂuence the behavior of the
brush. ese variables could be changed by the user
2.4.4 Multi-atlas segmentation of the prostate: a zooming process with robust reg-
istration and atlas selection - SBIA
e multi-atlas based segmentation framework designed by Ou et al. 133 automatically seg-
ments the prostate in MR images. Atlases from 50 training subjects are nonrigidly registered
to the target image. e calculated deformations are used to warp expert annotated prostate
segmentations of the atlases into the target image space. e warped prostate annotations
are then fused by the STAPLE strategy134 to form a single prostate segmentation in the target
image.
e main challenge in this multi-atlas segmentation framework is image registration. To
account for the registration challenges, three measures are taken in the multi-atlas segmenta-
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tion framework. First, the DRAMMS image registration algorithm is used135. DRAMMS estab-
lishes anatomical correspondences by using high dimensional texture features at each voxel.
Voxel texture features are more distinct than just using intensity, which helps to improve
registration accuracy. Second, a two-phase strategy is used. In phase 1 the entire prostate
images from training subjects are used to compute an initial segmentation of the prostate in
target image. Phase 2 focuses only on the initially segmented prostate region and its imme-
diate neighborhood. ird, in each phase, atlas selection is used. ose atlases having high
similarity with the target image in the prostate regions aer registration are kept. Similarity
is measured using the correlation coeﬃcient, mutual information, as well as the DSC between
the warped prostate annotation and the tentative prostate segmentation.
2.4.5 Automatic prostate segmentation in MR images with a probabilistic active
shape model - Grislies
Kirschner et al. 136 segment the prostate with an Active ShapeModel (ASM)128. For training the
ASM, meshes were extracted from the ground truth segmentations using Marching Cubes137.
Correspondence between the meshes was determined using a nonrigid mesh registration algo-
rithm. e ﬁnal ASM has 2000 landmarks and was trained using principal component analysis
(PCA).e actual segmentation is done with a three step approach, consisting of 1) image pre-
processing, 2) prostate localization and 3) adaption of the ASM to the image.
In the preprocessing step, the bias ﬁeld is removed using coherent local intensity clus-
tering, and the image intensities are normalized138. Prostate localization is done using the
sliding window approach: a boosted classiﬁer based on 3D Haar-like features is used to decide
whether the subimage under the current detector window position contains the prostate or
not. is approach is similar to the Viola-Jones algorithm for face detection in 2D images139, .
e actual segmentation is done with a Probabilistic ASM. In this ﬂexible ASM variant,
shape constraints are imposed by minimizing an energy termwhich determines a compromise
between three forces: an image energy that draws the model towards detected image features,
a global shape energy that enforces plausibility of the shapes with respect to the learned ASM,
and a local shape energy that ensures that the segmentation is smooth. For detection of the
prostate’s boundary, a boosted detector using 1D Haar-like features is used, which classiﬁes
sampled intensity proﬁles into boundary and nonboundary proﬁles.
2.4.6 An eﬃcient convex optimization approa to 3D prostate MRI segmentation
with generic star shape prior - Robarts
e work by Yuan et al. 140 proposes a global optimization-based contour evolution approach
for the segmentation of 3D prostate MRI images, which incorporates histogram matching and
a variational formulation of a generic star shape prior.
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e proposed method overcomes the existing challenges of segmenting 3D prostate MRIs:
heterogeneous intensity distributions and a wide variety of prostate shape appearances. e
proposed star shape prior does not stick to any particular object shape from learning or spec-
iﬁed parameterized models, but potentially reduces ambiguity of prostate segmentation by
ruling out inconsistent segments; it provides robustness to the segmentation when the image
suﬀers from poor quality, noise, and artifacts.
In addition, a novel convex relaxation based method is introduced to evolve a contour
to its globally optimal position during each discrete time frame, which provides a fully time
implicit scheme to contour evolution and allows a large time step size to accelerate the speed
of convergence.
Moreover, a new continuous max-ﬂow formulation is proposed, which is dual to the stud-
ied convex relaxation formulation and derives a new eﬃcient algorithm to obtain the global
optimality of contour evolution. e continuous max-ﬂow based algorithm is implemented on
GPUs to signiﬁcantly speed up computation in practice.
2.4.7 An automatic multi-atlas based prostate segmentation using local appearance
speciﬁc atlases and pat-based voxel weighting - ICProstateSeg
Gao et al. 141 present a fully automated segmentation pipeline for multi-center and multi-
vendor MRI prostate segmentation using a multi-atlas approach with local appearance speciﬁc
voxel weighting.
An initial denoising and intensity inhomogeneity correction is performed on all images.
Atlases are classiﬁed into two categories: normal MRI scans An and scans taken with a tran-
srectal coilAm. is is easily achieved by examining the intensity variation around the rectum
since the transrectal coil produces signiﬁcant physical distortion but also has a characteristic
bright appearance in the local region near the coil itself. e subatlas database whose atlas
appearance is closest to the new target is chosen as the initial atlas database. Aer that, the
top N similar atlases are further chosen for atlas registration by measuring intensity diﬀerence
in the region of interest around prostate.
Aer all the selected atlases are nonrigidly registered to a target image, the resulting trans-
formation is used to propagate the anatomical structure labels of the atlas into the space of the
target image. Finally, a patch-based local voxel weighting strategy is introduced, which was
recently proposed for use in patch-based brain segmentation142 and improved by introducing
the weight of the mapping agreement from atlas to target. Aer that, the label that the major-
ity of all warped labels predict for each voxel is used for the ﬁnal segmentation of the target
image.
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2.4.8 Prostate image segmentation using 3D active appearance models - Utwente
e segmentation method proposed by Maan and van der Heijden 143 is an adaptation of the
work presented by Kroon et al. 144 by using a Shape Context based non-rigid surface registra-
tion in combination with 3D Active Appearance Models (AAM).
e ﬁrst step in AAM training is describing the prostate surface in each training case by
a set of landmarks. Every landmark in a training case must have a corresponding landmark
in all other training cases. To obtain the corresponding points Shape Context based nonrigid
registration of the binary segmentation surfaces was used143,144. PCA is applied to determine
the principal modes of the shape variation. e appearance model can be obtained in a similar
way: ﬁrst each training image is warped so that its points correspond to themean shape points.
Subsequently, the grey-level information of the region covered by the mean shape is sampled.
Aer normalization, a PCA is applied to obtain the appearance model. e combined shape
and appearance model can generalize to almost any valid example.
During the test phase, the AAM is optimized by minimizing the diﬀerence between the
test image and the synthesized images. e mean model is initialized by manually selecting
the center of the prostate based on visual inspection. Subsequently, the AAM is applied using
two resolutions with both 15 iterations.
2.4.9 A multi-atlas approa for prostate segmentation in MR images - DIAG
Litjens et al. 145 investigated the use of a multi-atlas segmentation method to segment the
prostate using the Elastix registration package. e method is largely based on the work of
Klein et al. 108 and Langerak et al. 146 . e 50 available training data sets are used as atlases
and registered to the unseen image using localized mutual information as a metric. Localized
mutual information calculates the sum of the mutual information of image patches instead of
the mutual information of the entire image. is approach reduces the eﬀect of magnetic ﬁeld
bias and coil proﬁle on the image registration.
e registration process consists of two steps: ﬁrst a rough initial alignment is found, aer
which an elastic registration is performed. e 50 registered atlases are then merged to form
a signal binary segmentation using the SIMPLE optimization algorithm146. SIMPLE tries to
automatically discard badly registered atlases in an iterative fashion using the correspondence
of the atlas to the segmentation result in the previous iteration. e DSC was used as the
evaluation measure in the SIMPLE algorithm.
2.4.10 Deformable landmark-free active appearancemodels: application to segmen-
tation of multi-institutional prostate MRI data - Rutgers
Toth and Madabhushi 147 propose a Multi-Feature, Landmark-Free Active Appearance Model
(MFA) based segmentation algorithm, based on148. e MFA contains both a training module
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and a segmentation module. e MFA is constructed by ﬁrst aligning all the training images
using an aﬃne transformation. Second, the shape is estimated by taking the signed distance
to the prostate surface for each voxel, which represents a levelset, such that a value of 0 cor-
responds to the voxels on the prostate surface. ird, principal component analysis is used
to map the shape and intensity characteristics of the set of training images to a lower dimen-
sional space. en a second PCA is performed on the joint set of lower dimensional shape and
appearance vectors to link the shape and appearance characteristics.
To segment an unseen image, the image must be registered to the MFA, resulting in trans-
formation T mapping the input image to the MFA. is is performed by ﬁrst calculating the
PCA projection of the intensities learned from the training data. en the linked projections
are reconstructed and subsequently the intensities and shape. e normalized crosscorrela-
tion between the reconstruction and the original image are calculated and the transform T is
optimized to obtain maximum normalized cross-correlation. e shape corresponding to the
optimal transformation was thresholded at 0 to yield the ﬁnal segmentation.
While the original algorithm148 deﬁned “T” as an aﬃne transformation, to account for the
high variability in the prostate shape and appearance (e.g. with or without an endorectal coil),
a deformable, b-spline based transformwas used to deﬁne “T”.is resulted in a more accurate
registration than aﬃne, although further studies suggest that separate subpopulation based
models could potentially yield more accurate segmentations, given enough training data.
2.4.11 A random forest based classiﬁcation approa to prostate segmentation in
MRI - UBUdG
e method proposed by Ghose et al. 149 has two major components: a probabilistic classiﬁca-
tion of the prostate and the propagation of region based levelsets to achieve a binary segmen-
tation. e classiﬁcation problem is addressed by supervised random decision forest.
During training, the number of slices in a volume containing the prostate is divided into
three equal parts as apex, central and base regions. e individual slices are resized to a reso-
lution of 256x256 pixels and a contrast-limited adaptive histogram equalization is performed
to minimize the eﬀect of magnetic ﬁeld bias. Each feature vector is composed of the spatial
position of a pixel and the mean and standard deviation of the gray levels of its 3 x 3 neighbor-
hood. ree separate decision forests are built corresponding to the three diﬀerent regions of
the prostate the apex, the central region and the base. Only 50% of the available training data
was used for each of the regions.
During testing the ﬁrst and the last slices of the prostate are selected and the test dataset is
divided into the apex, the central and the base regions. Consecutively preprocessing is done
on in the same way as for the training images. Decision forests trained for each of the regions
are applied to achieve a probabilistic classiﬁcation of the apex, the central and the base slices.
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Finally evolution of the Chan and Vese levelsets on the so classiﬁcation ensures segmentation
of the image into prostate and the background regions.
2.4.12 Combinations of algorithms
It is well known that combining the results of multiple human observers oen leads to a beer
segmentation than using the segmentation of only a single observer134. To investigate whether
this is also true for segmentation algorithms, diﬀerent types of combinations were tried. First,
combining all the algorithm results using a majority voting approach was explored. e ma-
jority voting combination considered a voxel part of the prostate segmentation if the majority
of the algorithms segmented the voxel as a prostate voxel. Second, only the top 5 (expert) al-
gorithms were combined based on the overall algorithm score. A ‘best combination’ reference
was also included by selecting the algorithm with the maximum score per case, for both the
top 5 and all algorithms.
2.5 Results
2.5.1 Online allenge
e results of the online challenge are summarized in Tables 2.3, 2.6 and Figure 2.3. In Table
2.3 the average algorithm scores and standard deviations are presented, which are used to rank
the algorithms. e ordering of the algorithms represents the ranking aer both the online
and live challenges. e online and live components were weighted equally to determine the
ﬁnal ranking. Metric values and scores for all algorithms on the online challenge data are
presented in Table 2.6. In Figure 2.3 we provide the results per algorithm per case to give a
more complete view of algorithm robustness and variability.
2.5.2 Live allenge
Tables 2.3, 2.7 and Figure 2.4 show the results of the live challenge at the MICCAI2012 work-
shop. In Table 2.3 (column 2) the average scores for each algorithm are presented including
standard deviations. Metric values and scores for all algorithms on the live challenge data are
presented in 2.7. Figure 2.4 shows the scores per case per algorithm for the cases processed at
the live challenge. Algorithms that were unable to segment all cases during the period of the
challenge (4 hours), or produced segmentations that were considered to be a failure according
to algorithm-speciﬁc checking criteria or the group, are indicated with an asterisk in Table 2.
Unsegmented or failed cases were given a score of 0.
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Figure 2.3: Results of the online challenge. e overall score is on the vertical axis and the case number on the
horizontal axis. Teams are given a diﬀerent symbol and color. Case distributions per center were: 1:7 RUNMC,
8:14 BIDMC, 15:22 UCL, 23:30 HK.
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Figure 2.4: Results of the live challenge. e overall score is on the vertical axis and the case number on the
horizontal axis. Teams are given a diﬀerent symbol and color. Case distributions per center were: 1:5 UCL, 6:10
HK, 11:15 BIDMC, 16:20 RUNMC.
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2.5.3 Overall
e overall ranking of the algorithms is presented in Table 2.3. Additionally, the results of the
algorithm combinations are shown in Table 2.2. Furthermore, statistical analysis on the com-
plete set of case scores was also performed to determine which algorithms are signiﬁcantly
beer than other algorithms. As a test repeated measures ANOVA was used in combina-
tion with Bonferroni correction at a signiﬁcance level of 0.05. e results indicated that the
top 2 algorithms by Imorphics and ScrAutoProstate are signiﬁcantly beer then every algo-
rithm outside of the top 3. is also holds for both combination strategies. However, none
of the algorithms or combinations strategies performed signiﬁcantly beer than the second
observer. Finally, the robustness of the algorithms against multi-center data was also tested
using ANOVA, but the center did not have a signiﬁcant impact on the overall algorithm score
(p=0.118). e average scores and standard deviations for the algorithms on a per-center basis
are presented in Tables 2.4 and 2.5
Name Online Live Average
Imorphics 84.36 7.11 87.07 3.36 85.72 5.90
All combined 82.96 8.25 87.70 3.11 85.33 6.68
Top 5 combined 85.38 6.13 87.09 3.22 86.24 5.16
Maximum 87.57 3.37 88.88 1.73 88.23 2.83
Table 2.2: Results for the single best algorithm and combinations of algorithms, average over all cases including
standard deviation.
2.6 Discussion
2.6.1 Challenge setup and participation
e images used in the challenge are a good representation of what would be encountered
in a clinical seing, with large diﬀerences in acquisition protocol, prostate appearance and
size. Additionally, the images originated from diﬀerent centers and scanner manufacturers.
e training and test sets were also large enough to draw statistical conclusions on algorithm
performance.
e reference standard was constructed by 3 diﬀerent observers, who each segmented a
part of the data. ese segmentations were subsequently inspected by the experienced ob-
server for correctness and consistency. Obtaining additional observers for each case would be
preferable, however recruiting multiple observers to spend time contouring 100 prostate MR
cases is extremely challenging.
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Rank Team Name Type Online Live Average
1 Imorphics Automatic 84.36 7.11 87.07 3.36 85.72 5.90
2 ScrAutoProstate Automatic 83.49 5.92 85.08 3.54 84.29 5.10
3 CBA Interactive 80.66 6.46 81.21 9.60 80.94 7.86
4 Robarts Semi-automatic 77.32 4.04 80.08 7.18 78.70 5.51
5 Utwente Semi-automatic 75.23 10.53 80.26 7.30 77.75 9.37
6 Grislies Automatic 77.56 12.60 74.35 11.28 75.96 12.08
7 ICProstateSeg Automatic 76.06 9.40 75.74 8.81* (84.16 4.43) 75.90 9.17
8 DIAG Automatic 73.30 13.69 77.01 12.09 75.16 13.07
9 SBIA Automatic 78.34 8.22 61.38 28.22* (76.72 7.44) 69.86 18.95
10 Rutgers Automatic 65.97 13.13 71.77 11.02 68.87 12.32
11 UBUdG Semi-automatic 70.44 9.12 00.00 0.0* 35.22 9.12
- SecondObserver - 85.00 4.50 85.00 4.91 85.00 4.67
Table 2.3: Overall challenge results. e last three columns contain the scores including standard deviations.
ese scores are an average of all individual metric scores over all cases, as explained in section 2.3.2. For the
live challenge scores with an asterisk, teams had either missing or incomplete segmentations for some cases.
Incomplete or failed cases were assigned a score of 0. e scores of these groups over all completed cases is
shown in brackets. e UBUdG team did not participate in the live challenge and as such received a zero score.
RUNMC BIDMC UCL HK
Imorphics 82.55  8.72 89.05  2.29 84.78  7.52 81.44  7.41
ScrAutoProstate 85.76  3.56 86.26  3.73 83.12  4.95 79.47  8.46
CBA 76.05  7.71 80.82  6.37 83.16  6.17 82.06  4.94
Robarts 77.38  4.73 76.34  5.13 77.57  3.55 77.88  3.77
Utwente 72.52  10.27 78.85  8.11 76.50  13.02 73.16  11.46
Grislies 81.10  9.69 86.10  6.35 77.99  14.82 66.54  10.99
ICProstateSeg 72.70  10.58 82.12  4.71 77.37  7.49 72.40  11.92
DIAG 66.60  13.25 77.48  5.09 81.45  6.76 67.51  20.15
SBIA 81.02  8.77 77.04  10.41 77.31  7.32 78.15  8.19
Rutgers 63.98  14.82 67.00  11.99 69.98  11.02 62.79  16.46
UBUdG 73.17  2.88 67.52  14.90 74.31  6.39 66.73  8.33
Average 75.69  8.63 78.96  7.19 78.50  8.09 73.47  10.19
Table 2.4: Average scores and standard deviations per team over the diﬀerent centers for the online challenge.
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(d) (e) ()
(g) (h) (i)
Figure 2.5: alitative segmentation results of case 3 (a, b, c), case 10 (d, e, ) and case 25 (g, h, i) at the center (a,
d, g), apex (b, e, h) and base (c, f, i) of the prostate. Case 3 had the best, case 10 reasonable and case 25 the worst
algorithm scores on average. e diﬀerent colors indicate the results for the diﬀerent teams.
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RUNMC BIDMC UCL HK
Imorphics 86.86  3.39 88.54  4.17 86.96  3.22 85.92  3.59
ScrAutoProstate 85.06  2.26 85.44  3.03 86.39  3.67 83.44  5.44
CBA 81.32  8.52 83.11  7.88 77.86  16.87 82.53  4.59
Robarts 81.29  5.27 74.77  11.76 81.96  3.99 82.31  5.34
Utwente 80.42  5.48 79.46  7.51 80.64  10.40 80.50  8.42
Grislies 79.98  6.64 77.91  12.30 72.18  16.30 67.33  7.22
ICProstateSeg 82.75  4.67 86.36  3.18 85.60  1.71 80.25  5.83
RUNMC 61.77  15.90 81.51  6.82 83.16  5.35 81.61  3.80
SBIA 79.03  7.21 13.57  30.33 75.50  10.38 77.41  4.39
Rutgers 72.39  14.09 75.10  8.95 65.45  14.78 74.14  6.24
Average 79.09  7.34 74.58  9.59 79.57  8.67 79.54  5.49
Table 2.5: Average scores and standard deviations per team over the diﬀerent centers for the live challenge. Note
that team UBUdG did not participate in the live challenge and as such is not included here.
emetrics that were used result in a good separation between algorithms and the conver-
sion into per case scores keeps these diﬀerences intact. Other metrics were also considered,
for example the Jaccard index, sensitivity/speciﬁcity and regular Hausdorﬀ distance. Jaccard
index is a volume-based metric with similar characteristics as the Dice coeﬃcient, however,
in prostate segmentation literature, the Dice coeﬃcient is more oen used. To allow beer
comparison to existing and future literature we chose the Dice coeﬃcient. Sensitivity and
speciﬁcity are generally not useful in prostate segmentation because speciﬁcity will not be
very discriminative: the prostate is always a relative small part of the total image volume.
Finally, the modiﬁed 95% Hausdorﬀ distance was used because the regular Hausdorﬀ distance
can be harsh and sensitive to noise: a single pixel can determine overall image segmentation
outcome.
One issue with basing case scores on observer reference standards is that very high scores
end up in the realm of inter-observer variability. A score higher than 85 is probably still
indicative of improved performance, as the second observer segmentations are less accurate
than the reference standard, but it is diﬃcult to say whether a score of e.g. 94 is indeed beer
or just diﬀerent and equally accurate than a score of 92. However, in general, the algorithms in
this challenge do not obtain these scores on average, so this is not an issue. Visual inspection
of the segmentation results also conﬁrms this, the largest segmentation errors made by the
algorithms would not be made by an experienced observer.
An alternative scoring approach that is not sensitive to inter-observer variability is to rank
algorithms based on their average rank for each of the sub-scores over all algorithms (e.g. if
an algorithm has the highest average Dice of all algorithms, it will have rank 1 for Dice. If the
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Team Name Average Boundary Distance
Overall Base Apex Score (Overall) Score (Base) Score (Apex)
Imorphics 2.10  0.68 2.18  1.14 1.96  0.80 82.66  5.60 85.20  7.75 88.44  4.71
ScrAutoProstate 2.13  0.48 2.23  0.70 2.18  0.68 82.42  3.93 84.87  4.73 87.17  3.98
CBA 2.33  0.59 2.60  1.47 2.44  0.81 80.77  4.88 82.31  9.96 85.62  4.75
Robarts 2.65  0.37 2.92  0.88 3.49  0.95 78.09  3.06 80.14  5.97 79.45  5.58
Utwente 3.03  1.06 3.45  1.96 2.68  0.98 74.96  8.73 76.54  13.34 84.20  5.79
Grislies 2.96  1.55 3.19  2.00 2.46  1.26 75.55  12.80 78.35  13.59 85.50  7.42
ICProstateSeg 2.86  0.82 3.18  1.32 2.89  1.05 76.34  6.78 78.38  9.00 82.99  6.21
DIAG 3.40  1.72 4.23  3.06 2.72  1.75 71.90  14.18 71.29  20.81 84.01  10.33
SBIA 2.85  0.72 2.82  1.02 2.13  0.80 76.47  5.94 80.86  6.93 87.44  4.74
Rutgers 4.06  1.80 4.82  2.64* 3.71  1.26* 66.47  14.87 63.06  23.71 74.68  16.56
UBUdG 4.26  1.58 4.21  1.42 4.53  1.71 64.84  13.09 71.40  9.63 73.33  10.08
All combined 2.06  0.78 2.60  1.53 2.04  0.81 82.96  6.46 82.30  10.36 87.98  4.76
Top 5 combined 1.94  0.48 2.10  0.82 1.77  0.62 84.00  3.95 85.70  5.56 89.57  3.63
Maximum 1.78  0.35 1.82  0.52 1.58  0.35 85.28  2.91 87.66  3.51 90.70  2.06
SecondObserver 1.82  0.36 2.21  0.80 2.55  1.08 85.00  2.93 85.00  5.42 85.00  6.34
Team Name 95% Hausdorﬀ Distance
Overall Base Apex Score (Overall) Score (Base) Score (Apex)
Imorphics 5.94  2.14 5.45  2.58 4.73  1.68 84.20  5.70 86.98  6.15 88.84  3.97
ScrAutoProstate 5.58  1.49 5.60  2.35 4.93  1.38 85.15  3.98 86.63  5.62 88.37  3.25
CBA 6.57  2.11 6.64  4.07 5.75  1.91 82.50  5.61 84.15  9.73 86.43  4.52
Robarts 6.48  1.56 6.83  2.26 7.36  2.11 82.76  4.15 83.70  5.39 82.62  4.98
Utwente 7.32  2.44 7.69  3.75 5.89  1.93 80.52  6.48 81.64  8.94 86.11  4.57
Grislies 7.90  3.83 7.61  4.11 5.82  2.82 78.97  10.19 81.85  9.81 86.26  6.65
ICProstateSeg 7.20  1.96 7.27  2.92 6.51  2.31 80.84  5.21 82.64  6.97 84.62  5.46
DIAG 8.59  4.00 9.00  4.62 5.91  3.68 77.15  10.66 78.52  11.04 86.05  8.69
SBIA 7.73  2.68 6.99  2.25 4.60  1.31 79.43  7.14 83.32  5.37 89.14  3.10
Rutgers 9.25  3.76 9.88  4.04* 7.58  2.35* 75.37  10.00 71.18  21.41 78.82  16.23
Rutgers 9.25  3.76 9.88  4.04* 7.58  2.35* 75.37  10.00 71.18  21.41 78.82  16.23
UBUdG 9.17  3.48 9.06  2.71 9.54  3.52 75.59  9.27 78.38  6.46 77.48  8.30
All combined 5.43  2.18 6.00  3.06 4.97  1.94 85.55  5.81 85.67  7.30 88.26  4.57
Top 5 combined 5.30  1.60 5.37  2.38 4.22  1.25 85.91  4.26 87.19  5.67 90.04  2.94
Maximum 4.63  1.06 4.32  1.28 3.67  0.70 87.67  2.81 89.68  3.05 91.34  1.64
SecondObserver 5.64  1.73 6.28  2.95 6.36  2.40 85.00  4.61 85.00  7.04 85.00  5.66
Team Name Dice Coeﬃcient
Overall Base Apex Score (Overall) Score (Base) Score (Apex)
Imorphics 0.88  0.04 0.86  0.08 0.85  0.08 81.96  6.62 84.76  8.93 88.57  6.13
ScrAutoProstate 0.87  0.04 0.86  0.04 0.83  0.07 81.14  5.39 85.02  4.58 87.79  5.23
CBA 0.87  0.04 0.84  0.07 0.80  0.11 79.80  5.36 82.87  8.07 85.46  7.98
Robarts 0.84  0.03 0.81  0.05 0.71  0.12 75.32  4.25 79.77  5.82 78.70  8.84
Utwente 0.82  0.07 0.78  0.13 0.78  0.09 72.97  9.77 76.12  13.85 84.10  6.44
Grislies 0.83  0.08 0.81  0.11 0.82  0.10 75.10  12.38 79.17  11.85 86.65  7.09
ICProstateSeg 0.82  0.06 0.76  0.13 0.74  0.13 72.68  9.40 74.12  14.15 80.47  9.41
DIAG 0.80  0.09 0.71  0.22 0.79  0.12 69.62  14.20 68.38  23.42 84.82  8.77
SBIA 0.84  0.06 0.81  0.08 0.84  0.07 75.29  8.27 79.29  9.07 88.11  5.31
Rutgers 0.74  0.10 0.61  0.25 0.66  0.17 61.05  15.36 57.75  25.70 74.93  12.60
UBUdG 0.71  0.11 0.71  0.12 0.63  0.14 56.73  16.09 68.17  12.80 72.53  10.20
All combined 0.88  0.05 0.81  0.13 0.81  0.11 81.29  7.55 78.90  14.20 86.31  8.39
Top 5 combined 0.89  0.03 0.87  0.05 0.87  0.06 83.65  4.82 85.79  5.96 90.32  4.63
Maximum 0.90  0.02 0.89  0.03 0.88  0.03 85.08  3.55 88.20  3.80 91.46  2.50
SecondObserver 0.90  0.03 0.86  0.06 0.80  0.11 85.00  3.82 85.00  6.14 85.00  8.39
Team Name Relative Volume Diﬀerence
Overall Base Apex Score (Overall) Score (Base) Score (Apex)
Imorphics 2.92  15.71 1.01  19.56 0.65  30.68 72.53  25.31 84.03  16.94 84.20  16.97
ScrAutoProstate 11.53  14.05 9.65  16.52 14.08  34.25 68.18  27.94 82.67  14.82 82.52  18.44
CBA 12.75  13.99 18.85  24.88 0.41  28.63 63.48  25.38 72.51  24.00 82.04  11.91
Robarts 10.31  17.92 12.69  26.26 -3.27  39.09 61.70  28.63 70.65  18.41 74.96  15.61
Utwente 22.30  27.88 27.52  41.86 15.10  41.30 50.19  32.42 57.94  31.74 77.45  23.46
Grislies 19.81  31.93 23.12  44.71 15.46  43.71 59.25  38.47 64.73  31.20 79.31  23.00
ICProstateSeg -2.61  24.86 -4.47  35.14 -13.31  43.42 57.96  34.16 66.62  25.50 75.09  20.77
DIAG 4.66  28.30 -9.34  43.13 11.66  54.14 51.04  31.02 60.62  31.86 76.15  24.37
SBIA 16.19  25.35 13.47  30.78 11.26  35.57 51.63  35.95 67.71  23.49 81.33  21.19
Rutgers -5.83  30.81 -22.11  57.39 -16.68  46.37 52.18  30.04 44.52  31.99 71.58  24.00
UBUdG -5.16  21.40 -7.33  28.05 -14.55  33.25 59.02  24.71 69.96  16.63 77.87  16.16
All combined -10.02  14.62 -15.45  25.94 -19.44  22.45 67.17  25.33 73.19  23.89 81.67  13.00
Top 5 combined 7.63  13.45 7.32  18.53 6.37  27.31 73.70  25.02 82.15  15.60 86.50  16.37
Maximum 2.76  3.05 4.50  4.80 4.23  4.21 93.48  7.19 94.61  5.76 96.78  3.21
SecondObserver -1.87  7.32 -6.17  13.49 -16.24  21.13 85.00  9.23 85.00  9.23 85.00  13.57
Table 2.6: Averages and standard deviations for all metrics for all teams in the online challenge. Entries indicated
with an asterisk had cases with inﬁnite boundary distance measures removed from the average, which could
occur due to empty base or apex segmentation results.
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Team Name Average Boundary Distance
Overall Base Apex Score (Overall) Score (Base) Score (Apex)
Imorphics 1.95  0.36 2.45  0.65 1.83  0.53 85.53  2.70 87.12  3.41 88.21  3.39
ScrAutoProstate 2.18  0.36 2.34  0.78 2.16  0.70 83.86  2.65 87.73  4.12 86.05  4.50
CBA 2.56  0.96 2.48  1.55 119.28  522.54 81.03  7.10 86.95  8.13 80.06  21.12
Robarts 2.67  0.62 2.66  0.90 3.93  2.42 80.23  4.56 86.01  4.74 74.64  15.57
Utwente 2.87  0.79 3.47  1.33 2.43  0.72 78.79  5.87 81.76  6.96 84.32  4.62
Grislies 4.17  2.35 3.75  2.25 2.82  1.06 69.14  17.43 80.31  11.80 81.81  6.84
ICProstateSeg 2.35  0.99 2.62  1.37 1.95  0.96 82.63  7.35 86.23  7.21 87.46  6.16
DIAG 3.21  1.39 237.53  718.80 2.31  0.71 76.26  10.29 71.09  27.15 85.11  4.57
SBIA 3.13  0.74* 3.13  0.64* 2.89  1.03* 61.49  31.92 66.83  34.41 65.10  33.91
Rutgers 3.84  1.37 3.70  1.12* 4.21  1.83 71.54  10.18 72.52  25.41 72.87  11.80
All combined 1.97  0.34 2.18  0.64 1.82  0.53 85.43  2.51 88.55  3.35 88.28  3.41
Top 5 combined 1.90  0.32 2.15  0.80 1.92  0.64 85.93  2.37 88.70  4.18 87.61  4.14
Maximum 1.87  0.30 1.82  0.45 1.53  0.30 86.17  2.20 90.44  2.36 90.17  1.88
SecondObserver 2.03  0.50 2.86  1.26 2.33  1.35 85.00  3.73 85.00  6.63 85.00  8.69
Team Name 95% Hausdorﬀ Distance
Overall Base Apex Score (Overall) Score (Base) Score (Apex)
Imorphics 5.54  1.74 6.09  1.61 4.58  1.36 86.35  4.28 87.96  3.19 87.03  3.86
ScrAutoProstate 6.04  1.67 5.64  2.17 4.60  1.39 85.11  4.12 88.84  4.29 86.96  3.94
CBA 7.34  3.08 6.29  3.03 122.28  523.16 81.90  7.59 87.55  6.00 80.72  20.05
Robarts 7.15  2.08 6.12  2.14 7.76  3.20 82.38  5.12 87.89  4.22 78.01  9.06
Utwente 6.72  1.42 7.42  2.38 5.68  1.66 83.43  3.51 85.33  4.71 83.91  4.70
Grislies 11.08  5.85 8.68  4.61 6.88  2.21 72.68  14.42 82.83  9.11 80.49  6.27
ICProstateSeg 5.89  2.59 5.64  2.73 4.58  2.35 85.48  6.38 88.83  5.41 87.00  6.67
DIAG 7.95  3.21 242.13  719.85 4.74  1.34 80.40  7.91 75.30  26.69 86.56  3.79
SBIA 7.07  1.64* 7.21  1.96* 5.93  1.69* 66.05  34.07 68.59  35.35 66.54  34.40
Rutgers 8.48  2.53 242.00  719.42 7.82  2.42 79.09  6.23 75.29  26.10 77.82  6.86
All combined 5.67  1.82 5.14  1.40 4.46  1.46 86.01  4.49 89.84  2.78 87.35  4.13
Top 5 combined 5.49  1.54 5.48  2.24 4.56  1.51 86.45  3.80 89.16  4.43 87.07  4.27
Maximum 4.80  1.02 4.20  0.94 3.53  0.76 88.17  2.52 91.69  1.86 90.13  2.10
SecondObserver 6.08  2.23 7.58  3.90 5.29  2.53 85.00  5.50 85.00  7.71 85.00  7.17
Team Name Dice Coeﬃcient
Overall Base Apex Score (Overall) Score (Base) Score (Apex)
Imorphics 0.89  0.03 0.84  0.06 0.86  0.07 85.51  3.92 86.98  5.21 89.15  5.66
ScrAutoProstate 0.87  0.03 0.85  0.06 0.83  0.10 83.17  3.53 87.35  5.20 86.81  7.47
CBA 0.85  0.08 0.85  0.10 0.77  0.23 79.69  10.77 87.82  8.16 82.13  17.39
Robarts 0.84  0.04 0.84  0.06 0.67  0.22 78.82  5.40 86.62  4.90 74.31  17.27
Utwente 0.83  0.06 0.77  0.10 0.79  0.10 77.46  7.61 81.40  7.81 84.12  7.47
Grislies 0.77  0.12 0.78  0.12 0.79  0.09 70.04  16.09 81.93  9.79 83.82  7.30
ICProstateSeg 0.76  0.26 0.72  0.26 0.74  0.26 71.70  25.03 77.24  21.30 80.26  20.36
DIAG 0.80  0.07 0.63  0.30 0.82  0.07 73.81  9.43 69.73  24.09 86.18  5.71
SBIA 0.65  0.34 0.64  0.34 0.63  0.33 60.41  31.93 70.99  27.41 71.78  25.83
Rutgers 0.75  0.10 0.68  0.25 0.62  0.22 67.41  13.75 73.93  20.13 70.85  17.08
All combined 0.89  0.03 0.87  0.05 0.86  0.08 86.10  3.30 89.01  4.10 88.93  5.88
Top 5 combined 0.89  0.02 0.87  0.06 0.85  0.09 86.12  2.90 89.03  4.94 88.21  6.58
Maximum 0.90  0.02 0.89  0.03 0.89  0.03 86.51  2.47 90.97  2.82 91.90  1.97
SecondObserver 0.89  0.03 0.82  0.10 0.81  0.15 85.00  4.18 85.00  8.32 85.00  11.56
Team Name Relative Volume Diﬀerence
Overall Base Apex Score (Overall) Score (Base) Score (Apex)
Imorphics -1.50  9.15 -8.31  18.08 -1.03  23.97 86.31  13.01 87.15  7.70 87.55  10.37
ScrAutoProstate 10.05  11.56 7.77  22.01 9.59  30.51 73.96  17.56 86.55  11.38 84.60  15.29
CBA 12.26  17.73 24.75  41.69 -7.05  39.63 63.49  24.70 81.63  24.91 81.50  20.08
Robarts -1.72  17.47 5.30  25.52 -29.19  37.14 71.84  21.87 86.46  14.29 73.77  18.61
Utwente 12.62  22.25 20.75  37.43 0.66  28.70 62.15  30.81 75.02  20.62 85.40  12.77
Grislies 43.13  65.32 36.41  58.73 7.23  38.19 37.72  40.30 72.42  29.35 79.01  15.76
ICProstateSeg -8.49  34.17 -14.15  34.88 -14.88  36.55 69.10  29.32 81.82  22.02 80.77  18.68
DIAG -12.34  18.38 -38.10  32.87 1.61  28.65 64.59  25.81 70.54  24.65 84.60  11.74
SBIA 6.55  59.45 2.66  57.32 12.12  68.31 30.65  34.34 64.84  24.89 62.50  28.06
Rutgers -14.59  26.52 -24.79  31.88 -24.37  47.01 50.76  27.17 76.87  20.18 72.31  22.95
All combined 2.69  9.75 -0.16  13.09 -2.25  24.49 83.77  12.66 91.64  5.14 87.48  10.93
Top 5 combined 4.69  9.95 6.89  20.16 -3.07  26.74 82.19  13.65 88.57  11.35 86.10  11.74
Maximum 1.80  1.43 3.65  3.24 3.58  3.99 96.28  2.94 97.21  2.47 97.52  2.74
SecondObserver -5.72  7.44 -17.49  18.12 -17.97  22.90 85.00  12.07 85.00  11.93 85.00  13.03
Table 2.7: Averages and standard deviations for all metrics for all teams in the live challenge. Entries indicated
with an asterisk had cases with inﬁnite boundary distance measures removed from the average, which could
occur due to empty segmentation results.
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same algorithm has rank 5 for average boundary distance over all algorithms, his average total
rank would be 3). is approach has its own disadvantage, e.g. high ranks do not mean good
segmentations and algorithm ranking is not only based on the performance of the algorithm
itself, but also on the results of other algorithms, i.e. a new algorithm which does very poorly
on all metrics except one might inﬂuence the ranking of all other algorithms by changing their
average rank.
Participation in the initial phase of the challenge was similar to what we have seen in
other segmentation challenges, for example113 and the knee cartilage segmentation challenge
(SKI10, http://www.ski10.org). e literature on prostate segmentation is well represented
by the competing algorithms, which include active shapemodels, atlas-basedmethods, paern
recognition algorithms and variants.
We speciﬁcally chose to allow only single submissions per algorithm instead of allowing
each group to submit results with diﬀerent parameter seings, to make sure there would be
’no training on the test set’.
2.6.2 Challenge results
All algorithms submied to the challenge produced reasonable to excellent results on average
(online and live challenge combined scores ranging from 68.97 - 85.72). One point to note is
that although some algorithms may have received the same average score, the variability can
diﬀer substantially, as shown in Tables 2.6, 2.7 and 2.3. For example, the algorithm presented
by Robarts140 scored 77.32 and 80.08 in the online and live challenge respectively, but has a very
low variability: 5.51 score standard deviation overall. is is much lower than the algorithms
that had similar scores, for example 7.86 for CBA132 and 9.37 for Utwente143. Depending on
the purpose for which an algorithm is used in the clinic, this can be a very important aspect.
As such, it might be good to incorporate performance variability directly in algorithm ranking
in future challenges.
It is worth noting that the top 2 algorithms by Imorphics126 and ScrAutoProstate129 were
completely automatic and even outperformed the completely interactive method presented by
CBA. Whereas the algorithm by Imorphics performed best overall, the algorithm by ScrAuto-
Prostate should be noted for its exceptionally fast segmentation speed (2.3 seconds, Table 2.8),
the fastest of all algorithms. Further details about interaction, implementation details and
computation time can be found in Table 2.8. Algorithm computation times varied, with the
active shape model based approaches oen having computation times in the order of minutes,
whereas the atlas based approaches required substantially more time or computing power
(e.g. clusters, GPU). It is important to note that some algorithms were implemented in higher
level programming languages like Matlab, whereas some where implemented in low-level lan-
guages like C++, computation time is thus not only dependent on algorithm eﬃciency but also
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on the development platform.
Inspecting the illustrative results in Figure 2.5 one can see that algorithms can diﬀer quite
substantially per case. In this ﬁgure we present the best, worst and a reasonable case with re-
spect to average algorithm performance. Case 25 was especially tricky as it had a large area of
fat around the prostate, especially near the base which appears very similar to prostate periph-
eral zone. Most algorithms oversegmented the prostatic fat, and as the prostate was relatively
small, this results in large volumetric errors. However, if one inspects case 25 carefully, it is
possible to make the distinction between fat and prostate, especially if you go through the
diﬀerent slices. It is thus no surprise that the interactive segmentation technique of CBA per-
formed the best. Further inspection of the results shows that in the cases with low average
algorithm performance the interactive method is usually the best algorithm (e.g. (Figure 2.3):
cases 4, 16 and 21 of the online challenge). is indicates that these cases cause problems for
automated methods.
In this challenge we explicitly included segmentation results at the base and the apex of
the prostate into the algorithm scoring because these areas are usually the most diﬃcult to
segment. is can also be observed in the results, especially Tables 2.6 and 2.7. Every algorithm
performed worse on the apex and base if we look at the metric values (especially the Dice
coeﬃcient and the relative volume diﬀerence) themselves; however, as these areas are also the
most diﬃcult for the human observer, the scores for apex and base tend to be higher than the
overall score. Interesting to note is that the top 2 algorithms outperform the second observer at
almost every metric for both apex and base, whereas the overall score is lower than the second
observer. For the live challenge the Imorphics algorithm even outperforms the second observer
in the overall score. is indicates that for this part of the prostate automatic algorithms might
improve over human observers.
Interestingly, similar to the SLIVER07-challenge, active shape based algorithms seemed to
give the best results (places 1, 2, 4 and 5), although two of these systems are semi-automatic.
Looking at the results in more detail, we can see that the atlas based systems comparatively
have more trouble with cases which are not well represented by the training set, for example
case 23, which has a prostate volume of 325 mL, while the average is around 50 mL.
One interactive method was included (team CBA) which on average scored 80.94, which is
considerably lower than the second observer. is is mostly caused by over-segmentation at
the base of the prostate, oen the seminal vesicles were included in the prostate segmentation.
us this algorithm is very dependent on the operator; in principle the algorithm should be
able to get close to expert performance given an expert reader.
ere were several semi-automatic algorithms (e.g. Robarts, UTwente and UBUdG) which
needed manual interaction to initialize the algorithms. e interaction types and the inﬂuence
this interaction has on segmentation accuracy will diﬀer between the algorithms. Although
none of the teams have explicitly tested the robustness to diﬀerent initializations, some gen-
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eral comments can be made. For the Robarts algorithm a number of points on the prostate
boundary have to be set (8 to 10) to initialize a shape and the initial foreground and back-
ground distributions. As such, the algorithm is robust to misplacing single points. For the
Utwente algorithm, the prostate center has to be indicated to initialize the active appearance
and shape models. Big deviations in point selection can cause problems for active appearance
and shape models, however in general they are prey robust against small deviations128. For
the UBUdG method, the user has to select the ﬁrst and last slice of the prostate. As such, the
algorithm will be unable to segment the prostate if it extends beyond those slices, which is an
issue if users cannot correctly identify the start and end slice of the prostate.
Another aspect which plays a role in this challenge was the robustness of the algorithms
to multi-center data. e image diﬀerences between the centers were actually quite large,
especially between the endorectal coil and non-endorectal coil cases, as can be seen in Figure
2.1. Diﬀerences include coil artifacts near the peripheral zone, coil proﬁles, image intensities,
slice thickness and resolution. However, if we look at for example Tables 2.4, 2.5 and Figure
2.3, it can be seen that all submied algorithms are at least reasonably robust against these
diﬀerences. We could not ﬁnd any signiﬁcant diﬀerences in the performance of the algorithms
relative to the diﬀerent centers using ANOVA (p=0.118).
We also investigated whether segmentation performance could be improved by making
several algorithm combinations. First, a majority voting on the segmentation results of all
algorithms and the top 5 best performing was calculated. Second, to get a reference for the
best possible combination we took the best performing score per case. e summary results
of these combinations can be found in Table 2.2. Taking the best results per case results in
a substantially beer average score than the best performing algorithms. is might be an
indication that certain cases might be beer suited to some algorithms, and as such, that algo-
rithm selection should be performed on a case-by-case basis. e combinations of algorithms
using majority voting also shows that given the correct combination, algorithm results can
be improved (84.36 to 85.38 for the online challenge and 87.07 to 87.70 for the live challenge).
Although the increase in score is small, it is accompanied by a reduction of the standard devi-
ation (for the top 5 combination strategy, Table 2.2), as the improvements especially occur in
poor performing cases. ese scores and the reduction in standard deviation thus show that
combining algorithms might result in more robust segmentation. ese scores also show that
there still is room for improvement for the individual algorithms. How to combine and which
algorithms to combine is a nontrivial problem and warrants further investigation.
Finally, to assess the statistical signiﬁcance of diﬀerences in algorithm performance we
used repeated measures ANOVA with Bonferroni correction. e methods by Imorphics and
ScrAutoProstate perform signiﬁcantly beer than all the algorithms outside of the top 3 (p <
0.05).
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Team Name Avg. time System MT GPU
Imorphics 8 minutes 2.83GHz 4-cores No No
ScrAutoProstate 2.3 seconds 2.7GGz 12-cores Yes
CBA 4 minutes 2.7GHz 2-cores No No
Robarts 45 seconds 3.2GHz 1-core, 512
CUDA-cores
No Yes
Utwente 4 minutes 2.94GHz 4-cores Yes No
Grislies 7 minutes 2.5GHz 4-cores No No
ICProstateSeg 30 minutes 3.2GHz 4-cores, 96
CUDA-cores
No Yes
DIAG 22 minutes 2.27GHz 8-cores No No
SBIA 40 minutes 2.9GHz, 2 cores No No
Rutgers 3 minutes 2.67GHz, 8-cores Yes No
UBUdG 100 seconds 3.2GHz 4-cores No No
Team Name Availability Remarks
Imorphics Commercially available (http:
//www.imorphics.com/).
ScrAutoProstate Not available No
CBA Binaries available at: http://www.cb.uu.
se/~filip/SmartPaint/
Fully interactive painting
Robarts Available at http://goo.gl/ZAbPpC User indicates 8 to 10 points on prostate sur-
face
Utwente Not available User indicates prostate center
Grislies Not available
ICProstateSeg Not available
DIAG Registration algorithm available on http:
//elastix.isi.uu.nl/
Runs algorithm on a cluster of 50 cores, av-
erage time without cluster 7 minutes per at-
las
SBIA Registration algorithm available on
http://www.rad.upenn.edu/sbia/
software/dramms/
Runs algorithm on a cluster of 140 cores, av-
erage time without cluster 25 minutes per
atlas
Rutgers Not available
UBUdG Not available User selects ﬁrst and last prostate slice
Table 2.8: Details on computation time, interaction and computer systems used for the diﬀerent algorithms. If
algorithms where multi-threaded (MT) or used the GPU this is also indicated.
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2.7 Future work and concluding remarks
Although in general the segmentation algorithms, especially the top 2, gave good segmenta-
tion results, some challenges still remain. As we could see in case 25 (Figure 2.5), algorithms
sometimes struggle with the interface between the prostate and surrounding tissue. is is
not only true for peri-prostatic fat, but also for the interface between the prostate and the
rectum, the bladder and the seminal vesicles. Part of these challenges could be addressed by
increasing through-plane resolution, but integration of these structures into the segmentation
algorithms might also improve performance. Examples included coupled active appearance
models150 or hierarchical segmentation strategies151. Furthermore, the enormous volume dif-
ferences that can occur in the prostate can also be problematic: case 23 had a volume which
was approximately 6 times as large as the average. Automatically selecting appropriate atlas
sets or appearance models based on an initial segmentation could be a solution. In the diﬃcult
cases the interactive segmentation method of team CBA was oen the best. is shows that
automated performance could still be improved.
Future work on prostate segmentation might also focus on the segmentation of related
prostatic structures or substructures. Examples are segmentation of the prostatic zones (tran-
sition, central and peripheral), the neurovascular bundles or the seminal vesicles.
Solving these remaining issues might lead to algorithms which, for any case, can replace
the tedious task of manually outlining by humans without any intervention. Until we are at
that level, the challenge itself will remain online for new submissions and can thus be used
as a reference for algorithm performance on multi-center data. As such it could lead to more
transparency in medical image analysis.
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3.1 Introduction
Prostate cancer is a major health problem in the Western world, with one in six men af-
fected during their lifetime152. Multi-parametric magnetic resonance imaging (MPMR) has
been shown to play an important role in the diagnosis of prostate cancer32. A typical MR
exam contains T2-weighted, dynamic-contrast-enhanced and diﬀusion-weighted imaging. In-
terpretation of MPMR prostate studies is challenging, and therefore the use of computer-aided
diagnosis techniques has been investigated88. For correct interpretation of MPMR knowledge
about the zonal anatomy of the prostate is required, because the occurrence and appearance
of cancer is dependant on its zonal location95. From a radiological point of view the prostate is
usually considered to have two visible zones onMRI, the central gland (CG) and the peripheral
zone (PZ)153. We are exploring options to integrate knowledge about the zonal anatomy into
CAD systems. For this automated segmentation of the zones is the ﬁrst step. e availability
of zonal segmentation is also mandatory for those CAD methods in literature that focus on
the PZ only, as for example in88.
Although much research has been done on prostate segmentation108,110, only recently the
ﬁrst study on segmentation of the individual zones was published by Makni et al.154. In their
study they investigated the use of an evidential C-means clustering (ECM) approach to cluster
voxels into their respective zones. In addition, they extended the ECM approach to incorporate
the spatial relation between voxels. Using this method they obtained good results on their
data set (0.87  0.04 mean Dice coeﬃcient for the central gland compared to a simultaneous
truth and performance level estimation (STAPLE) obtained ground truth134). To the best of
the authors knowledge their paper remains the only published paper evaluating prostate zone
segmentation.
e purpose of this paper was to investigate a paern recognition algorithm to segment
the prostate zones. e paern recognition approach uses several image features with a voxel
classiﬁer to detect the zones. is is a method that has been explored in many other segmen-
tation problems. We compare it to a multi-parametric multi-atlas approach which is used to
simultaneously segment the prostate and the prostate zones. Additionally, we will compare
our results to inter-observer variability and the results obtained by Makni et al.154
3.2 Methods
3.2.1 Multi-parametric multi-atlas segmentation
Multi-atlas segmentation is an accurate method for prostate segmentation, as has been shown
by Klein et al.108 We have chosen a similar approach, but extended it to use multi-parametric
data. We evaluated the atlas method with both majority voting and STAPLE134 to obtain the
ﬁnal binary segmentation.
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(a) (b)
(c) (d)
(e) ()
Figure 3.1: Example data set with T2-W image and ADC map in a and b and segmentation results in c, d, e
and f. Figure c shows a central gland observer segmentation (red, cyan and green contours for observer 1,2
and 3). Figure d shows the corresponding peripheral zone segmentation. Figures e and f show the automatic
segmentation results for the central gland and peripheral zone respectively. Contours are colored red, cyan
and green for atlas (voting), atlas (STAPLE) and voxel classiﬁcation respectively, the STAPLE constructed ’true’
segmentation is overlayed in yellow
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e registration of the atlases to the new case is performed using the elastix soware pack-
age155. For the registration we use local normalized mutual information as a similarity metric.
We register both the T2-weighted image and the quantitative apparent diﬀusion coeﬃcient
(ADC) map simultaneously. We chose to add the ADC map to the registration because it
contains additional information on the zonal distribution within the prostate. In a previous
experiment we investigated the added value of the ADC in zonal segmentation and we noticed
that it improved performance. e cost function we then optimize can be expressed as
C(T; IF, IM) = 1PN
i=1!i
NX
i=1
!iC(T; IiF, IiM) (3.1)
were C is the cost function, T is the registration transformation, IF is the ﬁxed (the unknown
case) and IM the moving image (the atlas). Furthermore, !i is the weight for each of the
multi-parametric images i were i = 1 is the T2-weighted image and and i = 2 is the ADC
map. We chose! to be 0.5 for both i.
e registration consists of two distinct steps. In the ﬁrst step we register using only a
translation transform to align the images to the new case. e second step is an elastic regis-
tration using a b-spline transformation. Aer the registration the obtained transformation is
used to transform the known binary segmentation to the target image space. ese can sub-
sequently be used to construct the unknown binary segmentation. Several approaches exist
in literate, of which majority voting is the simplest and best known method108. We compare
this approach with optimizing the segmentation by using STAPLE134.
3.2.2 Voxel classiﬁcation segmentation
For the voxel classiﬁcation segmentation we determined a set of features that represent the dif-
ference between the two zones. ese features can be separated into three categories: anatomy
(positional), intensity and texture.
For the anatomy features we use the information we know from the normal prostate com-
position. e peripheral zone is usually situated at the dorsal side of the prostate, geing
thicker towards the apex of the prostate. We chose to model this by developing a set of three
relative position and distance features. Given the whole prostate mask we can calculate a
relative position in each direction for each voxel, resulting in a value between 0 and 1. We
calculate this feature in the ventrodorsal direction and the craniocaudal direction. In addition,
the relative distance (also between 0 and 1) to the prostate boundary is given as a feature.
Two intensity features are included in the voxel classiﬁcation step. e ﬁrst intensity fea-
ture we use is the apparent diﬀusion coeﬃcient (ADC) for each voxel, which itself should be
a quantitative feature. e second intensity feature we use is a calculated T2 value for each
voxel. Using the T2 relaxation time instead of the T2-weighted voxel values will make this
feature much more robust to changes in scan parameters. To this end we used the following
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signal model equation for turbo-spin-echo sequences:
T2p = -TE
 
log e-TET2m S
PD
m S
T2W
p
ST2Wm SPDp
!-1
(3.2)
Here T2 is the estimated T2 relaxation time, TE is the echo time for the MR pulse sequence, S
the signal intensity. e superscript PD and T2W represent either the proton density weighted
image or the T2-weighted image. e subscript p and m denote prostate and muscle respec-
tively. Using this equation and a region of interest placed in a skeletal muscle we can calculate
the true T2 relaxation time for each voxel given the proton density and T2-weighted images.
e muscle ROI is automatically selected using a search method. Starting from the boom
slice of the T2-weighted image an Otsu threshold is performed to separate the dark areas
(including the muscles) from the bright areas. We are looking for the two muscles alongside
the prostate, sowe suppress the center of the imagewith a rectangular block. en a connected
component analysis is used to ﬁnd individual dark components in the image. e two largest
connected components should correspond to the le and right muscle. We make sure this
is the case by investigating the shape and symmetry of the two connected components. e
muscle are less wide than long and they should have approximately the same shape on the le
and right. We mirror the le connected component and investigate the Jaccard index with the
right connected component. e minimum value for width divided by the length is 0.75 and
the threshold for the Jaccard index is 0.5. e resulting connected components are eroded to
ensure that the ROI is completely in the muscle.
e third set of features consists of ﬁve texture features. e ﬁrst two features are homo-
geneity and correlation calculated using the co-occurrence matrix156. We used 16 gray value
bins for the histogram and took the average over all 2D directions. e third and fourth feature
are entropy and texture strength, based on the Neighborhood Gray-Tone Diﬀerence Matrix157.
Here also 16 gray level bins were used, in combination with an evaluation distance of 1. For all
of these features the kernel size was 10x10x1 voxels. e ﬁh feature was the local binary pat-
tern at each voxel158, which was calculated over a 3x3x1 voxel neighborhood. For this feature
the images were down-sampled using Gaussian re-sampling such that a 3x3x1 neighborhood
corresponded to a 12x12x1 neighborhood.
Aer calculating the features a balanced training set is constructed. Hard classiﬁcation us-
ing a linear discriminant classiﬁer is performed to obtain a binary segmentation of the central
gland. To smoothen the initial boundary some post-processing is performed. Firstly, con-
nected component analysis is used to select the largest connected component. Erosion and
dilation are then performed to remove small objects aached to the segmentation. Finally the
edge voxels between the central gland and the peripheral zone are selected and a thin plate
spline is ﬁed through these voxels. is results in our ﬁnal segmentation.
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3.3 Validation
For validation we used 48 multi-parametric MR studies with manual segmentations of the
whole prostate. For each case the transversal T2-weighted scan (resolution 0.6x0.6x4 mm)
and the apparent diﬀusion coeﬃcient map (2x2x4 mm) were used. In addition, for the voxel
classiﬁcation step, the proton density weighted image was used to calculate the T2 values. e
ADC and proton density images were inspected to assess the alignment with the T2-weighted
image. If needed, they were corrected to obtain good alignment.
e ground truth was constructed by STAPLE134 to merge the manual segmentations done
by three observers. e observers made manual segmentations by indicating the zonal bound-
ary on each T2-weighted image slice given the the manual whole prostate segmentation. We
validated the automatic segmentations by calculating three similarity measures: the Jaccard
index (JI), the Dice similarity coeﬃcient (DSC) and the volume diﬀerence (VD). e Jaccard
index is given as J = jV1\V2j
jV1[V2j , were V1 and V2 are the automated segmentation and the STAPLE
ground truth respectively. e Dice coeﬃcient is similar to the Jaccard index and can be ex-
pressed as D = 2jV1\V2j
jV1j+jV2j . Lastly, the volume diﬀerence can be expressed as VD = jV1j - jV2j.
Validation was performed in a leave-one-out-manner, thus the case to be segmented was re-
moved from the set of atlases for the atlas method and from the training data for the voxel
classiﬁcation.
3.4 Results
In ﬁgures 3.2a, 3.2c and 3.2e the results of the segmentations of the central gland are presented.
An example case is also shown in ﬁgure 3.1. We can see that the observers all performwell with
respect to the STAPLE ground truth. For the segmentation methods the voxel classiﬁcation
approach outperforms the atlas based methods (mean DSC 0.89  0.03 vs 0.80  0.013 for
majority voting and 0.80 0.17 for STAPLE), although it is not as good as the human observers
(mean DSC’s 0.95  0.06, 0.97  0.05, 0.96  0.06). e JI and VD (ﬁgure 3.2b and ﬁgure 3.2c)
show similar results. e VD results show that our methods in general under-segment the
central gland. If we compare our results to those in Makni et al.154 we perform slightly beer
using our voxel classiﬁcation approach, as they report a mean DSC of 0.87  0.04. For the
peripheral zone we see similar results (ﬁgures 3.2b, 3.2d and 3.2f). Our paern recognition
approach outperforms the atlas based method and is relatively close to the observer scores.
Here the paern recognition approach has a mean DSC of 0.75  0.07 compared to 0.82 
0.15, 0.89  0.12 and 0.86  0.11 for the observers. e atlas methods both perform poorly
with respect to the peripheral zone with a mean DSC of 0.57 0.19 and 0.48 0.22. Compared
to the state of the art we perform slightly worse, with a mean DSC of 0.76 0.06 compared to
our 0.75  0.07.
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Figure 3.2: Results of the segmentation methods. e captions on the x-axes correspond to observers 1, 2 and 3,
the atlas method using majority voting, the atlas method using STAPLE and the voxel classiﬁcation approach.
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3.5 Discussion
In this paper we investigated a paern recognition approach to zonal segmentation of the
prostate. We compared our method to an atlas based method and to the method published by
Makni et al. Our results show that the voxel classiﬁcation method outperforms the atlas based
method. It also shows similar performance compared to the method published by Makni et
al. We believe the paern recognition approach outperforms the atlas-based method because
it is less restrictive as an atlas, which is limited to the shapes available within the atlases.
Additionally, paer recognition allow for non-linear combination of all features, including
texture features.
is study also has limitations. A true comparison with the results from Makni et al. is
diﬃcult, mostly due to diﬀerences in the data used, for example in resolution. Additionally,
for the atlas method we did not use the manual whole prostate segmentations because this
method segments the whole prostate and the zones at the same time. is might cause some
bias compared to the voxel classiﬁcation approach were we did use the whole prostate manual
segmentation. We did investigate using the manual whole prostate mask for the atlas method
by only evaluating the registration metric within the mask. However, this approach gave
worse results than not using the whole prostate mask at all. Both methods performed worst
when the peripheral zone is very thin, then partial volume eﬀects and unclear boundaries
between the zones make it diﬃcult to segment them. Finally, our voxel classiﬁcation approach
might be improved by incorporating additional texture features (e.g. Gaussian or Gabor based
texture features) or by incorporating global information like prostate volume154.
Summarizing, a new paern recognition approach to segment the prostate zones was pre-
sented, incorporating anatomical, intensity and texture features. It outperforms an atlas based
method, is relatively close to the inter-observer performance and shows similar performance
compared to the state of the art.
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4.1 Introduction
MRI is becoming an increasingly popular tool for prostate cancer diagnosis31,32,44,49, leading to
the release of standardized guidelines for acquiring, reading and reporting prostate MRI by the
European Society of Urogential Radiologists (ESUR): the Prostate Imaging and Reporting Data
Standard (PIRADS)33. Initial results on reporting prostate MRI using the ESUR guidelines have
been promising, both with respect to overall performance and inter-reader agreement58–60,62.
However, these initial studies have also shown a large trade-oﬀ between sensitivity and speci-
ﬁcity, depending on the PIRADS score used as a threshold for biopsy58,59,62.
In a recent publication by Rosenkrantz et al.159, 5 out of the 10 named pitfalls in prostate
MRI are related to benign confounders, i.e. benign disease mimicking the appearance of can-
cer. Some typical confounders are prostatic intra-epithelial neoplasia (PIN), atrophy, inﬂam-
mation and benign prostatic hyperplasia (BPH). For example, it is well known that the ap-
parent diﬀusion coeﬃcient (ADC) obtained from diﬀusion-weighted imaging (DWI) is a very
capable feature in identifying cancer in the peripheral zone51,160. However, it is much more
diﬃcult to use in the transition zone103,161, where the presence of BPH, which tends to have
similar appearance to adenocarcinoma on ADC maps, is a major confounder. Additionally,
prostatitis and other inﬂammatory processes within the prostate have been known to cause
similar appearance to cancer on dynamic-contrast enhanced (DCE) MRI162. Improved under-
standing of the imaging characteristics of these confounders across MRI parameters might
help radiologists improve their diagnostic ability.
Previous research has only peripherally focused on identifying discriminatory features to
separate cancer from speciﬁc confounders163–166. Oto et al. investigated the use of the appar-
ent diﬀusion coeﬃcient (ADC) to diﬀerentiate between central gland tumors and glandular
and stromal hyperplasia by visually registering the pathology slides to the MR images. ey
were able to achieve an area under the curve of 0.78 and 0.99 for diﬀerentiation of stromal and
glandular hyperplasia and prostate cancer, respectively. Liu et al. designed a bi-exponential
diﬀusion model using 10 b-values to characterize central gland lesions as prostate cancer and
BPH. ey found that the bi-exponential model (AUC of 0. 92 for ADCs) signiﬁcantly im-
proved the discriminative performance of DWI compared to a mono-exponential model (ADC
of 0.8 for ADC). Chesnais et al. used a multi-parameter approach to diﬀerentiate central gland
nodules. ey found that the T2-weighted features and the ADC values appeared to play a
substantial role in characterizing central gland nodules and that DCE imaging did not seem to
provide complementary information. However, they did not evaluate the accuracy of diﬀerent
feature subsets.
e goal of this work is to identify the best combination of MRI parameters and computer-
extracted features for each pair-wise classiﬁcation task, i.e. cancer vs. BPH, PIN, inﬂammation
and atrophy, respectively. is approach has recently seen successful application in discrim-
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inating diﬀerent types of breast cancer167. Our hypothesis is that each confounding class
requires a distinct set of features to be able to discriminate it from prostate cancer successfully
and that this pair-wise classiﬁcation approach will yield improved discriminability compared
to a monolithic classiﬁer aempting to distinguish cancer from all benign classes simultane-
ously.
4.2 Materials and methods
4.2.1 Patient data
Pre-operative multi-parametric MRIs and radical prostatectomy specimens were included ret-
rospectively for 70 patients at the Radboud University Nijmegen Medical Centre. MRIs were
acquired between January 1st 2009 and June 1st 2013. e Institutional Review Board waived
the need for informed consent.
4.2.2 MRI acquisition
MRI acquisition was performed using a 3 Tesla MRI scanner (either a TrioTim or a Skyra;
Siemens, Erlangen, Germany). Cases were acquired both with and without an endorectal coil.
A pelvic phased array coil was always used. e multi-parametric protocol consisted of three
T2-weighted images in orthogonal directions, diﬀusion-weighted imaging (three b-values av-
eraged over three orthogonal directions, 50, 400-500 and 800) and dynamic contrast-enhanced
imaging (15 mL of Dotarem; Guerbet, France). e transversal T2-weighted images were
acquired perpendicular to the rectal wall, the diﬀusion-weighted imaging and the dynamic
contrast-enhanced imaging were acquired in the same orientation. Further acquisition details
can be found in Table 4.1.
4.2.3 Prostatectomy slide selection and annotation
staining the specimens were evaluated by one expert urological pathologist (C.H.v.d.K, with 20
years of experience). e pathology slides were cut in the same orientation as the acquisition
of the transversal MRI to remove angulation errors in subsequent registration steps. Tumors
were outlined on the microscopic slides and subsequently transferred to the macroscopic pho-
tographs of the specimens.
e H&E stained slide containing the tumor with the highest Gleason score was selected
to be digitized using a digital slide scanner (VS120-S5, Olympus, Japan) at 10x or 20x, cor-
responding to a resolution of 0.6 um and 0.3 um respectively. If multiple slices contained a
tumor with the same Gleason grades, the slice with the largest tumor volume was digitized.
Approximately half of the specimens were whole-mount slides, the other half consisted of
parts (usually two or four). In case the specimen consisted of parts, all parts belonging to
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PS SR ST NS ET RT FA Other
T2W Turbo
spin-
echo
0.28 – 0.6
mm
3.0 – 4.0
mm
13 - 19 101 – 104
ms
3540 –
6840 ms
120 - 160 Acquired in three orthogo-
nal directions: transversal,
sagial and coronal.
DWI Echo pla-
nar
1.6 - 2
mm
3 mm - 4
mm
15 - 20 61 – 81
ms
2300 –
3600 ms
90 3 b-values: 50, 400 – 500, 800
averaged over 3 directions.
Apparent diﬀusion coeﬃ-
cient map calculated by the
scanner soware. Some
scans also include b-value 0.
DCE Turbo
Flash
1.5 – 1.8
mm
3.2 – 5
mm
12 - 15 1.41 -
1.47 ms
36 ms 10 - 14 Temporal resolution of 3.38
– 4.65 seconds, 36 – 50
timepoints. 15 mL contrast
agent used (Dotarem, Guer-
bet, France)
Table 4.1: MRI sequence details for the diﬀerent types of acquisitions. PS = pulse sequence, SR = spatial resolution,
ST = slice thickness, NS = number of slices, ET = echo time, RT = repetition time, FA = ﬂip angle.
one slide were digitized. Aer digitization the digital slides were annotated using the Aperio
ImageScope soware (Aperio, USA) for the presence of cancer, BPH, PIN, atrophy or inﬂam-
mation by one of two urological pathologists (N.S. with 8 years of experience or R.E. with 7
years of experience).
4.2.4 Co-registration of prostatectomy specimens and MRI
Tomap the annotations on the histopathology sections to the corresponding MRI sections, the
MRI and the pathology slide have to be registered. First, the slice in the MRI corresponding to
the prostatectomy slide has to be established168. e number of slices in the MRI the prostate
was visible on were counted. Subsequently, the number of slides in the prostatectomy was
counted. Using the number of the prostatectomy slide the most likely corresponding MRI
slice is then given as:
SMR =
TMR
TP
SP (4.1)
where SMR is the slice number in the MRI, TMR the total number of prostate slices in the MRI,
TP the total number of prostate slices in pathology and SP the slice number of the selected
pathology slice. is is similar to the approach presented by Hambrock et al.51. e selected
MR and pathology slices where subsequently visually assessed for correspondence by a med-
ical imaging researcher (G.L., four years of experience with prostate MRI) and corrected if
deemed necessary. Aer establishing the corresponding slice it was registered to the MRI us-
ing an interactive b-spline elastic registration method, which has successfully been applied in
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a number of studies94,95. To drive the registration corresponding points on the boundary of the
prostate on the MRI and the pathology were selected by a medical imaging researcher (G.L.,
four years of experience with prostate MRI). Aer the corresponding points were established,
the registration algorithm mapped the prostatectomy slide and the annotations to the corre-
sponding MRI section. During selection of the boundary points, the researcher was blinded to
the pathology annotations. An example of the process is illustrated in Figure 4.1.
4.2.5 Computer-extracted features
Following co-registration, a number of MRI and computer-extracted features were obtained
fromwithin the regions corresponding to the cancer, BPH, PIN, atrophy and inﬂammation. To
obtain a single feature vector per region of interest (ROI) mapped onto the MRI, the median
value of each feature across the voxels within the ROI is calculated. All features are calculated
in 2D, as we register a single prostatectomy slide to the MRI, resulting in 2D annotations. A
listing of these features and their associated descriptions can be found in Table 4.2.
Category Feature name Calculated on Parameters
Intensity
T2Ws 169 T2W (Transversal)
ADC DWI
b800 DWI
Texture
2D multi-scale Gaussian
derivatives
T2Ws Up to 2nd order, =2.0, 2.7,
4.1 and 6.0mm
2D multi-angle Gabor T2Ws =0, 4 , 2 , 34 . =2, 3 and 4
mm
2D Li multi-scale blob-
ness 170
T2Ws, ADC, b800, Ktrans,
kep, ve, time-to-peak, max-
imum enhancement, wash-
out rate
=2.0, 2.7, 4.1 and 6mm
Pharmacokinetic
Time-to-peak 55 DCE
Maximum enhancement 55 DCE
Wash-out rate 55 DCE
Ktrans 57 DCE
ve
57 DCE
kep 57 DCE
Table 4.2: Overview of all the features that are used in this paper including references to the relevant papers.
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MR intensity features
MR intensity features are extracted from the transversal T2-weighted image volume and the
diﬀusion-weighted imaging. In T2-weighted imaging the non-standardness of the MR intensi-
ties, especially between endorectal coil and non-endorectal coil cases, can cause problems for
quantitative computerized analysis. As such we developed a method which uses MR pulse se-
quence equations, a proton-density-weighted image and an automatically segmented muscle
ROI to remove most of the T2-weighted intensity non-standardness169.
In addition to the standardized T2-intensity we included the apparent diﬀusion coeﬃcient
(ADC) as a feature in combination with the image intensity of the b800 image.
Texture features
We calculated several popular texture ﬁlters, namely Gaussian derivatives and Gabor features,
which have shown to be successful in discriminating prostate cancer from other tissue in previ-
ous studies94,95. To make sure these feature do not also suﬀer from intensity non-standardness
we calculated them on the standardized T2W image.
Furthermore, to assess the focality of lesion appearance on the diﬀerent MRI parameters,
several blobness features were calculated using the techniques presented by Li et al170. Pa-
rameter seings for these features are listed in Table 4.2.
Pharmacokinetic features
DCE MRI has been shown to diﬀerentiate between inﬂammation and prostate cancer relative
to normal tissue162. In clinical diagnosis oen the shape of the enhancement curve is used to
assess lesion malignancy. However, several groups have developed methods to more quanti-
tatively evaluate the tissue curves, including pharmacokinetic modelling55,162,171. We use the
methods presented by Huisman et al.55 and Vos et al.57 to calculate pharmacokinetic features.
4.2.6 Feature selection and classiﬁcation
We used sequential forward ﬂoating feature selection (SFFS,172) in combination with a linear
discriminant classiﬁer to assess the most discriminative features. SFFS is a feature selection
technique in which at each step one feature is added or removed based on a performance met-
ric; we used the area under the receiver-operating characteristic curve (AUC). In our setup we
force the feature selection to ﬁnd the 5 most relevant features for each pair-wise classiﬁcation
task (cancer vs. BPH, atrophy, inﬂammation and PIN, respectively).
We repeated the SFFS procedure to investigate whether the selected features are inﬂuenced
by cancer grade. We speciﬁcally looked at intermediate- and high-grade cancer. Intermediate-
grade cancer was deﬁned as cancer with a Gleason grade 3+4 and high-grade cancer was
deﬁned as any cancer with a major 4 or any 5 component.
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In order not to bias the feature selection scheme, a two-fold, patient-stratiﬁed, cross-
validation scheme was employed to select the features and the procedure was repeated 100
times. We identiﬁed the 5 features that most frequently appeared in the top 5 selected fea-
tures.
Subsequently we wanted to assess whether using these features could result in accurate
classiﬁcation. A ten-fold, patient-stratiﬁed, cross-validation scheme was employed to train
a random forest classiﬁer (RFC)74 in conjunction with the top ranked features identiﬁed for
each of the pair-wise classiﬁcation tasks (BPH, PIN, inﬂammation and atrophy vs. cancer).
is experiment was also performed speciﬁcally for the subsets of the intermediate-grade and
high-grade cancers to assess whether any diﬀerences in classiﬁcation performance could be
observed. e performance of the classiﬁers was evaluated using the area under the receiver
operating characteristic curve (AUC). Bootstrapping was used to obtain the 95% conﬁdence
intervals for the AUCs. Finally, we also performed the feature selection and classiﬁcation
experiments for a monolithic classiﬁer that aempted to distinguish cancer from all the benign
confounders, grouped as a single benign category.
4.3 Results
4.3.1 Patient data
Aer annotation and co-registration of the prostatectomy slides and the multi-parametric MRI
for all patients 92 PIN, 64 atrophy, 120 inﬂammation and 73 BPH ROIs were identiﬁed. In
addition, 128 cancer ROIs were identiﬁed: 33 Gleason 3+3, 55 Gleason 3+4, 23 Gleason 4+3, 8
Gleason 4+4 and 9 Gleason 4+5. ese results are also summarized in Table 4.3. Additionally,
two example results for the MRI/pathology fusion are illustrated in Figure 4.1.
4.3.2 Feature selection
e results for the feature selection experiments are shown in Table 4.4, Figure 4.2 and Figure
4.3. In Table 4.4 it is interesting to note that the most highly ranked feature is diﬀerent for
all pair-wise classiﬁcation tasks. Furthermore, distinctly diﬀerent feature sets are chosen for
each of the confounder classes. To gain some insight into why these features are selected, we
present some quantitative and qualitative results in Figure 4.2 and Figure 4.3. e graphs in Fig-
ure 4.2 represent ﬁed histograms for the feature value distributions of a speciﬁc confounder,
all benign confounders grouped together, and cancer. Figures 4.2a, 4.2b, 4.2c and 4.2d show
atrophy, BPH, inﬂammation and PIN, respectively. e plots illustrate that the value distribu-
tion for the top selected feature in all pair-wise classiﬁcation tasks shows a distinctly diﬀerent
distribution than when all the confounders are grouped together. For example, in Figure 4.2d
we show that the ADC value of PIN has less overlap with cancer than all the confounders
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Number of patients 70
PSA level, mg/ml, median (range) 9.2 (1 – 76)
Age, yr, median (range) 62 (48 – 70)
Gleason score No. of lesions Category
Normal/Benign 349 Total 477
3 + 3 33 Atrophy 64
3 + 4 55 Inﬂammation 120
4 + 3 23 BPH 73
4 + 4 8 PIN 92
4 + 5 9 Cancer 128
Table 4.3: Characteristics of patients and identiﬁed lesions. PSA ranges were determined on 49 patients, for 21
patients PSA levels prior to MRI were unknown.
Figure 4.1: Two examples of co-registration results of the MRI and the prostatectomy slide. e last column
shows the annotations made on the pathology images overlayed on the MRI/pathology fused images.
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grouped together. In Figure 4.3 qualitative results for the top three features for each of the
benign classes versus cancer are presented. Here one can appreciate the visual diﬀerence for
the feature values in cancer and the individual benign confounding classes. e inﬂuence of
cancer grade on the selected features was also assessed and is presented in Table 4.4. It may be
appreciated that for high-grade cancer, ADC is the most important feature across all pair-wise
classiﬁcation tasks. e variety in selected features across the diﬀerent pair-wise classiﬁca-
tion tasks is reduced compared to discriminating confounders from all cancer grades grouped
together, with a focus mostly on T2-weighted (texture) and diﬀusion-weighted imaging fea-
tures. For intermediate grade cancer (Gleason score 3+4) the types of selected features show
more variety between the pair-wise classiﬁcation tasks (similar to all cancer grades grouped
together) and also include more dynamic contrast-enhanced features.
4.3.3 Classiﬁcation
Table 4.5 shows the quantitative classiﬁcation results illustrating the performance of the pair-
wise classiﬁers when using only the selected ﬁve features.
e average area under the curve for the pair-wise classiﬁcation was 0.70 (BPH, PIN, in-
ﬂammation and atrophy versus cancer had AUCs of 0.69, 0.73, 0.63 and 0.75, respectively) and
for the monolithic classiﬁer (cancer versus all benign classes) 0.62 using only the top-selected
features.
e results for discriminating confounders from high-grade and intermediate-grade cancer
are also presented in Table 4.5 (2nd and 3rd rows). On average the AUCs for discriminating
high-grade cancer from the benign confounders are a bit higher, whereas the AUCs for dis-
criminating intermediate-grade cancers are a bit lower.
4.4 Discussion
Presence of benign confounding disease (e.g. BPH, inﬂammation, PIN, atrophy) is the most
common reason for false positives in prostate cancer diagnosis on multi-parametric prostate
MRI159. In this study we used computerized image analysis and feature extraction to identify
sets of features to best separate each of the confounding classes (BPH, PIN, inﬂammation and
atrophy) from prostate cancer on MP-MRI.
Our study shows that the appearance of a lesion on a high b-value image might have a
higher discriminatory value than the ADC when BPH is present (Figures 4.2b and 4.3, second
row, second column), which also is in line with previous reports in literature103,161. Addition-
ally, if the patient is at high risk of prostate inﬂammation at the time of the MRI, for example
due to recent biopsy, the results suggest that looking at lesion focality (i.e. roundness, diﬀuse
or well-deﬁned edges) on both T2-weighted imaging and dynamic contrast-enhanced imaging
(Table 4.4, Figure 4.2c) could help in discriminating inﬂammatory processes from prostate can-
78 Features to discriminate benign disease from prostate cancer
All PIN N Atrophy N Inﬂammation N BPH N Monolithic N
1 ADC 117 Blob. (ve) 117 Blob.
(T2Map)
127 Blob. (b800) 105 ADC 179
2 Gauss. Deriv.
(XX, =4.1)
99 Blob. (b800) 116 ADC 83 Blob.
(T2Map)
94 Blob. (b800) 101
3 T2Map 81 Ktrans 109 Blob. (ve) 69 ADC 86 Gabor (b=1,
=2, =0.4)
79
4 Blob. (Ktrans) 66 Washout 91 Blob. (Ktrans) 63 Blob. (kep) 86 Blob.
(T2Map)
77
5 Gauss. Deriv.
(XX, =6)
65 ADC 87 Washout 52 Time-to-peak 59 Blob (Max.
Enh.)
75
HG PIN N Atrophy N Inﬂammation N BPH N Monolithic N
1 ADC 117 ADC 114 ADC 83 ADC 117 ADC 149
2 Blob. (Time-
to-peak)
88 Blob. (Max.
Enh.)
52 Blob. (ADC) 80 Blob.
(T2Map)
82 Blob. (ADC) 106
3 Blob. (ADC) 84 Gabor (b=1,
=2, =0)
52 Blob.
(T2Map)
76 Blob. (b800) 50 Gauss. Deriv.
(YY, =4.1)
50
4 Gabor (b=1,
=4, =0.4)
70 Ktrans 52 Gauss. Deriv.
(XY, =6)
72 Gauss. Deriv.
(YY, =4.1)
50 ve 49
5 Gauss. Deriv.
(Y, =6)
57 kep 51 Blob. (kep) 71 Gauss. Deriv.
(XY, =6)
49 Blob. (Time-
to-peak)
47
Inter. PIN N Atrophy N Inﬂammation N BPH N Monolithic N
1 Gauss. Deriv.
(XX, =4.1)
128 Gabor (b=1,
=2, =0)
105 ADC 84 Blob. (b800) 145 Blob.
(T2Map)
121
2 ADC 98 Washout 84 Ktrans 73 ADC 86 Blob. (ve) 120
3 Gabor (b=1,
=2, =0)
86 Ktrans 80 Blob. (ve) 57 Gabor (b=1,
=2, =0)
70 ADC 109
4 Blob. (Time-
to-peak)
67 Blob. (b800) 77 Gabor (b=1,
=2, =0.8)
53 Blob.
(T2Map)
66 Blob. (b800) 84
5 Gauss. Deriv.
(XX, =6)
58 Time-to-peak 76 Gabor (b=1,
=4, =0.8)
51 Gabor (b=1,
=4, =0)
62 Blob. (Ktrans) 77
Table 4.4: Selected features for each of the diﬀerent pair-wise classiﬁcation tasks considered in this work (e.g.
PIN versus cancer, BPH versus cancer).e N columns show how oen a feature was selected during the feature
selection phase. e last two columns show the features selected for the monolithic classiﬁcation task. e top
part of the table shows the results for discriminating the benign confounders from all cancer. e middle part
for discriminating confounders from only high-grade cancer and the boom part for discriminating confounders
from intermediate-grade cancer. For features which were calculated with diﬀerent parameters the parameter
values are presented in addition to the feature, e.g. Gaussian derivatives show the order and the scale on which
they are calculated.
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Grade PIN Atrophy Inﬂammation BPH Monolithic
All 0.73 (0.67 – 0.80) 0.75 (0.69 – 0.82) 0.63 (0.54 – 0.70) 0.69 (0.61 – 0.76) 0.62 (0.53 – 0.70)
High 0.73 (0.63 – 0.81) 0.77 (0.66 – 0.86) 0.77 (0.67 – 0.84) 0.69 (0.55 – 0.82) 0.64 (0.55 – 0.74)
Intermediate 0.65 (0.57 – 0.72) 0.70 (0.61 – 0.79) 0.57 (0.47 - 0.66) 0.63 (0.54 – 0.73) 0.62 (0.56 – 0.69)
Table 4.5: Classiﬁcation performance (area under the receiver operating characteristic curve, AUC) of a random
forest classiﬁer for each of the pair-wise classiﬁcation tasks (PIN, atrophy, inﬂammation and BPH vs. cancer).
Furthermore, the AUC for amonolithic classiﬁcation (grouping all benign confounders together as a single benign
class) is presented in the last column. e second and third row show the AUCs when looking at a high-grade or
intermediate-grade subset of cancer.
cer. is appears to support our initial hypothesis that each benign confounding class appears
to have a distinct set of imaging descriptors that can help characterize them. is is further
conﬁrmed by the classiﬁcation results presented in Table 4.5, where the average and individ-
ual AUCs of the pair-wise classiﬁcation tasks seem higher than the AUC for the monolithic
classiﬁcation.
If we inspect the inﬂuence of cancer grade on the selected features it is apparent that
for high-grade cancer the variety of selected features across the pair-wise classiﬁcation tasks
(Table 4.4) is reduced. is is accompanied by an increased AUC for the diagnosis of high-
grade cancer relative to all cancer grades grouped together (Table 4.5). Both these results
indicate that high-grade cancer seems to have its own distinct imaging characteristics (low
ADC, distinctly diﬀerent texture) compared to all other classes (even to low- and intermediate-
grade cancer) and is easier to discriminate from benign disease than intermediate-grade cancer
(which has a lower AUC on average). Results presented in literature on ADC also show that
the diﬀerence between benign/normal prostate lesions and high-grade cancer is so large that
it is relatively easy to discriminate between the two, even in the presence of BPH, by just using
ADC51,163, whereas the overlap in ADC between intermediate-grade cancer and benign disease
is much larger, requiring more and more speciﬁc features to allow discrimination.
We acknowledge that our study had its limitations. ere is invariably a time lapse be-
tween the MRI and the prostatectomy, as such sometimes the appearance or size of a lesion
is not completely similar between the two. Additionally, we limited our analysis to a single
prostatectomy slide, as 3D reconstruction of an entire prostatectomy and subsequent mapping
to the MRI is diﬃcult and oen impossible in current diagnostic practice. Choyke et al. pre-
sented a method using a 3D printed mold, which could be an avenue for future research173.
Additionally, to keep the data unbiased we did not edit or remove annotations based on size
or MR visibility. Some annotations on the prostatectomy resulted in lesions which are only a
couple of voxels large and suﬀer from partial volume eﬀect, making it diﬃcult to register and
characterize them correctly. No statistical signiﬁcance test was performed on the diﬀerence
between the monolithic and the pairwise classiﬁcation. e monolithic classiﬁcation contains
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Figure 4.2: Distributions of the feature values of the top selected feature of each of the classiﬁcation tasks for
cancer, all benign confounders and the confounder to discriminate. Figures (a) and (b) show atrophy and BPH
respectively,
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Figure 4.2: Distributions of the feature values of the top selected feature of each of the classiﬁcation tasks for
cancer, all benign confounders and the confounder to discriminate. Figures (c) and (d) show inﬂammation and
PIN, respectively.
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all benign samples, whereas each pair-wise classiﬁcation only contains the speciﬁc benign
confounder class, making it impossible to perform a paired t-test. As the samples are not in-
dependent a regular t-test is also not applicable. In the future this could be solved by including
a completely separate test set for the monolithic classiﬁcation. Last, multi-center evaluation
is an important pre-requisite for further validation of the results.
4.5 Concluding remarks
We explored and showed the utility of computerized image and feature analysis in conjunction
with multi-parametric MRI to distinguish between prostate cancer and benign confounders.
For each pair of HGPIN, atrophy, BPH, inﬂammation versus cancer we identiﬁed a unique set
of features which could help improve the diﬀerential diagnosis of prostate cancer.
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Figure 4.3: Feature maps of the top 3 selected features for each of the classiﬁcation tasks. Cancer is contoured
in red and the speciﬁc benign confounder in yellow. e ﬁrst column contains the axial T2-weighted image as a
reference. e ﬁrst row is atrophy, the second row is BPH, the third row is PIB and last row is inﬂammation.
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5.1 Introduction
Only 15% of men diagnosed with prostate cancer show a disease speciﬁc mortality. e mor-
tality in the US in 2010 was 30000, with 220000 new prostate cancer cases diagnosed174. us
in order to tailor treatment from more radical therapy to active surveillance protocols, accu-
rate cancer aggressiveness risk stratiﬁcation is very important. e most useful estimator of
cancer aggressiveness is the Gleason score (GS), a histopathological scoring system used on
biopsy and prostatectomy specimens. It has become such an integral part in prostate cancer
evaluation, that patient management is largely inﬂuenced by the assessment thereof175–177.
Recently, the apparent diﬀusion coeﬃcient (ADC) values determined in diﬀusion-weighted
magnetic resonance imaging (DWI-MRI) showed to be inversely correlated to GS51,178,179. As
a result, ADC has been proposed as a useful non-invasive biomarker for prostate cancer ag-
gressiveness. However, the discriminative power of ADC depends in part on the variability of
the ADC measurement. is variability is machine – i.e. vendor, seings, noise - and patient
dependent, the laer caused by natural tissue heterogeneity. Based on the large inter-patient
distribution of normal PZ ADC values (1.2 – 2.210-3 mm2
s
) observed on a single MR scanner,
we hypothesize that a substantial histo-physiological heterogeneity between patients must
exist (inter-patient variation)51,160.
Inter-patient ADC variation could aﬀect the discriminative power of ADC both for prostate
cancer localization as well as for the determination of prostate cancer aggressiveness. Since
normal prostate PZ tissue ﬂuctuates signiﬁcantly in ADC value, the ADC values of an aggres-
sive tumor may show similar ﬂuctuations. Considering normal PZ and tumor ADC simulta-
neously may lead to beer estimates of aggressiveness.
e purpose of this study was to determine the inter-patient variability of prostate periph-
eral zone (PZ) apparent diﬀusion coeﬃcient values (ADC) at 3T and the eﬀect this has on the
assessment of prostate cancer aggressiveness.
5.2 Materials and Methods
5.2.1 Patients
Imaging data of two retrospective patient cohorts was used in our experiments. e require-
ment to obtain institutional review board approval was waived for both cohorts. To deter-
mine the signiﬁcance of the inter-patient variance relative to the measurement variability we
included 10 patients (February 2008 to June 2011, interval between scans 6 – 12 months) who
had repeated measurements of normal PZ ADC values at three separate MR imaging sessions
at 3T. e indication for the studies was continuously high PSA level and at least one nega-
tive transrectal ultrasound biopsy. Patients were followed up if PSA level remained high. In
these patients no peripheral zone cancer was found in all three imaging sessions by an expert
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radiologist (J.O.B., with 18 years of experience). If a suspicious lesion was indicated by the
radiologist subsequent MR-guided biopsy found no traces of tumor.
In addition, to determine the eﬀect of the inter-patient variation of ADC on the predic-
tion of prostate cancer aggressiveness a second cohort was included. Between August 2006
and January 2009, 70 consecutive patients with biopsy proven PZ prostate cancer , sched-
uled for radical prostatectomy, were referred from the departments of urology at the Radboud
University Nijmegen Medical Centre and the Canisius Wilhelmina Hospital in Nijmegen, e
Netherlands, for clinically routine pre-operative MRI of the prostate.
Clinical aracteristics
Prostate Speciﬁc Antigen (PSA) level (ng/mL) 6.8 (1.7 – 42)
Age (y) 64 (49 – 69)
Pathologic aracteristics (per patient)
Stage T2a 5
Stage T2c 23
Stage T3a 18
Stage T3b 4
Stage T4 1
Gleason grade (per tumor)
3 + 2 3
3 + 3 18
2 + 4 1
3 + 4 13
3 + 4 + 5 4
4 + 3 13
4 + 3 + 5 5
4 + 4 2
4 + 5 3
Table 5.1: Summary of clinical and pathologic characteristics for the second cohort of 51 patients.
5.2.2 MR Imaging Protocol
MR imaging of the prostate was performed using a 3T MR scanner (Siemens Trio Tim, Erlan-
gen, Germany). e ﬁrst cohort of 10 patients was scanned with only the pelvic phased array
coils.
e second cohort was scanned with the use of combined endorectal coil (ERC) (Medrad,
Pisburgh, U.S.A) and pelvic phased array coils. e ERC was ﬁlled with a 40-mL Perﬂuoro-
carbon preparation (Fomblin, Solvay-Solexis, Milan, Italy)
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Figure 5.1: Flowcharts expressing the diagnostic accuracy of (a) the method including only tumor ADC and (b)
the method incorporating both tumor and normal PZ ADC. FN = false negative, FP = false positive, TN = true
negative, TP = true positive.
5.2 Materials and Methods 89
In both cohorts peristalsis was suppressed with an intramuscular administration of 20-mg
Butylscopolaminebromide (Buscopan, Boehringer-Ingelheim, Ingelheim, Germany) and 1 mg
of glucagon (Glucagen, Nordisk, Gentoe, Denmark).
e MR imaging protocol included: anatomical T2-weighted turbo spin echo sequences in
axial, sagial and coronal planes covering the entire prostate and seminal vesicles. Axial diﬀu-
sion weighted imaging was performed using a single-shot-echo-planar imaging sequence with
diﬀusion modules and fat suppression pulses implemented. Water diﬀusion was measured in
3-scan trace mode using b-values of 0, 50, 500, and 800 smm2 . ADC-maps were automatically
calculated by the scanner soware using all b-values. Complete pulse sequence details can be
found in Table 5.2 for the ﬁrst cohort containing 10 patients with repeated measurements and
Table 5.3 for the second cohort.
PS ST NS SR RT ET AV Other
T2W TSE 3.5 - 4 mm 13-19 0.6 mm 3540 ms 104 ms 2 -3 ree orthog-
onal directions
(axial, sagial,
coronal)
DWI SE-EPI 3.5 - 4 mm 15-20 1.6 – 2.0 mm 2300 ms 61 ms 6 - 10 b-values used 0,
50, 500, 800 mm2
s
DCE Turbo FLASH 3.5 - 4 mm 14 1.8 mm 37 ms 1.47 ms 1 -
Table 5.2: Pulse sequence details for the ﬁrst patient cohort with repeated measurements. In-plane resolution is
the same in both directions. PS = pulse sequence, SR = spatial resolution, ST = slice thickness, NS = number of
slices, ET = echo time, RT = repetition time, FA = ﬂip angle, AV = number of averages.
PS ST NS SR RT ET AV Other
T2W TSE 4 mm 15-19 0.4 - 0.5 mm 3540 - 3810 ms 105 ms 2 ree orthogonal
directions (axial,
sagial, coronal)
DWI SE-EPI 4 mm 15-19 2.0 mm 2800 ms 81 ms 10 b-values used 0,
50, 500, 800 mm2
s
DCE Turbo FLASH 4 mm 14 1.8 mm 37 ms 1.47 ms 1 -
Table 5.3: Pulse sequence details for the second patient cohort with repeated measurements. In-plane resolution
is the same in both directions. PS = pulse sequence, SR = spatial resolution, ST = slice thickness, NS = number of
slices, ET = echo time, RT = repetition time, FA = ﬂip angle, AV = number of averages.
5.2.3 Whole-Mount Step-Section Preparation
e second cohort of patients underwent radical prostatectomy aer imaging. Aer the radi-
cal prostatectomy, prostate specimens were uniformly processed and submied for histologic
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investigation in their entirety. Aer histologic staining, all specimens were evaluated by one
expert urological pathologist (C.A.H.v.d.K. with 17 years of experience). Each individual tu-
mor was graded according to the 2005 International Society of Urological Pathology Modiﬁed
Gleason Grading System.
Peripheral zone tumors, with a size of >0.5 cc in volume, were divided in two groups,
and classiﬁed as low- and high-grade tumors. Tumors with a Gleason grade 4 or 5 component
were deﬁned as high-grade. Low-grade tumorswere deﬁned as tumors harboring onlyGleason
grades 2 and 3.
5.2.4 Annotation of MR images
All annotations were performed using an in-house developed MR viewing and reporting sys-
tem. In the ﬁrst cohort the center slice of the prostate in the axial direction was used to
annotate the peripheral zone. For this slice the whole peripheral zone was annotated and the
median ADC value was extracted from this annotation.
For the second cohort, ADC maps were acquired in the same orientation and of similar
thickness as the histopathology step-section. A previously described translation technique
was used to match every tumor containing histopathology step-section to a corresponding
ADC map51. Using histopathology as gold standard, a region of interest (ROI) was placed by
one radiologist (T.H. with four years of experience) and one urologist (with one year of expe-
rience) in consensus, on the ADC maps. e size and extent of the ROI were chosen such that
it matched the tumor size and extent obtained from histological examination as closely as pos-
sible. Median ADC values were extracted for each tumor slice separately. In clinical practice,
the ADC slice revealing the lowest signal intensity for tumor alerts radiologists. erefore,
for each individual PZ tumor, the tumor slice revealing the lowest ADC values was used for
further assessment.
Lastly, to determine the eﬀect of incorporating normal PZ ADC values on the prediction
of cancer aggressiveness, an ROI was placed in the normal PZ tissue of every patient. is
region was always selected adjacent to the tumor, in order to be the most representative area
of normal PZ ADC value at the tumor location. is was done to aempt to minimize intra-
patient heterogeneity. Median ADC values were extracted from all ROIs. Median values were
used because they are more robust to image artifacts that might occur due to ADC calculation
by the scanner.
5.2.5 Statistical analysis
Our ﬁrst hypothesis is that there is a signiﬁcant degree of inter-patient variation in normal PZ
ADC values. is was assessed using a repeated-measures ANOVA. Mauchly’s sphericity test
will be performed to test the hypothesis of sphericity. If sphericity can not be assumed the
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Figure 5.2: ree median ADC measurements of the peripheral zone of 10 patients. e circles represent the
individual measurements, the vertical axis shows the median ADC value, the horizontal axis shows to which
patient the measurement belongs.
Greenhouse-Geisser corrected p-value will be reported. e repeated measure was the median
ADC value of normal PZ tissue, which was obtained three times for each of the 10 patients in
the ﬁrst cohort.
Our second hypothesis is that joint analysis of the normal PZ ADC values and the tumor
ADC values will result in an improved prediction of cancer aggressiveness, because this im-
plicitly corrects for the inter-patient variations in normal PZ ADC. Multivariate linear logistic
regression was used to test this hypothesis. We can express a regression model of cancer grade
as:
z = C+ TADCT + NADCN (5.1)
p =
ez
1+ ez (5.2)
e p indicates the probability that a cancer is high-grade and the ADC variables indicate
the median ADC of the corresponding ROI. Subscripts T and N are tumor and normal PZ
respectively. e beta terms are the regression coeﬃcient corresponding to these variables.
Equation 2 represents the conversion from z to the probability p.
e linear logistic regression results in values for T and N and the signiﬁcance of these
variables in the regression model. Two regression models were created to compare diagnostic
performance: using only tumorADCvalues and using tumor and normal PZADCvalues. SPSS
(SPSS, version 16.0.01, Chicago, U.S.A.) was used for the statistical analysis. Furthermore, a
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Figure 5.3: Decision Boundary at p=.5 of the logistic regression model. e line represents the decision boundary,
the green dots the low-grade cancer and the red dots the high-grade cancers.
visual assessment is given for the correlation between tumor ADC and normal peripheral zone
ADC by ploing the low- and high-grade tumors with respect to their ADC values and the
corresponding normal PZ ADC values.
Our third hypothesis is that the improved prediction of prostate cancer aggressiveness may
result in a signiﬁcant improvement in diagnostic accuracy in separating low- and high-grade
cancer. Receiver-operating characteristic (ROC) curves were constructed for a standalone tu-
mor ADC regressionmodel and the regressionmodel, which incorporates normal PZADC val-
ues. e areas under the ROC curves were tested for signiﬁcant diﬀerences using the ROCKIT
soware package (Kurt Rossmann Laboratories, University of Chicago, Chicago).180
5.2.6 Nomogram construction
Additionally, the regression model incorporating tumor and normal PZ ADC can be used to
construct a nomogram by evaluating the obtained equation for a range of ADC values. e
ranges used to construct the nomogram are 0.5 – 1.710-3 mm2
s
for the tumor ADC value and
0.8 – 2.210-3 mm2
s
for the normal PZ ADC value. ese ranges are slightly larger than the
ranges found in this study to accommodate more extreme values.
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5.3 Results
For the ﬁrst cohort of 10 patients, no patients were excluded. e median patient age was 58.5
years (47 – 67). e median PSA at the time of the ﬁrst MRI was 8.25 (1.8 – 26).
For the second cohort of 70 consecutive patients, 56 patients had clinically signiﬁcant tu-
mor (>0.5mL). Of the remaining 14 patients 11 had a tumor in the central gland and 3 had a
peripheral zone tumor smaller than 0.5 mL. Of the 56 patients 5 patients were excluded due
to severe motion artifacts (n=3), hemorrhage (n=1) or ghosting (n=1). Characteristics of these
patients are reported in Table 5.1. In these 51 patients a total of 62 diﬀerent peripheral zone tu-
mors were found. Of these tumors 21 were low-grade tumors and 41 were high grade tumors.
emean ADC for the low-grade tumors was 1.35 0.2610-3 mm2
s
and 0.926 0.1810-3 mm2
s
for the high-grade tumors. e mean value of the normal peripheral zone for patients with a
low grade tumor was 1.65  0.2110-3 mm2
s
and 1.60  0.2110-3 mm2
s
for patients with a high
grade tumor.
5.3.1 Assessment of inter-patient variation of normal PZ ADC values
Normal PZ ADC values diﬀered signiﬁcantly between patients relative to measurement vari-
ability (Mauchly’s sphericity test p-value < 0.0001, Greenhouse-Geisser corrected p-value =
0.0058) as assessed using the repeated measures ANOVA. e ADC measurements are ploed
in Figure 5.2.
5.3.2 Eﬀect of including normal PZ ADC values in the prediction of cancer aggres-
siveness
Normal peripheral zone ADC correlates with ADC of high-grade tumors. Its addition to the
regression model results in a signiﬁcantly improved prediction of aggressiveness (p = 0.013).
is was determined using the logistic regression procedure; the results are summarized in
Table 5.4.
Both regression models show a signiﬁcant contribution of the tumor ADC (p = 0.003).
Normal PZ ADC values also show a signiﬁcant contribution to the regression model (p =
0.013). e regression model using standalone tumor ADC values can then be expressed as:
z = 10.76- 9.103ADCT (5.3)
and the model combining tumor and normal PZ ADC values can be expressed as:
z = 0.126- 18.82ADCT + 13.43ADCN (5.4)
In combination with equation 2 these models result in a probability that a given sample is a
high-grade cancer. e model incorporating normal PZ ADC (Eq. 4), together with the data
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Tumor median ADC Tumor and normal PZ median ADC
Parameter Value p Value p
ADCT 9.103 < 0.001 -18.82 0.003
ADCN - - 13.43 0.013
C 10.76 < 0.001 0.126 0.978
Table 5.4: Result of the linear logistic regression for three regressions based on equation 1 and 2. Regressions
performed: using only tumor ADC and using tumor and normal PZ median ADC. e second row shows the
values used in each regression. e regression parameters are presented in the boom three rows, their value
and signiﬁcance respectively for each regression.
used in the regression, is shown in Figure 5.3. is plot indicates that a relatively high tumor
ADC value might still constitute a high-grade tumor if the normal PZ ADC is high. In addition
one can appreciate that using a static threshold on tumorADC (a vertical line/contour in Figure
5.3) to determine cancer aggressiveness could result in incorrect diagnosis in some patients.
5.3.3 Diagnostic performance of the regression models
Including normal PZ signiﬁcantly (p = 0.0401) improved diagnostic accuracy. e ROC curves
for the regression models in equations 3 and 4 are shown in Figure 5.5. e area under the
curve increases from 0.91 to 0.96.
e constructed nomogram is shown in Figure 5.4. is nomogram can be used in a clinical
setup to quickly look up the chance that a certain region within the peripheral zone is an
aggressive cancer.
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Figure 5.4: Contour of the probabilities of having an aggressive cancer given the adjacent PZ tissue ADC (vertical
axis) and the tumor ADC (horizontal axis). e point corresponding to these two values will correspond to the
probability of a high-grade cancer. e probability values are speciﬁed along the contours and in the color bar
on the right of the ﬁgure.
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Figure 5.5: ROC curve of the regression models. e red line shows the diagnostic accuracy when including the
adjacent PZ tissue median ADC in addition to the tumor ADC, the blue line show the diagnostic accuracy when
only using tumor ADC.
5.4 Discussion
In this studywe have shown that there is a signiﬁcant inter-patient variation in normal periph-
eral zone ADC values (1.2 – 2.010-3 mm2
s
), which cannot be solely aributed to measurement
variability (average measurement standard deviation 0.068  0.02710-3 mm2
s
) . We hypothe-
size that the inter-patient variations arise from natural variations in prostate physiology.
Secondly, adding normal PZ ADC values to the linear logistic regression, results in a sig-
niﬁcantly improved prediction of cancer aggressiveness (p = 0.013). is suggests that tumor
ADC values should not be considered absolute but that these values are inﬂuenced by “back-
ground” variation of normal PZ tissue composition.
irdly, the improvement also results in an increased area under the ROC curve, from 0.91
to 0.96 (p < 0.05), thus an improved diagnostic accuracy.
is study has a number of limitations. First, the use of ADC to assess aggressiveness
of transition zone tumors has not been investigated in this study. Second, this study was
limited to the peripheral zone. is was done because it is known that ADC in peripheral and
transition zone tumors can diﬀer substantially. However, the majority of prostate tumors arise
in the PZ. ird, the annotation of ROIs was performed by a single observer; the eﬀect of the
inter-observer variability on the regression model was not assessed. Our nomogram must be
tested and validated in a prospective multi-reader study.
In conclusion, there is a large inter-patient variation in prostate peripheral zone ADC val-
ues. is variation propagates into tumor ADC values. Compensating for this variation by
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combining tumor and normal PZ ADC when assessing cancer grade signiﬁcantly increases
diagnostic performance.
CAD system
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6.1 Introduction
Prostate cancer is one of themajor causes of cancer death formen in theWesternworld181. Due
to the increased ageing of the general population the incidence of prostate cancer is steadily
rising181. Current clinical practice for the diagnosis of prostate cancer is to perform a transrec-
tal ultrasound (TRUS) biopsy, which usually is performed due to a positive prostate speciﬁc
antigen (PSA) blood test. A large screening trial using PSA and TRUS has shown that is is pos-
sible to reduce prostate cancer mortality by 20-30%21. However, these studies have also shown
that PSA testing in combination with TRUS biopsies has a relatively low speciﬁcity. Addition-
ally, cancers are oen undergraded in TRUS biopsies28. ese problems lead to overdiagnosis
and overtreatment of patients and are prohibiting screening for prostate cancer.
MRI is increasingly used to diagnose prostate cancer as it has improved sensitivity and
speciﬁcity over PSA and TRUS32. Currently, MRI is most oen used as a second-line modality
aer repeat negative TRUS biopsies. One of the reasons MRI has not yet progressed to a ﬁrst
line modality for prostate cancer diagnosis is that it requires substantial expertise from the
radiologist to read prostate MRI and such expertise is not widely available. Additionally, due
to the large amount of 3D images, reading prostate MR is quite time consuming.
Automated computer-aided detection and diagnosis (CAD) of prostate cancer could help
reduce both of these problems and open the door to prostate cancer screening using MRI. In
the past several other areas have seen successful CAD applications, such as mammography182,
CT colonography183 and retinopathy184. In the last decade several researchers have investi-
gated the use of these techniques for prostate MRI. erefore, computer-aided detection and
diagnosis of prostate cancer is becoming an active ﬁeld of research88,89,93,96.
Chan et al.88 were the ﬁrst to implement a multi-parametric CAD system for the diagno-
sis of prostate cancer. In their approach they used line-scan diﬀusion, T2 and T2-weighted
images in combination with an SVM classiﬁer to identify predeﬁned areas of the peripheral
zone of the prostate for the presence of prostate cancer. Langer et al.89 included dynamic-
contrast enhanced images and pharmacokinetic parameter maps as extra features to a CAD
system for prostate peripheral zone cancer. ey evaluated their system in predeﬁned regions
of interest, but on a per-voxel basis. Tiwari et al.93 investigated the use of magnetic reso-
nance spectroscopy in combination with T2-weighted imaging to identify the voxels that are
aﬀected by prostate cancer. ey also introduced the use of wavelet embedding to map MRS
and T2-W texture features into a common space. is work was further expanded and evalu-
ated in94. Niaf et al.185 presented the use of computer-aided diagnosis in the peripheral zone of
the prostate (similar to Vos et al.57. ey conﬁrmed the results in discriminating prostate can-
cer from normal regions (area under the ROC curve (AUC)=0.89) and discriminating prostate
cancer from suspicious benign regions (AUC of 0.82). is is a limited CAD method as it is
constrained to predeﬁned regions of interest in only the peripheral zone. Firjani et al.186 in-
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vestigated the use of computer-aided detection in single-parameter MRI using DWI imaging
with transrectal ultrasound guided biopsies as ground truth. ey included registration of
diﬀerent b-values to obtain a less motion sensitive apparent diﬀusion coeﬃcient map. Lastly,
Vos et al.96 recently implemented a two-stage computer-aided detection system for prostate
cancer using an initial blob detection approach combined with a candidate segmentation and
classiﬁcation using statistical region features.
In this paper we investigate a fully automated computer-aided detection system including
a novel combination of segmentation, voxel classiﬁcation, candidate extraction and candidate
classiﬁcation, which expands on the work published in187. Other novel aspects include a voxel
classiﬁcation stage in combination with a candidate classiﬁcation stage and inclusion of sym-
metry, local contrast and anatomical features like peripheral zone likelihood. Feature design
was based on the standardized guidelines for reading prostate MR, PI-RADS, and include tex-
ture, pharmacokinetic, shape and anatomy, among others33. Furthermore, to the best of the
authors’ knowledge this is the ﬁrst prostateMRI CAD system that is evaluated on a per-patient
basis and compared to the prospective performance of radiologists. e system was validated
on a large cohort of 347 patients using per-region FROC and per-patient ROC to show the
value of a two stage approach incorporating both voxel and candidate classiﬁcation.
6.2 Materials and Methods
6.2.1 MRI data
In our hospital we collected a total of 165 consecutive studies with prostate cancer (187 lesions)
and 183 cases without prostate cancer on which to evaluate our CAD-system for a total of 348
studies of 347 patients.
Each MR study was read and reported by or under the supervision of an expert radiologist,
J.B. with more than 20 years of experience in prostate MR. e radiologist indicated areas of
suspicion with a score per modality using a point marker. If an area was considered likely
for cancer a biopsy was performed. All biopsies were performed under MR-guidance and
conﬁrmation scans of the biopsy needle in situ were made to conﬁrm accurate localization.
Biopsy specimen were subsequently graded by a pathologist and these results were used as
ground truth.
All studies included T2-weighted (T2W), proton density-weighted (PD-W), dynamic con-
trast enhanced (DCE) and diﬀusion-weighted (DW) imaging. It is currently established clinical
consensus that prostate cancer should be diagnosed by T2-weighted imaging with at least two
functional modalities (from DWI, DCE and spectroscopic imaging)32,33. e images were ac-
quired on two diﬀerent types of Siemens 3T MR scanners, the MAGNETOM Trio and Skyra.
T2-weighted images were acquired using a turbo spin echo sequence and had a resolution of
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around 0.5 mm in plane and a slice thickness of 3.6 mm. e DCE time series was acquired
using a 3D turbo ﬂash gradient echo sequence with a resolution of around 1.5 mm in-plane, a
slice thickness of 4 mm and a temporal resolution of 3.5 seconds. e proton density weighted
image was acquired prior to the DCE time series using the same sequence with diﬀerent echo
and repetition times and a diﬀerent ﬂip angle. Finally, the DWI series were acquired with
a single-shot echo planar imaging sequence with a resolution of 2 mm in-plane and 3.6 mm
slice thickness and with diﬀusion-encoding gradients in three directions. ree b-values were
acquired (50, 400 and 800), and subsequently, the ADC map was calculated by the scanner
soware. All images were acquired without an endorectal coil, as per the PI-RADS guidelines
for acquisition of prostate MRI33. Although an endorectal coil would allow for further im-
proved resolution of the images, the added value is considered negligible compared to added
patient comfort when only using a pelvic phased array coil. e transversal T2W image, the
PD-W image, the entire DCE time series and from the DWI the apparent diﬀusion coeﬃcient
map and the b800-image were used in this study. ese images were chosen because they are
explicitly incorporated in the PI-RADS standard, except the PD-W image, which was added
purely for feature calculation purposes.
6.2.2 Overview of the CAD pipeline
e pipeline of the CAD system is visualized schematically in ﬁgure 6.1 and follows a two
stage approach.
Prostate 
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Voxel feature 
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Figure 6.1: Flowchart showing the diﬀerent steps of the computer-aided detection system
e ﬁrst (detection) stage consists of segmentation of the prostate on the transversal T2-
weighted image, extraction of voxel features from the image volumes, classiﬁcation of the vox-
els and candidate selection. e second (diagnosis) stage consists of candidate segmentation,
candidate feature extraction and candidate classiﬁcation. Each of the steps will be described
in more detail in the corresponding subsections.
6.2.3 Segmentation
e segmentation of the prostate is required to reduce the complexity of the detection task for
the classiﬁers in the later stages. In our system we use an atlas based segmentation approach
similar to the one presented in108, using the atlas selection mechanism presented in146, named
SIMPLE (Selective and Iterative Method for Performance Level Estimation).
Let the image to be segmented be denoted as I(x), where x is a spatial location within the
image. A labeled image, L(x) has to be determined. e following steps are similar in most
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multi-atlas based systems. A set of N manually labeled images A is non-rigidly registered to
the unknown case I(x). e i-th atlas in this set A is denoted as Ai(x), where each Ai(x)
consists of the atlas image and the label image: Ai(x) = fIi(x),Li(x)g. Aer registration of
the atlas image Ii(x) the obtained transformation Ti(x) is applied to the label image of the
atlas, Li(x).
An important part of the registration procedure is the similarity metric that is used. In this
approach we used the localized mutual information metric188. Aer atlas registration we have
a transformed label image Li  Ti(x) for each atlas. We use the SIMPLE method, presented by
Langerak et al146, to combine these label images into one ﬁnal segmentation. Example results
are shown in ﬁgure 6.2. is algorithm competed in the prostate MR image segmentation
(PROMISE12) challenge (http://promise12.grand-challenge.org), where it obtained a
9th place out of 12. Overall segmentation results were still reasonably good, with a median
Dice’s coeﬃcient of 0.83.
6.2.4 Voxel features
Aer prostate segmentation we calculated voxel features from the image volumes. e types
of features can be categorized in intensity, pharmacokinetic, texture, blobness and anatomical
features. A complete overview of the voxel features is given in table 6.1, implementation
details are given in the corresponding subsections.
Intensity
One of the major issues in image analysis for MRI is the absence of a standardized signal
intensity, like Hounsﬁeld units in CT. is usually means that an algorithm will give diﬀerent
results as scanners, sequences or even sequence parameters are changed. Tomitigate this issue
we developed several algorithms to standardize signal intensity in the diﬀerent MRmodalities.
First, for the T2-weighted imaging a T2-estimate map is generated by using the MR signal
equation, the proton density image and a reference tissue. is process was automated and is
explained in more detail in169. is map was added as a voxel feature in addition to the original
transversal T2-weighted image. Second, the MR scanner soware automatically calculates the
apparent diﬀusion coeﬃcient map from the diﬀusion-weighted images, by ﬁing a mono-
exponential function to the signal decay across the diﬀerent b-values. Furthermore, studies
have shown that the highest b-value image has additional diagnostic value, therefore, the b800
image was also added as a feature.
Anatomical
For the anatomical features we used the relative distance to the prostate boundary:
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Name Type Description
T2W Intensity T2-weighted voxel grey value, related to voxel T2
ADC Intensity Apparent diﬀusion coeﬃcient, measure for cellular density
b800 Intensity High b-value image, areas with low diﬀusivity appear bright
T2-map Intensity T2-map based on proton density and transversal T2W image 169
x-pos Anatomical Relative cumulative position within the prostate in the x-direction
y-pos Anatomical Relative cumulative position within the prostate in the y-direction
z-pos Anatomical Relative cumulative position within the prostate in the z-direction
Distance Anatomical Relative distance to the prostate boundary between 0 and 1
PZ likelihood Anatomical Likelihood of being a peripheral zone voxel between 0 and 1 169
Ktrans Pharmacokinetic Parameter related to vessel permeability
kep Pharmacokinetic Parameter related to permeability and extracellular volume
tau Pharmacokinetic Time-to-peak of contrast agent concentration
LateWash Pharmacokinetic Curve parameter related to the washout of contrast agent
Gaussian texture bank Texture Calculate multi-scale Gaussian derivatives on the T2W image
ADC Blob Blobness Multi-scale blob detection using the Li blobness ﬁlter 170
KtransBlob Blobness Multi-scale blob detection using the Li blobness ﬁlter 170
LateWash Blob Blobness Multi-scale blob detection using the Li blobness ﬁlter 170
tau Blob Blobness Multi-scale blob detection using the Li blobness ﬁlter 170
Table 6.1: Overview of voxel features used in the CAD system.
B(x) = min
y2Pb
d(x,y) (6.1)
RD(x) = B(x)max
x2P
B(x)
(6.2)
where x is the position of a voxel, d is the Euclidean distance operator, P is the set of
prostate voxels and Pb the set of prostate boundary voxels.
Additionally, we also use relative position features in x, y, and z directions. e relative
position features are deﬁned as:
RP(xi) =
xi -min
x2P
xi
max
x2P
xi -min
x2P
xi
(6.3)
where x is the position of a voxel and i is the image axis, either x, y or z, and P the set of prostate
voxels. Both the relative distance and the relative position features are calculated with respect
to the prostate mask obtained through the multi-atlas method. Finally, we also implemented
6.2 Materials and Methods 105
a peripheral zone probability feature, which gives a likelihood per voxel that it belongs to the
peripheral zone. is feature uses a paern recognition framework incorporating intensity,
texture and anatomical features. is results in a likelihood for each voxel within a prostate
mask of belonging to either the peripheral zone or the central gland. More implementation
details of this ﬁlter can be found in169. is feature is important because we know from clinical
practice that prostate cancer appearance can diﬀer substantially between the peripheral zone
and the central gland33.
Pharmacokinetic
In the clinic it is common practice to use the DCE time curve to diagnose prostate cancer33. e
approach used is described as the curve type method, were the radiologist looks at the curve
and assesses two characteristics based on the ﬁrst, last, and peak enhancement time points33.
ese characteristics are whether there is fast initial enhancement and if there is persistent
enhancement, an enhancement plateau or wash-out. Slow initial, persistent enhancement
(curve type I) or slow initial, constant enhancement (curve type II) are associated with normal
and benign ﬁndings whereas fast initial enhancement combined with washout are indicative
for malignancy (curve type III).
e traditional analysis is incorporated in our CAD system by using a curve-ﬁing tech-
nique to ﬁt, per voxel, a bi-exponential curve to the time data, as presented in55. Of these curve
parameters we incorporated the parameter tau (which corresponds to time-to-peak of the en-
hancement curve) and the parameter LateWash (which corresponds to the slope of the last part
of the curve). ere are two major problems with only using this type of analysis. First, the
assessment of the curve is scanner and patient dependent, e.g. diﬀerent protocols or patient
anxiety (which increases blood ﬂow). Second, not all information present in the curve is used.
To counter these disadvantages pharmacokinetic modeling of the contrast agent concentra-
tions has been proposed and applied in breast, brain and prostate MRI57,189. We implemented
the standard Tos pharmacokinetic model35 including an automated reference tissue method
to estimate the arterial input function, as proposed in55,57. is model provides us with three
parameter maps for the DCE time series. e parameters represent the permeability of the
micro-vasculature, Ktrans, the fraction of extracellular, extravascular space, veand the quotient
of the two, kep. Due to fast and sloppy vessel construction and tightly packed cells in a can-
cerous region it is expected that Ktransand vewill diﬀer between cancerous and normal/benign
tissue.
Texture and blobness
Most cancers show textural distortions in T2-weighted images33,95. To capture these charac-
teristics in features we use a Gaussian texture bank. For the Gaussian feature bank we used
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5 diﬀerent scales, from 2 mm to 8 mm exponentially and derivatives up to the second order.
is scale range was selected to encompass the typical size ranges of lesions in prostate MRI
(between 5mm and 20mm in diameter)190–192. Due to the large slice thickness the features were
calculated on a slice-by-slice basis. is results in a total of 30 Gaussian texture features.
Prostate cancer tends to appear as a focal, blob-like lesion in diﬀusion-weighted and dy-
namic contrast enhanced MRI. is characteristic has been previously used to detect prostate
cancer96. ere are many diﬀerent blobness measures, we chose to incorporate the blobness-
ﬁlter presented by Li et al.170 because this ﬁlter incorporates both a shape term and a blobness
strength term. e blobness feature was calculated with scales ranging from 2 mm to 8 mm,
with 5 diﬀerent, exponentially increasing scales. Again, this range encompasses the size of
most lesions encountered in prostate MRI190–192. e maximum (bright blobs) or minimum
(dark blobs) value of the blobness output across scales at each voxel was used as the ﬁnal blob-
ness measure. Blobness was calculated on the ADC, tau and LateWash images (dark blobs) and
on the Ktrans and Kep images (bright blobs).
6.2.5 Voxel classiﬁcation
Aer feature calculation a voxel classiﬁcation is performed, which results in a likelihood be-
tween 0 and 1 per voxel, 0 indicating no suspicion of prostate cancer and 1 indicating very high
suspicion of prostate cancer. In this step we experimented with three diﬀerent classiﬁers, a lin-
ear discriminant classiﬁer, a GentleBoost classiﬁer73 (with regression stumps as weak learners)
and a RandomForest-classiﬁer with regression trees74. Both the GentleBoost and the Random-
Forest classiﬁers are very robust to over-training73,74, thus parameter optimization is usually
not needed93. erefore, both the RandomForest and the GentleBoost classiﬁer were le at the
default seings. For the RandomForest the default seings are that a minimum of 0.1 percent
of all samples in the dataset is required to split a tree node, the square root of the number of
features is used as the number of active variables at each node and the maximum tree depth
was equal to the number of features. For both classiﬁers the number of weak learners has to be
set, where, as explained in73 and74, adding more weak learners does not result in over-ﬁing,
but produces a limiting value of the generalization error. We did a small pilot experiment
using two fold cross-validation to roughly determine the amount of weak learners needed to
achieve the minimal generalization error. is resulted in around 100 regression stumps for
the GentleBoost classiﬁer and 300 trees for the RandomForest classiﬁer.
We compared the performance of the diﬀerent classiﬁers using ROC-analysis. e output
of the classiﬁer with the highest area under the ROC curve was used for further analysis. An
example of a obtained likelihood map is shown in ﬁgure 6.2.
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Figure 6.2: Example results for the CAD system for diﬀerent patients. Figure (a) shows a prostate segmentation
result, Figure (b) a likelihoodmap aer voxel classiﬁcation and Figure (c) a region classiﬁcation result.
6.2.6 Candidate selection
Aer voxel classiﬁcation a likelihoodmap is obtained, indicating per voxel the likelihood that it
contains cancer. On this likelihood-map we perform local maxima detection using a spherical
windowwith a diameter of 10mm, which is about the average lesion size in prostateMRI190–192.
Aer initial local maxima detection the local maxima which are less than 10 mm apart are
merged. is merging step leaves only the local maximumwith the highest probability within
the 10 mm range. is is iterated until no more merging occurs.
6.2.7 Candidate segmentation
For each of the local maxima obtained in the previous step, a region segmentation will be per-
formed. e SmartOpening-algorithm, which has had successful applications in both nodule
segmentation in CT and cancer segmentation in breast MRI, was used193,194. e segmenta-
tion was performed on the likelihood-map itself instead of one of the original clinical images.
e main reason for this is that lesions can show slight deviations in size and even position
between the diﬀerent diagnostic images. e likelihood map is essentially a combination of
all original images through a classiﬁcation step and thus should give a good approximation
of the lesion extent across all diagnostic images. Aer initial segmentation, regions which
overlapped for more than 50% were merged.
6.2.8 Candidate features
Aer candidate segmentation and merging new candidate features can be calculated given
the original feature images and the candidate segmentation. ese can be categorized as:
statistical (voxel feature statistics), local contrast, symmetry and shape features.
Statistical
Statistical candidate features are calculated within the candidate segmentation. Statistics in-
clude mean, standard deviation and histogram percentiles. On all the initial voxel features we
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calculate the mean and standard deviation of the feature values within the candidate segmen-
tation. Additionally, for the ADC and pharmacokinetic features we calculate either the 25th
or 75th percentiles, depending on whether low or high values are indicative of malignancy.
e percentiles are calculated because 60% of all tumors are heterogeneous191, with a more
aggressive hot spot within the tumor that for example has lower ADC values. In addition, we
also calculated the mean, standard deviation and 75th percentile of the voxel likelihood.
Local Contrast
In previous work we have shown that relating tumor feature values to those of surrounding
normal tissue can lead to improved characterization of tumor aggressiveness195. We incor-
porate this knowledge into our CAD system by using local contrast candidate features. e
local contrast feature is calculated by dilating the original segmentation and then subtracting
the original to obtain a rim of tissue outside the candidate. e local contrast is then obtained
by taking the quotient of the average candidate and the average rim intensities. We use a 2D
kernel with a size of 3 mm for dilation. e local contrast feature is calculated on the b800,
ADC, Ktrans, Kep, tau and LateWash voxel feature maps. Additionally, it was also calculated
on the voxel likelihood map.
Symmetry
A normal prostate has a distinct symmetric appearance in the transversal plane. Radiologist
have reported that symmetry in prostate MRI can be important to detect prostate cancer33.
e CAD system incorporates this knowledge by including a symmetry feature. We take the
relative position of a candidate along the x-axis in the transversal plane and mirror it to the
other side of the prostate (e.g. if the relative position is 0.25 we map the mirrored candidate
segmentation to a relative position of 0.75). en we calculate the mean intensity value for
both the mirrored and the original candidate segmentation and take the quotient. e result is
used as the symmetry feature. We calculate this symmetry feature on the b800, ADC, Ktrans,
Kep, tau, LateWash voxel feature maps and the voxel likelihood map.
Shape
e last candidate feature set are the shape features. Prostate lesions tend to be somewhat
spherical and compact. During initial stages of development, most false positives we encoun-
tered were due to small segmentation errors , large non-spherical areas of low ADC due to
extensive benign prostatic hyperplasia and small artifacts caused by the scanner. By incorpo-
rating shape features like volume, sphericity and compactness the classiﬁer can easily remove
these false positives from the data. e sphericity is calculated as the ratio of the volume of
a sphere having the same diameter as the maximum bounding box length of the candidate
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segmentation and the total volume of the candidate segmentation. e compactness is calcu-
lated as the candidate segmentation volume divided by the volume of the bounding box of the
candidate segmentation.
6.2.9 Candidate classiﬁcation
Aer candidate feature extraction the ﬁnal classiﬁcation is performed. ree diﬀerent clas-
siﬁers were tried to obtain the best possible performance, a linear discriminant classiﬁer, a
GentleBoost classiﬁer (with regression stumps as weak learners) and a RandomForest classi-
ﬁer with regression trees. e seings we used at this stage were the same as in the voxel
classiﬁcation stage. Aer classiﬁcation we obtain a likelihood between 0 and 1 per candidate,
0 indicating no prostate cancer and 1 indicating deﬁnite prostate cancer. Examples of a ﬁnal
candidate result can be seen in ﬁgure 6.2
6.2.10 Relative feature and MR sequence importance in voxel and candidate classi-
ﬁcation
To establish the importance of individual features and MR sequences to the overall classiﬁ-
cation results, we performed two experiments at both the voxel and candidate levels. First,
using the selected classiﬁers, we established the classiﬁcation performance of each feature in-
dividually based on area under the ROC curve (using leave-one-patient-out crossvalidation).
Subsequently, we repeated this experiment on a per-sequence basis, i.e. only include features
calculated using one MR sequence, for example only using T2-texture features or only using
DWI features.
6.2.11 Validation
Training data
For the voxel classiﬁcation stage voxels in a 10 mm area around the radiologist annotation
were extracted as prostate cancer samples. is area was truncated by the prostate mask, to
ensure no voxels outside the prostate were included in the training set. Furthermore, we only
selected voxels which had speciﬁc feature characteristics: the ADC value had to be below the
median of the area and the pharmacokinetic features had to be above the median of the area.
We know from clinical experience and literature that these are usually good characteristics of
prostate cancer and reduces the chance of sampling normal voxels into the malignant class.
For the normal class we randomly sample within the prostate mask of normal patients. e
resultant voxel dataset is used to train the voxel classiﬁers.
In the candidate classiﬁcation stage we extract candidate features from the initially de-
tected true positives and the false positives in normal patients aer initial classiﬁcation. e
deﬁnition of true and false positives is given in the next section.
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FROC analysis
e detection performance of the CAD system is evaluated using free-response receiver op-
erating characteristic curve (FROC) analysis. FROC analysis provides the number of false
positives per normal patient for a given sensitivity (i.e. the percentage of cancer detected).
e occurrence of false positives in normal patients is one of the most relevant problems in
prostate cancer diagnosis on MRI as each false positive in a normal patient has the potential
to lead to an unnecessary biopsy, and thus patient morbidity and healthcare cost. As such,
the number of false positives should be as low as possible at reasonable sensitivity. FROC
analysis can be used both aer the initial and ﬁnal stage, which also allows us to assess the
performance gained by the second stage of the CAD system. For evaluation of the ﬁrst stage
the criterion for a true positive is that a local maximum should be within 10 mm of the marker
annotated by the radiologist. 10 mm corresponds to the average lesions size190–192. For the
ﬁnal classiﬁcation a true positive is deﬁned as a candidate segmentation which has a center
of gravity within 10 mm of the marker. Each candidate segmentation is only allowed to cor-
respond to one annotation. is rule is chosen to make sure the system does not have a bias
toward large segmentations, i.e. a candidate segmentation covering the entire prostate would
cover all lesions, but would generally not result in an accurate localization. We evaluated the
system both for the detection of all tumors and the detection of high-grade tumors (ﬁrst or
secondary Gleason component > 3). In the second seing a hit on a low-grade tumor is not
considered a false positive, the reasoning for this is that in principle low-grade prostate cancer
will not require treatment, but it is not detrimental for the patient to detect it.
ROC analysis and comparison to the radiologists
In addition to FROC analysis we also performed patient based receiver operating characteristic
(ROC) analysis both aer the initial voxel classiﬁcation and aer the candidate classiﬁcation.
is is relevant evaluation in a screening seing, where the ﬁrst thing a clinician wants to
know is whether a patient has cancer or not (i.e. the localization aspect captured by the FROC
analysis in the previous section is of secondary importance). A CAD system could play a role
here by separating out the easy from the diﬃcult to diagnose patients, which could improve
the eﬃciency of the radiologist. In each patient, the voxel (voxel stage) or candidate (candidate
stage) with the highest likelihood is used as the patient score, both for patients with prostate
cancer and normal patients. In this setup the CAD system can stratify patient as requiring a
biopsy or not requiring a biopsy.
Additionally, we compare the system to the overall radiologist performance on this data set.
In total 10 radiologists read cases in our patient cohort, each case was read prospectively by
one radiologist. erefore, we can compare the system performance to the actual prospective
clinical performance in our hospital.
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Figure 6.3: Classiﬁer comparison using leave-one-patient-out ROC analysis at the voxel and candidate levels.
95% conﬁdence intervals estimated using bootstrapping are shown as transparent areas around the mean curves.
Input for the comparison at the voxel level are voxel in a cancerous areas and voxels in the prostate of normal
patients. Input for the comparison at the candidate level is true and false positives aer initial voxel classiﬁcation.
Figure a shows the voxel classiﬁcation results and Figure b the region classiﬁcation results.
6.3 Results
6.3.1 Classiﬁer comparison and selection
Bootstrapping and ROC analysis were used to compare classiﬁers for both CAD stages: the
voxel classiﬁcation stage and the candidate classiﬁcation stage. For both stages we performed
a leave-one-patient-out cross-validation on the training data. Results are shown in ﬁgure
6.3. Statistical signiﬁcance testing was performed using the area under the ROC curve. Both
the RandomForest and the Gentleboost classiﬁer performed signiﬁcantly beer than the linear
discriminant classiﬁer in both stages (p < 0.001). For the voxel classiﬁcation stage the random
forest classiﬁer also performed signiﬁcantly beer than the Gentleboost classiﬁer (p < 0.01).
Further analysis of the system was performed using the RandomForest classiﬁer for the voxel
stage. Although the mean area under curve was higher for the RandomForest classiﬁer than
the Gentleboost classiﬁer in the candidate stage, this was not signiﬁcantly diﬀerent. Because
the mean area under the curve was slightly higher we chose to use the RandomForest classiﬁer
for the candidate stage.
6.3.2 Relative feature and MR sequence importance
e rankings for each feature and each MR sequence based on there individual classiﬁcation
performance using the RFC classifer are shown in Tables 6.2 and 6.3. Although the ADC
intensity is the single most important feature in the voxel stage, overall the features calculated
using the T2W MR sequence are the most important in voxel classiﬁcation. Additionally, we
can see from the performance of individual features in the voxel stage that features from each
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Figure 6.4: ROC analysis on a per-patient level, comparison of the CAD system aer the voxel stage and aer the
candidate stage to the prospective radiologist performance. e raw ROC curve is shown as the solid line and the
mean bootstrapped curve as a dashed line. e 95% conﬁdence intervals obtained using bootstrapping are shown
as transparent areas around the mean bootstrapped curve. e radiologist ROC curve and conﬁdence intervals
are only ploed for the four PIRADS thresholds. Figure (a) shows the results for cancer versus normal/benign
and Figure (b) shows the results for high-grade cancer versus normal/benign.
of the MR sequences are selected, showing the importance of using multi-parametric MRI over
single-parameter MRI. Finally, the performance per modality is much lower than the overall
per-voxel performance (0.76 area under the ROC curve for just T2W and 0.89 when combining
all MR sequences).
Inspecting Table 6.3, it is interesting to see that especially heterogeneity of feature values
within the candidates have high individual performance. Additionally, in the candidate stage,
DWI is by far the best performing individual sequence. Furthermore, the initial voxel like-
lihood plays an important part in classiﬁcation in the candidate stage. Finally, in this stage
features from the DWI imaging are almost as good as using features from the combination of
the three MR sequences.
6.3.3 FROC analysis
e FROC curves for detection of prostate cancer and the detection of high-grade prostate
cancer are shown in ﬁgure 6.5. e results show that adding a candidate classiﬁcation step
reduced the number of false positives at constant sensitivity, e.g. a reduction from approxi-
mately 7 to 1.5 false positives per normal case at a sensitivity of 80%. At similar false positive
levels, sensitivities were signiﬁcantly higher aer the candidate classiﬁcation step, e.g. aer
voxel classiﬁcation, at 1 false positive per normal case, a sensitivity of 55% is reached, whereas
the sensitivity is 75% aer the candidate stage (p < 0.001). Additionally, the partial area under
the curve between 0.1 to 10 false positives per normal case is also signiﬁcantly higher (7.11
versus 8.74, p < 0.01). Furthermore, in ﬁgure 6.5b the FROC curves are shown for the de-
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Figure 6.5: FROC analysis of the results of the CAD system. Number of false positives per normal case is shown
on a logarithmic scale. e raw FROC curve is shown as the solid line and the mean bootstrapped curve as a
dashed line. e 95% conﬁdence intervals obtained using bootstrapping are shown as transparent areas around
the mean bootstrapped curve. Figure (a) compares the results aer voxel classiﬁcation and the results aer
candidate classiﬁcation. Adding the candidate classiﬁcation step shows a marked improvement over just voxel
classiﬁcation. Figure (b) shows the results of the candidate classiﬁcation step for cancer vs. normal/benign and
high-grade cancer vs. normal/benign
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tection of high-grade cancer vs. normal/benign in addition to the detection of all cancer vs.
normal/benign. Here, at one false positive per normal case the sensitivity for detecting high-
grade cancer is 0.82 and 0.75 for all cancer. is diﬀerence is not signiﬁcant. Additionally, the
partial area under the curve between 0.1 and 10 false positives per normal case is not signiﬁ-
cantly diﬀerent (8.74 versus 9.06). e maximum sensitivity reached by the system in cancer
versus normal/benign case is 0.94 and 0.97 for the high-grade cancer versus normal/benign
case. is is caused by 11 and 5 false negatives in those cases respectively. Examples of a
true positive and a false positive are shown in ﬁgure 6.7. An example of two false negatives is
shown in ﬁgure 6.6.
6.3.4 ROC analysis
eROC curves for classifying patients as either having prostate cancer or not having prostate
cancer are shown in ﬁgure 6.4. Again we also show the improved performance obtained by
adding a candidate classiﬁcation step compared to just using a voxel classiﬁcation step. In
these ﬁgures the CAD system is also compared to the clinical diagnosis made by the radiologist
for each patient on the basis of the PIRADS system. A radiologist scores each suspicious lesion
on a scale from 1 to 5, 1 meaning deﬁnitely not cancer and 5 meaning deﬁnitely cancer. e
patient score is than obtained by taking the highest PIRADS score. For the radiologist only
the conﬁdence intervals for the four actual PIRADS thresholds are used for evaluation, as the
ROC curve is not well deﬁned at other positions due to the low number of thresholds.
e addition of the candidate classiﬁcation shows a marked improvement when evaluating
on a per-patient basis, with an increase in AUC from 0.722 to 0.81 (p < 0.01) and from 0.73
to 0.83 (p < 0.01) for high-grade cancer versus normal/benign. At a high speciﬁcity (le part
of the ROC curve) of 0.88 (PIRADS score 5), there is no signiﬁcant diﬀerence between the
radiologist and the CAD system (p = 0.334 for detection of cancer, p = 0.37 for detection of
high-grade cancer). At the other thresholds the radiologist performance is signiﬁcantly beer
than the CAD system (p < 0.01). e radiologist is signiﬁcantly beer at every PI-RADS
threshold compared to CAD system when only using the voxel stage.
6.4 Discussion
A CAD system which detects prostate cancer in MRI images was presented in this paper.
e performance of the system was evaluated on a large consecutive set of patients, with
MR-guided biopsy as a reference standard. antitatively, the area under the ROC curve for
classifying patients was 0.81. If we investigate the performance from an FROC perspective,
at 1 false positive per image we obtain a sensitivity of 0.75 for detecting any cancer lesion
and 0.83 for detecting a high-grade cancer lesion. Compared to the radiologist, the system
shows no signiﬁcant diﬀerences in performance at high speciﬁcity (Figure 6.4, le part of
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Figure 6.6: Examples of false negatives (FN). e location of the false negatives is indicated with the red circle.
False negative 1 (a,b) is caused by segmentation errors. In Figure (a) (axial view) the prostate segmentation is
indicated in yellow. e segmentation most likely fails due to the fact that the prostate is growing into the
bladder, as can be seen in (b) (sagial view). False negative 2 is caused by our evaluation criterion, the region
segmentation (indicated in yellow in ﬁgures (c) (ADC) and (d) (DCE+Ktrans) is quite large and therefore the mark
(the red sphere) and the center of gravity of the region segmentation are more than 10mm apart.
the curve). However, at lower speciﬁcity the radiologist performs signiﬁcantly beer (p <
0.01). Furthermore, in both Figure 6.5 and Figure 6.4 we show that adding a candidate stage in
addition to a voxel stage signiﬁcantly improves performances on both a per-lesion (sensitivity
at 1 false positive per normal patient increases from 0.55 to 0.75) and per-patient level (area
under the ROC curve increases from 0.72 to 0.81).
If we compare our system to the current state-of-the-art, two types of systems can be dis-
tinguished: systems which perform only a voxel-based analysis and systems which perform
both a voxel-based analysis and a candidate evaluation step. For the ﬁrst type of system, Ti-
wari et al. have shown the best voxel classiﬁcation performance using a system with manual
prostate segmentation and MR spectroscopy. ey obtain an average area under the curve
of 0.89, which is similar to our results obtained during the classiﬁer comparison at the voxel
level ﬁgure 6, average area under the curve of 0.889). However, we show in our study set
that a voxel classiﬁcation performance of 0.89 only results in a per-lesion classiﬁcation per-
formance of 0.55 sensitivity at 1 false positive per normal patient and a per-patient area under
the ROC curve of 0.72. Our addition of a subsequent candidate classiﬁcation step increases the
performance of the system by a signiﬁcant amount (0.75 sensitivity at 1 false positive per nor-
mal patient (p < 0.01), ﬁgure 8 and 0.81 area under the ROC curve for a per-patient analysis
(p < 0.01). However, as Tiwari et al. did not extend their system to a per-region and per-
patient evaluation we cannot directly compare this. We do have to note that this comparison
has not been made on the same data set, which is unfortunate, but there is no open availability
of a signiﬁcant amount of multi-parametric prostate MRI data. We are currently considering
organizing a prostate cancer detection challenge similar to other grand challenges in medical
image analysis to allow our algorithm to fairly compete against others. For the second type of
system incorporating a candidate detection and a candidate classiﬁcation step we can compare
our results to Vos et al.96, which is the only other two-stage system. Instead of a voxel classi-
ﬁcation step, they use a blob detector to obtain the candidates. At 0.1, 1 and 10 false positives
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Figure 6.7: Examples of a true positive (a-b) and a false positive (c-d) on T2-weighted imaging (a,c) and the ADC
map (b,d).
Feature AUC Modality AUC
ADC 0.666 T2W 0.760
Gauss. Texture (Order=-, Scale=2.0) 0.633 DWI 0.746
tau Blob 0.632 DCE 0.714
KTrans 0.629
T2-map 0.620
kep 0.604
KTrans Blob 0.600
Gauss. Texture (Order=YY, Scale=5.1) 0.599
Gauss. Texture (Order=-, Scale=3.17) 0.597
b800 0.588
Table 6.2: Results for relative feature and modality importance experiment based on leave-one-patient-out cross-
validation for voxel classiﬁcation.
per normal case they obtained a sensitivity of 0.15, 0.48 and 0.89 where we obtain a sensitivity
of 0.42, 0.75 and 0.89. Especially at the lower false positive rates we obtain a substantially
beer performance.
e use of multi-parametric MRI over single-parameter MRI is already part of clinical
guidelines33. In this study we investigated the performance of individual features and MR
sequences in both the voxel and candidate stages of our CAD system. Especially in the voxel
stage, the combined interpretation of all three MR sequences, T2-weighted imaging, diﬀusion-
weighted imaging and dynamic contrast-enhanced imaging shows a large improvement over
using any single MR sequence (highest performing single sequences AUC is 0.76, combination
is 0.89), and all play about an equal role. In the subsequent candidate stage there is a preference
for DWI over DCE over T2W., is experiment also showed that the individual performance
of features was relatively low compared to the combination of all features (best performing
feature in the voxel stage had a AUC of 0.66, whereas the overall voxel stage AUC was 0.89).
ese observations conﬁrm clinical practice. A limitation of this study is the fact that the
ROC evaluation is positively biased toward the radiologist. Although the reference standard
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Feature AUC Modality AUC
b800 (standard deviation) 0.805 DWI 0.910
ADC (standard deviation) 0.790 DCE 0.814
Voxel likelihood (mean) 0.765 T2W 0.719
LateWash Blob (standard deviation) 0.750
ADC Blob (standard deviation) 0.741
LateWash (standard deviation) 0.731
Voxel likelihood (75th percentile) 0.727
Voxel likelihood (standard deviation) 0.723
kep (standard deviation) 0.723
Volume 0.716
Table 6.3: Results for relative feature and modality importance experiment based on leave-one-patient-out cross-
validation for voxel classiﬁcation.
for cancerous regions is well deﬁned by the MR-guided biopsy specimens, for most of the nor-
mal regions we have to depend on the opinion of the radiologist. While we incorporated only
data with either negative biopsy results or very low PI-RADS scores (1 and 2) there is still
the risk that some areas we deem normal are actually prostate cancer. Furthermore, in the
evaluation and the comparison to the radiologist, it may well be that the radiologists did have
some false negatives. Recently, prospective preliminary results were published by ompson
et al.62 ey found that the sensitivity for radiologists for detecting high-grade prostate cancer
was 96%. If we look at the potential of our CAD system in such a seing, at a operating point
with a sensitivity of 96%, the speciﬁcity of the CAD system is between 15-40%. is could
indicate that between 15-40% of all studies could be read by the CAD system and would po-
tentially require no human intervention, which could reduce the workload of the radiologist
substantially. Another limitation is the fact that although the multi-parametric MRI is implic-
itly registered (all sequences are acquired in one go, without the patient leaving the scanner),
registration errors between the diﬀerent sequences could occur due to patient movement. is
was mostly circumvented in our data by a. not using an endorectal coil, which signiﬁcantly
improves patient comfort and as such reduces patient movement and b. by administering Bus-
copan prior to the MRI to reduce bowel movement and c. using multi-scale features (Gaussian
texture, blobness) where exact voxel alignment is less important. Further improvement could
be achieved by implementing a registration algorithm for prostate MRI, however, this is cur-
rently an unsolved problem. To the best of our knowledge there are currently no publications
on the registration of multi-parametric prostate MRI.
e false negatives in our system are mostly caused by prostate segmentation errors. Of
the 11 false negatives aer candidate classiﬁcation, 6 are caused by the prostate segmentation
118 Development of a computer-aided detection system for prostate cancer in MRI
missing the lesion entirely or partly. Most of these issues can be solved by incorporating a
segmentation method which is more robust to strange prostate shapes. An example is shown
in ﬁgure 6.6. Although the prostate segmentation algorithm is a candidate for improvement,
it is missing only 6 out of 183 lesions (or 3% of total sensitivity), which is still a reasonable
result. e segmentation algorithm only ﬁnished 9 out of 12 in the PROMISE12-challenge,
however overall segmentations were prey accurate, with a median Dice’s coeﬃcient of 0.83.
For the remaining false negatives, in four cases the lesion was detected, but the candidate
segmentations were so large that the center of the candidate segmentation and the lesion
marker were more than 10 mm apart, thus failing our criterion for a true positive. is can
happen because in big lesions the radiologist did not always put the point annotation at the
center of the lesion. For one false negative the areawas not identiﬁed by the voxel classiﬁcation
and the local maxima detection and thus lost to the second part of the system.
e motivation for the development of a CAD system is to aid radiologists by improving
eﬃciency and performance. e amount of cases a radiologist has to read in a screening
seing is enormous, and our CAD system will be most useful in such a situation. However,
we have not yet evaluated the system on screening data as the data in this study only includes
patients with previous negative TRUS biopsies. erefore we cannot make any claims on the
performance of the system in a screening seing. Summarizing, a fully automatic CAD system
was developed for the detection of prostate cancer in MRI images. Performance evaluation
shows that it outperforms the state-of-the-art, although the comparison has its limitations
due to diﬀerent evaluation data sets. Furthermore, the system is not signiﬁcantly diﬀerent
from radiologist performance at high speciﬁcity. erefore we believe it to be a potentially
valuable tool to aid radiologists in the clinic.
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7.1 Introduction
Multi-parametric magnetic resonance imaging (mpMRI) is emerging as an important modality
in prostate cancer diagnosis33,196,197. Multi-parametric MRI combines T2-weighted, diﬀusion-
weighted, and dynamic contrast-enhanced techniques to provide information, respectively,
on abnormal anatomy, cell-density, and neo-vascularity. Several studies have shown that in
patients with initial negative trans-rectal ultrasound-guided biopsies (TRUSGB) expert readers
using mpMRI ﬁnd cancer in 38 - 59% of the cases44,198. Furthermore, it has been shown that
mpMRI upgrades cancer aggression of previously TRUSGB detected cancers in up to 30% of
cases199. Several other studies found that the negative predictive value of mpMRI is high
enough to avoid TRUSGB in 30-50% of men with elevated PSA62,200. However, one of the main
limitations for broader acceptance of mpMRI is the lack of required expertise, especially in the
interpretation of the MR images31,32,102.
In order to improve the acquisition and interpretation of mpMRI the European Society for
Urogenital Radiology (ESUR) established initial guidelines for acquisition and standardized
interpretation of mpMRI33. ese guidelines have been evaluated by several groups, both for
detection of cancer prior to biopsy62,63 and aer initial negative TRUSGB58–61. Pokorny et al.
found that using mpMRI and MR-guided biopsy in biopsy-naïve men results in a large reduc-
tion of over-diagnosis of low-grade cancer (82%) while detecting 17% more intermediate/high-
grade cancers than TRUSGB. ompson et al.62 showed that an mpMRI score of 3 or higher
(on a 5 point scale) would result in a sensitivity of 97% and a speciﬁcity of 50% for the detec-
tion of high Gleason grade cancer using saturation template biopsy as a reference standard.
Deferring biopsy to a score of 4 or higher would result in a substantially improved speciﬁcity
of 92%, but a sensitivity of only 67%.
To further improve prostate mpMRI interpretation, biomarkers and computerized deci-
sion aids are actively researched to help detect intermediate/high-grade prostate cancer. Sev-
eral groups have focused on correlating individual MR parameters (DCE47, DWI51,160 or spec-
troscopy201) to cancer grade, estimating their usefulness as quantitative biomarkers of prostate
cancer aggressiveness. However, none have yet focused on multi-variate quantitative analy-
sis to determine cancer grade. Various groups are developing computer-aided diagnosis al-
gorithms (CAD) to detect aggressive tumours94,96,97. ey have shown that CAD can help
improve the interpretation, especially for inexperienced radiologists97,202. However, the eval-
uation of such systems has been limited to observer studies and ROIs pre-selected by the re-
searchers97,202, or to speciﬁc sub-parts of the prostate, like the peripheral zone202.
e purpose of this study is to investigate the clinical eﬀect of a recently developed, state-
of-the-art computer-aided diagnosis (CAD) system203 on the diagnostic accuracy of prostate
MRI PIRADS reporting and to study the ability of CAD to help assess prostate cancer aggres-
siveness.
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Eligible patients
N = 130
Included patients
N = 107
Excluded patients
N = 23
No dynamic contrast 
enhance imaging
N = 2
Failed diffusion-
weighted imaging
N = 2
Receive prior treatment 
for prostate cancer
N = 18
Lesion could not be 
found during MR-
guided biopsy
N = 1
Total cancer suspicious 
regions
N = 141
Benign/normal
N = 45
Low grade
N = 28
Intermediate grade
N = 37
High grade
N = 31
Figure 7.1: STARD diagram of inclusion and exclusion criteria of the prospective patient cohort.
7.2 Materials and Methods
7.2.1 Patient data
e institutional review board waived the need for informed consent as only imaging data and
MR-guided biopsy results obtained from regular care were used. To prospectively evaluate the
CAD system we included all 130 patients from January 1st to September 1st 2013 that received
both an mpMRI and a subsequent MR-guided biopsy at our institution. e inclusion criteria
for the detection MRI were an initial negative TRUSGB and persistently elevated PSA. Multi-
parametric MRIs were acquired according to the ESUR guidelines and included T2-weighted
imaging in three orthogonal directions, diﬀusion-weighted imaging and dynamic contrast en-
hanced imaging. All MRIs were performed at a Siemens 3T MRI scanner (TRIOTIM or Skyra)
without an endo-rectal coil. Full acquisition details are presented in Table 7.1.
MRIs were read prospectively by one radiologist out of the group of radiologists that re-
port prostate MRI in our clinic. Experience levels of the reporting radiologist ranged from
inexperienced (1 year) to very experienced (J.B., 20 years of experience with prostate MRI).
MRI studies were read according to the ESUR prostate imaging reporting and data system (PI-
RADS) classiﬁcation including ongoing local and international score reﬁnements63. Cancer
suspicious regions were given a ﬁnal PIRADS score from 1 to 5, where 1 means ‘deﬁnitely not
cancer’ and 5 means ‘deﬁnitely cancer’. Per patient all regions with a PIRADS 3, 4 or 5 were
indicated. If no lesion with PIRADS 3-5 was present, a lesion or normal tissue with a PIRADS
1 or 2 score was identiﬁed. us in each study at least one region was indicated. Cancer
suspicious regions (PIRADS 4 and 5) were subsequently biopsied under direct MR-guidance.
PIRADS 3 lesions were biopsied only if there was a high clinical suspicion for prostate cancer
(e.g. extremely high PSA, as assessed by the radiologist). A PIRADS 2 lesion was only biop-
sied, when a biopsy was already required due to the presence of a PIRADS 3, 4 or 5 lesion. All
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PS SR ST ET RT FA Other
T2W Turbo
spin-
echo
0.28 – 0.6
mm
3.0 – 3.2
mm
101 – 104
ms
4480 –
6840 ms
120 - 160 Acquired in three orthogo-
nal directions: transversal,
sagial and coronal.
DWI Echo
planar
2 mm 3 mm 63 – 81
ms
2800 –
3600 ms
90 3 b-values: 50, 400 – 500,
800 averaged over 3 direc-
tions. Apparent diﬀusion
coeﬃcient map calculated
by the scanner soware.
DCE Turbo
FLASH
1.5 – 1.8
mm
3.2 – 5
mm
1.41 ms 36 ms 10 - 14 Temporal resolution of 3.38
– 4.65 seconds, 36 – 50
timepoints. 15 mL contrast
agent used (Dotarem, Guer-
bet, France)
Table 7.1: MRI sequence details for the diﬀerent types of acquisitions. PS = pulse sequence SR = spatial resolution,
ST = slice thickness, ET = echo time, RT = repetition time, FA = ﬂip angle.
other PIRADS 1, 2 or 3 lesions were not biopsied and not further considered in this study.
Lesions were categorized into either benign/low-grade (indolent) or intermediate/high-
grade cancer (aggressive) based on the MR-guided biopsy Gleason scores. For brevity, the two
categories will be subsequently referred to as indolent and aggressive. e lesion categoriza-
tion strategy is similar to51. Details can be found in Table 7.2.
7.2.2 Computer-aided diagnosis system
e computer-aided diagnosis system evaluated in this paper was previously presented in203.
is system can fully automatically analyze prostate MRIs by ﬁrst segmenting the prostate.
Next, quantitative voxel features are computed based on the PIRADS guidelines (e.g. the ap-
parent diﬀusion coeﬃcient, the presence and amount of washout in the DCE MRI). Machine
learning techniques summarize the voxel features into a likelihood of cancer per voxel. Lo-
cal maxima detection is then used to identify suspicious regions in the voxel likelihood map.
ese regions are analyzed in more detail with region-based features (e.g. voxel statistics like
the 25th percentile of the ADC within a region, symmetry within the prostate and local con-
trast). A second machine learning step combines the region features into a region likelihood.
e systemwas trained with retrospective patient data, which had no overlap with the data set
used in this study. e retrospective data was acquired in a similar manner as the prospective
data and had the same reference standard strategy. Details of the retrospective cohort can be
found in Table 7.4.
For the study in this paper one modiﬁcation was made to the system. e system nor-
mally operates autonomously and chooses areas deemed suspicious enough for the second
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Grade Gleason scores
Low 3+3 or lower, no 4 or 5 component
Intermediate 2+4, 3+4, 2+5
High 3+5, any cancer with a major 4 or 5 component
Table 7.2: Mapping of Gleason scores to cancer grade
Detection
(radiologist)
PIRADS
(radiologist)
Likelihood
(CAD)
Decision
(urologist + 
radiologist)
Aggressive cancer?
Figure 7.2: Suggestedworkﬂow for the proposed CAD system. e biopsy decision can bemade by the radiologist,
another aending clinician or by using a nomogram (Figure 7.3) to independently combine the PIRADS score
and the CAD likelihood.
stage analysis independently. However, for the purpose of this study we used the radiologist-
indicated suspicious location(s) as input for the second stage of the CAD system (replacing
the local maxima detection). is modiﬁcation was made to ensure a likelihood from the CAD
system is obtained for each region indicated by the radiologist, even if the CAD system itself
deemed the region not suspicious enough aer the ﬁrst stage.
7.2.3 Combination of the CAD system and the radiologist
euse of the system as suggested in this paper is presented schematically in Figure 1. e ini-
tial identiﬁcation of potential suspicious regions was performed by the radiologist, aer which
the radiologist and the CAD system gave independent predictions on whether the suspicious
lesion is an indolent or aggressive lesion. e radiologist did this by assigning a PIRADS score,
while the CAD system assigned a continuous cancer likelihood score between 0 and 1.
e reported scores of the radiologists and CAD were combined aerwards using a nomo-
gram, which is a method to map several distinct measurements and observations to a single
outcome variable in an unbiased manner. We developed such a nomogram by using logistic
regression to independently combine the PIRADS score of the radiologist and the likelihood
from the CAD system. is nomogram was created based on the retrospective data that was
also used to train the CAD system and subsequently evaluated on the prospective data pre-
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sented in this paper. It is noted that in a clinical workﬂow alternativemethods of incorporating
CAD results may be used, such as asking the radiologist to make a ﬁnal decision based on the
two scores.
7.2.4 Statistical evaluation
e statistical evaluation consisted of three parts. First, we investigated the potential increase
in predictive power of the radiologist/CAD-combination over the radiologist alone using the
likelihood ratio test on the logistic regression models.
Second, the diagnostic performance of the CAD system, the radiologist and the combina-
tion of radiologist/CAD was evaluated using receiver-operating characteristic (ROC) analysis.
e signiﬁcance of improvement for both sensitivity and speciﬁcity was tested using boot-
strapping at the points for which the ROC curve of the radiologist was explicitly deﬁned (i.e.
the diﬀerent PIRADS thresholds). A total of 10,000 bootstrap samples was used to obtain the
95% conﬁdence intervals.
ird, we investigated whether the likelihoods of aggressive disease obtained from the
CAD system correlate to cancer grade. As cancer grade is an ordinal variable, Spearman’s rank
correlation coeﬃcient was used to estimate this correlation. Furthermore, the likelihood ob-
tained from the radiologist/CAD-combination nomogram was also correlated to cancer grade.
For the evaluation, a correctly identiﬁed aggressive lesion was a true positive result. When
an indolent lesion was identiﬁed as an aggressive lesion, this was considered a false positive.
Note that we explicitly considered diagnosis of low-grade cancer a false positive; identiﬁcation
of low-grade cancer can lead to over-diagnosis and over-treatment.
All analysis was done on a per-lesion basis. For all signiﬁcance tests a p-value threshold of
0.05 was chosen. SPSS (SPSS, version 20.0.01, Chicago, U.S.A) was used for statistical analysis.
7.3 Results
7.3.1 Patient data
e prospective cohort composition is detailed using a STARD diagram in Figure 7.1. Informa-
tion on patient age/PSA ranges and tumor grade distribution are shown in Table 7.3. PSA and
age ranges are similar to other studies using patient data with similar inclusion criteria (initial
negative TRUS biopsy and persistently elevated PSA)58–61. Furthermore, the distribution of
cases between the two categories indolent and aggressive was similar (73 versus 68 lesions).
Information on the retrospective cohort that was used to train the CAD system and ob-
tain the nomogram is presented in Table 7.4. A similar distribution of PSA levels, age and
cancer grade can be observed between the retrospective training cohort and the prospective
evaluation cohort.
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Clinical aracteristics
PSA level, mg/ml, median (range) 13 (1 – 56)
Age, yr, median (range) 66 (48 – 83)
Gleason score Grade No. of lesions
Normal/Benign Normal/Benign 45 No cancer 45
2 + 5 Intermediate 1 Low 28
3 + 2 Low 2 Intermediate 37
3 + 3 Low 26 High 31
3 + 4 Intermediate 36 Total 141
4 + 3 High 12
4 + 4 High 5
4 + 5 High 10
5 + 4 High 3
5 + 5 High 1
Table 7.3: Characteristics of patients and biopsy specimens for the prospective cohort (107 patients). PSA ranges
were determined on 103 patients, for 4 patients PSA levels were unknown.
Clinical aracteristics
PSA level, mg/ml, median (range) 11 (1 – 57)
Age, yr, median (range) 65 (42 – 78)
Gleason score Grade No. of lesions
Normal/Benign - 151 No cancer 151
2 + 3 Low 3 Low 61
2 + 4 Intermediate 1 Intermediate 67
3 + 2 Low 3 High 53
3 + 3 Low 55 Total 332
3 + 4 Intermediate 66
4 + 3 High 28
4 + 4 High 12
4 + 5 High 11
5 + 4 High 2
Table 7.4: Characteristics of patients and biopsy specimens for the retrospective cohort (254 patients). PSA ranges
were determined on 220 patients, for 34 patients PSA levels were unknown.
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Figure 7.3: Nomogram estimated using logistic regression for the combination of the radiologist and the CAD
system. e likelihood for intermediate/high-grade cancer is indicating by the color coding and the contour
labels and ranges from 0 to 1. Green indicates low likelihood and red indicates high likelihood.
7.3.2 Combination of PIRADS and CAD likelihood
TFirst, the logistic regression procedure showed that including the CAD system likelihood
in addition to the radiologist PIRADS score resulted in a model with signiﬁcantly improved
predictive power (p < 0.001, likelihood ratio test) for aggressive disease. e nomogram
obtained using logistic regression on the retrospective training data of the CAD system is
presented in 7.3. e equation describing this nomogram is:
Likelihood = 11+ e-t (7.1)
t = -7.629+ 3.886C+ 1.295P (7.2)
where C is the CAD system likelihood and P is the radiologist PIRADS score. Second, the
results of using this nomogram prospectively to combine the radiologist score and the CAD
system are presented in Figure 7.4. Here the ROC curves for the CAD system and the combi-
nation are shown. e performance of the radiologist is presented at three diﬀerent PIRADS
thresholds.
A signiﬁcantly improved sensitivity was obtained at the PIRADS 4 threshold (0.98 for
the radiologist/CAD-combination versus 0.93 for the radiologist alone, p = 0.029). Further-
more a signiﬁcantly improved speciﬁcity was found for the PIRADS 3 threshold (0.25 for the
7.4 Discussion 127
radiologist/CAD-combination versus 0.09 for the radiologist alone, p = 0.013).
7.3.3 Correlation of likelihood and cancer grade
ird, the relations between the CAD system likelihood and cancer grade is presented in Figure
7.5a as box-plots. In Figure 7.5b the same result is presented for the CDS/radiologist combi-
nation. A clear trend can be observed; higher likelihoods relate to higher cancer grade. e
Spearman’s rank correlation coeﬃcient was 0.536 when using only the CAD system, 0.582
for the radiologist alone and 0.694 when combining the CAD system and the radiologist. All
correlations were signiﬁcant (p < 0.01).
7.4 Discussion
e Results of this study indicate that computerized analysis of prostate regions to character-
ize cancer grade may help improve radiologist performance in selecting biopsy targets in a
prospective seing.
e likelihoods of intermediate-to-high-grade cancer of the CAD system (which combines
all MRI parameters) signiﬁcantly correlated with cancer grade. An even higher, signiﬁcant
Spearman’s rank correlation coeﬃcient of 0.694 was obtained by using the nomogram (Figure
7.3) combining the radiologist with the CAD system. As far aswe are aware, there are currently
no prospective studies assessing the correlation of multiple MR parameters with cancer grade.
To translate these results to clinical practice, we tested whether combining the radiolo-
gist and CAD system results in improved sensitivity or speciﬁcity at the diﬀerent PIRADS
thresholds. Inspecting the ROC curve (Figure 7.4) for the CAD system with respect to the
performance of the radiologist at the diﬀerent PIRADS thresholds, we can appreciate that the
performance of both the radiologist and the CAD system seem similar. However, they pro-
vided complementary information, as the combination of both predictions (PIRADS score and
CAD likelihood) results in an improved ROC curve (blue curve, Figure 7.4). At a PIRADS
threshold 3 a signiﬁcant increase in speciﬁcity was found (p = 0.013) and at the PIRADS 4
threshold a signiﬁcant increase in sensitivity was found (p = 0.029). us, combing radi-
ological expertise with computational methods to characterize prostate cancer results in an
improved sensitivity and speciﬁcity.
In the study by Pokorny et al. it was already established that MRI before any TRUSGB has
the potential to reduce the amount of biopsies by 51% compared to TRUSGB63. Improving the
performance of the reporting radiologist by adding the CAD system as an independent second
reader as presented in this paper might further reduce the amount of biopsies by beer char-
acterizing lesions as aggressive or indolent in vivo. Furthermore, the use of computer-aided
diagnosis system might make reporting prostate MRI feasible for less experienced radiologists
or urologists. Although this was not explicitly investigated in this paper, the high standalone
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Figure 7.4: Receiver-operating characteristic curve showing the performance of the CAD system (orange) and
the radiologist/CAD-system combination (blue). e shaded areas indicated the 95% conﬁdence intervals as
calculated using bootstrapping. e radiologist performance is indicated with point for the diﬀerent PI-RADS
thresholds. e vertical error bars indicate the 95% conﬁdence interval on the sensitivity and horizontal error
bars indicated the 95% conﬁdence interval on the speciﬁcity as estimated by bootstrapping.
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Figure 7.5: Relation between computer system likelihood and cancer grade (a) and the computer sys-
tem/radiologist combination and cancer grade (b) when the system is trained to detect only intermediate-to-
high-grade cancer.
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performance of the CAD system supports this idea.
is study has some limitations. First, although MR-guided biopsy has been described
to have a very high concordance with prostatectomy Gleason grade (95% detection rate for
Gleason 4 and 5 components), it is not 100% accurate28. is potentially implies, that some of
the cancers in our study are under- or over-graded by the MR-guided biopsy.
A second limitation is that each case in this study was read by one radiologist. is means
that inter-observer variability could not be established in this study. However, a consensus
meeting re-evaluated uncertain scores prior to biopsy. In future work it would be beneﬁcial to
compare the performance of the CAD system and radiologist to two radiologists performing a
ﬁrst and second read. A third limitation is that our evaluation only pertains to a single center,
so we could not test whether our results generalize to diﬀerent centers.
Last, due to the fact that PIRADS 1 and 2 lesions are generally not biopsiedwe cannot assess
the full performance of the CAD system and the radiologist in negative cases without long-
term follow-up or external reference tests like full template biopsy. However, this has lile
impact on the results of this study. Of all 7 biopsied PIRADS 2 lesions, none was categorized as
aggressive. is indicates that radiologists are already reading at a very high sensitivity level
and they do not need a computer-aid at the lower PIRADS scores. Literature also conﬁrms this
assessment, with the studies byompson et al.62 and Pokorny et al.63 reporting MRI sensitiv-
ities and negative predictive values of 97 and 96.9% respectively when PIRADS 3 and higher
lesions are biopsied. e CAD system has most potential in more accurately discriminating
which PIRADS 3, 4, or 5 lesions require biopsy and the results at these scores are not aﬀected
by the lack of PIRADS 1 or 2 biopsies.
7.5 Conclusions
In this paper the use of a computer-aided diagnosis system in conjunction with the radiologist
to accurately characterize prostate lesions was investigated. Result showed that a signiﬁcant
increase in diagnostic performance can be achieved when combining the radiologist PIRADS
score and the CAD system likelihood. Furthermore, a signiﬁcant correlation between CAD
likelihood and cancer grade exists; this increases further when the PIRADS score and the
CAD likelihood are combined using a logistic regression-based nomogram.
Summary and discussion

Summary
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134 Summary
e focus of this thesis was the research and development of a CAD system for detection of
cancer in prostate MRI. It covers segmentation of relevant structures (chapters 2 and 3), fea-
ture discovery (chapters 4 and 5), building the CAD system (chapter 6) and system evaluation
(chapter 7).
In chapter 2 the organization of a challenge for prostate segmentation in MRI is discussed.
e challenge was setup to allow fair and meaningful comparison of diﬀerent segmentation
algorithms. Challenge design included the acquisition ofmulti-center, multi-vendor andmulti-
protocol data and the development of evaluation measures that would allow us to show clear
separation between algorithms on the basis of performance. e challenge included both an
online component and a live challenge during a workshop at the MICCAI2012-conference in
Nice, France. In total 11 teams participated in this initial phase of the challenge, with distinctly
diﬀerent algorithms, ranging from active-shape models to multi-atlas registration approaches.
e results indicated that the top-two participating algorithms signiﬁcantly outperformed all
the algorithms outside of the top-three and had an eﬃcient implementation with a run time of
8 minutes and 3 second per case respectively. Overall, active-shape model based approaches
seemed to outperform other approaches like multi-atlas registration, both on accuracy and
computation time. Average algorithm performance was good to excellent and the Imorphics
algorithm even managed to outperform the second human observer on average. However,
we showed that algorithm combination might lead to further improvement, indicating that
optimal performance for prostate segmentation is not yet obtained.
Segmentation of the prostate zones is a relatively new research topic; initial results of
a paern recognition approach for zonal segmentation are discussed in chapter 3. Zonal
segmentation of the prostate into the central gland and peripheral zone is a useful tool in
computer-aided detection of prostate cancer because occurrence and characteristics of cancer
in both zones diﬀer substantially. We opted for a paern recognition approach because it can
capture the distinct appearance diﬀerences through a wide range of quantitative image char-
acteristics and is best suited to deal with the high variability in zonal shapes. e algorithm
incorporates three types of features that can diﬀerentiate between the two zones: anatomi-
cal, intensity and texture. It is evaluated against a multi-parametric multi-atlas based method
using 48 multi-parametric MRI studies. Segmentations from three observers were used to as-
sess inter-observer variability and we compared our results against the state of the art. We
obtained a mean Dice coeﬃcient of 0.89  0.03 for the central gland and 0.75  0.07 for the
peripheral zone, compared to 0.87 0.04 and 0.76 0.06 for the state of the art. Summarizing,
a paern recognition approach incorporating anatomy, intensity and texture has been shown
to give good results in zonal segmentation of the prostate.
Features to discriminate between speciﬁc types of benign disease and prostate cancer are
discussed in chapter 4. e presence of benign disease in the prostate acts as a confounder for
the diagnosis of prostate cancer. e most common types of benign ﬁndings in the prostate
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are benign prostatic hyperplasia (BPH), atrophy, inﬂammation and prostatic intra-epithelial
neoplasia (PIN). To establish the imaging characteristics of these classes we used fusion of MRI
and histopathology, computer-extracted features and classiﬁcation. Prostatectomy and pre-
operative multi-parametric prostate MRI of 70 patients were included in this study. Intensity,
texture and pharmacokinetic features were extracted for each of the confounding classes and
prostate cancer. Feature selection was performed for each of the pair-wise classiﬁcation tasks
(cancer vs. BPH, PIN, inﬂammation and atrophy, respectively) to identify the top ﬁve features
for each. In total 92 PIN, 64 atrophy, 120 inﬂammation and 73 BPH lesions, and 128 cancer
lesions were annotated. For each of the classiﬁcation tasks distinct features were identiﬁed
which provided the best discriminatory performance. Furthermore, for all classiﬁcation tasks
the area under the ROC curve improved signiﬁcantly compared to monolithic classiﬁcation
(all benign confounders considered a single class).
Chapter 5 assessed whether we could improve the potential of the apparent diﬀusion coef-
ﬁcient in assessing cancer aggressiveness by explicitly incorporating inter-patient variation in
the normal peripheral zone ADC. Intra-, and inter-patient variation of peripheral zone ADC
was determined by repeated measurements of normal regions in a retrospective cohort of 10
consecutive patients over three separate MR imaging sessions at 3T. e eﬀect of this intra-
and inter-patient variation on assessment of prostate cancer aggressiveness was examined in a
second retrospective cohort of 51 patients with prostate cancer who underwent an MRI, prior
to prostatectomy. Logistic regression was used to assess whether incorporating normal ADC
values improved the prediction of cancer aggressiveness. e eﬀect on the diagnostic perfor-
mance was assessed using receiver-operating characteristic analysis. e repeated-measures
ANOVA revealed that inter-patient variability was signiﬁcantly larger thanmeasurement vari-
ability. Analysis of standalone tumor ADC values showed an AUC of 0.91 for discriminating
low- vs. high-grade tumors. Incorporating normal PZ ADC using linear logistic regression,
signiﬁcantly improved the AUC to 0.96.
e development of the two-stage CAD system is detailed in chapter 6. In the ﬁrst stage
we detect initial candidates using multi-atlas-based prostate segmentation, voxel feature ex-
traction, classiﬁcation and local maxima detection. e second stage segments the candidate
regions and using a classiﬁer we obtain cancer likelihoods for each candidate. Features rep-
resent pharmacokinetic behavior, symmetry and appearance, among others. In both stages
a random forest classiﬁer is used to obtain cancer likelihoods. e system is evaluated on
a large consecutive cohort of 347 patients with MR-guided biopsy as the reference standard.
is set contained 165 patients with and 182 patients without prostate cancer. Performance
evaluation is based on lesion-based FROC and patient-based ROC analysis. e system is also
compared to the prospective clinical performance of radiologists. Results show a sensitivity
of 0.42, 0.75 and 0.89 at 0.1, 1 and 10 false positives per normal case. Additionally, the patient-
based ROC shows no signiﬁcant diﬀerence at high speciﬁcity between the CAD system and
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the radiologist.
In chapter 7 the independent combination of the CAD system and the radiologist is in-
vestigated with respect to the potential to improve radiologist performance and assess cancer
aggressiveness. We obtained MRI studies and subsequent histopathologic outcome of MR-
guided biopsies of a consecutive set of 130 patients from January 1st to September 1st 2013.
Logistic regression combined CAD with the radiologist. Bootstrapping was used to analyze
diﬀerences in sensitivity and speciﬁcity of the CAD/radiologist combination compared to the
radiologist alone. Spearmans’ rank correlation coeﬃcient was used to assess correlation be-
tween CAD likelihood and cancer grade. Of all biopsies performed under MR-guidance, a total
of 68% was positive and 32% was negative for prostate cancer. When detecting intermediate-
to-high-grade cancer a signiﬁcantly improved sensitivity was found for the CAD/radiologist
combination relative to the radiologist alone (0.98 versus 0.93). Furthermore, a signiﬁcant cor-
relation was found for the likelihood output of the CAD/radiologist combination and cancer
grade, with a rank correlation coeﬃcient of 0.696.
General discussion
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We focused on three areas of automated image analysis for prostate cancer MRI: feature dis-
covery, prostate segmentation, and development and evaluation of a computer-aided detection
system. In this chapter the major contributions of this thesis are covered and suggestions for
future work are given.
Feature discovery
MRI is becoming an increasingly popular modality for the detection of prostate cancer due
to its high sensitivity and speciﬁcity. However, results in literature on the performance of
prostate MRI vary, caused by diﬀerences in acquisition, reader experience, and evaluation
criteria. In the past couple of years guidelines on acquisition and reporting of prostate MRI
have been published and evaluated; they show potential for standardized reporting of prostate
MRI. e ﬁrst release of these guidelines still lacks granularity and focuses mostly on the
detection of any prostate cancer. Two important questions are not addressed: ’how do we
discriminate diﬀerent types of benign disease from prostate cancer?’ and ’how can we beer
discriminate aggressive and indolent prostate cancer in vivo?’
Several other groups have made a start in answering these questions, although most are
focused on single parameters or single types of benign disease. In chapter 4 we addressed
the ﬁrst question by combining histopathology and MRI to discover features which help dis-
criminate prostate cancer from four types of benign disease: BPH, inﬂammation, PIN and
atrophy. Multiple unique features for each of these classes were identiﬁed which had reason-
able performance in discriminating the speciﬁc confounding class from prostate cancer. Some
of these features may be explicitly incorporated into prostate MR reporting guidelines in the
near future.
In chapters 5 and 7 we tried to address the second question of assessing cancer aggressive-
ness in vivo. Chapter 5 focused on the use of a single feature, the apparent diﬀusion coeﬃ-
cient, to determine cancer aggressiveness (based on Gleason grading) in the peripheral zone.
In previous work it was discovered that the ADC correlates well with cancer grade. However,
we discovered that this correlation can be further improved by explicitly taking into account
inter-patient variation. In chapter 7 we correlated the output of the CAD systemwe developed
to cancer aggression and found a strong correlation between cancer grade and CAD-generated
likelihood.
Prospective evaluation of the features identiﬁed in chapter 4 and 5 would further help
cement them as useful contributions to the reporting guidelines. Especially how radiologists
should interpret the features and how to handle situations where there is uncertainty about
more than one class are still unknowns. Expanding the reporting guidelines to also establish
instructions for predicting cancer aggressiveness aer evaluation of multi-parametric MRI is
also an area of further research.
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Feature discovery for confounding disease and cancer aggressiveness would beneﬁt im-
mensely from improved registration of histopathology and prostate MRI. e advent of digital
pathology and the digitization of whole mount prostatectomy slides has opened the door to
more accurate evaluation of MR parameters with respect to the underlying ground truth. e
3D reconstruction of complete prostatectomies and the subsequent mapping to the MRI could
result in improved registration. Establishing artiﬁcial landmarks using strands and the use
of ex vivo prostate MRI might be a path to achieve this. Finally, further automation of the
registration process could help remove user variation and dependency.
MR spectroscopy is another method to, in vivo, determine cancer aggressiveness and has
in the past obtained good results in this respect. In this thesis we did not investigate the use
of spectroscopy, mostly because it is not acquired during the regular prostate cancer detection
protocol in our hospital. In general the use of spectroscopy is complex, both on the acquisition
side and the post-processing side, and as such its use in clinical practice is still limited. Never-
theless, it deﬁnitely has potential as a tool for cancer detection and aggressiveness assessment.
In addition to MR spectroscopy, several groups are investigating novel MRI acquisitions
and modeling approaches to discover new features. One such an example is the use of bi-
exponential diﬀusion models to assess slow and fast diﬀusion within tissue. Other groups
have investigated the use of fractional anisotropy for DWI or more complex pharmacokinetic
models for DCE MRI. Although there is deﬁnite value in more complex models and new ac-
quisition strategies, results are still preliminary. ey have not been evaluated in this thesis.
To truly assess cancer aggressiveness, the use of Gleason grading is not enough. Although
pathology is oen considered the ground truth, it is well known that the inter-observer vari-
ability between pathologists assigning Gleason grades is signiﬁcant. As such there is only one
reliable basis for establishing ground truth: ﬁnal patient outcome, either biochemical recur-
rence (rise of PSA aer treatment) or lack thereof aer 5 - 20 years.
Prostate segmentation
Chapter 2 discusses the standardization of prostate segmentation evaluation in MRI in the
form of a ’Grand Challenge’. e concept of challenges has entered medical image analysis in
2007, and has become increasingly popular since. e standardized evaluation of algorithms is
especially important in medical imaging, as most evaluation occurs on proprietary data sets,
algorithm code is not made publicly available and evaluation measures diﬀer. Furthermore,
re-implementing methods from literature is prone to errors without help from the original
author as most algorithms tend to be fairly complex, containing many parameters to optimize.
For any challenge to be successful, there are some prerequisites. First of all, the subject the
challenge addresses, e.g. prostate segmentation, needs to be relevant, both to ensure enough
participation and to generate interest. Second, the data provided in the challenge should have
140 General discussion
similar characteristics to the data encountered in an actual clinical seing to make sure the
results generalize well. ird, the evaluation measures used should be reasonable, represent a
quality which is clinically relevant, and allow separation between competing algorithms. For
the prostate MR segmentation challenge (PROMISE12) we tried to adhere to these rules.
e results obtained in the challenge show that several algorithms published in literature
already obtain excellent performance relative to humans. Although none of them are as of
yet able to automatically segment all the diﬃcult cases correctly, in general the top algorithms
will give good results. Depending on the use-case of the algorithm, performance might require
no further improvement. For example, for volume estimation or as a pre-processing step for
computer-aided diagnosis systems the methods are most likely accurate enough. For some
use-cases however, further improvement of the segmentation algorithms for prostate MRI can
be very helpful, e.g. automatically detecting extra-prostatic extension of a cancerous lesion.
As we expect algorithm performance to be further improved, the challenge is currently still
open for new submissions.
Most future work is related to optimizing details and expanding segmentation to the sub-
structures of the prostate and across diﬀerent MR parameters. Segmentation of the prostate
sub-structures, for example the prostate zones (Chapter 3), can be very useful. It is for example
well known that cancer appearance (and also the appearance and presence of diﬀerent types
of confounders) is prostate zone dependent. As such, for computer-aided detection algorithms
the knowledge about the locations of the prostate zones can be very useful. One of the most
diﬃcult issues is that the visibility of the zones diﬀerswidely frompatient to patient. Literature
on the segmentation of prostate zones (let alone other sub-structures like the neuro-vascular
bundles) is still sparse, and although a challenge on the segmentation of the prostate zones
has already taken place, algorithm performance is still far from the performance of the whole
prostate segmentation algorithms.
e segmentation of the neuro-vascular bundles and seminal vesicles are areas which are
worthwhile to investigate. Patient prognosis for a large part depends on whether the cancer
is still organ conﬁned. When we have accurate segmentations of these sub-structures we can
start to assess whether the tumor is invading these structures. is may help clinicians to
make a more accurate prognosis.
e PROMISE12-challenge focused on the segmentation of the prostate on T2-weighted
images as it contains the best anatomical detail (spatial resolution) and contrast (compared to
diﬀusion-weighted imaging and dynamic contrast enhanced imaging). However, the use of
the other MRI parameters might allow improvement of segmentation accuracy. In chapter 3
we already use both the ADC map and the axial T2-weighted image to segment the prostate
zones, however this has not yet been applied towhole prostate segmentation. erefore, multi-
parametric segmentation of the prostate is still an important topic for future research.
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Development and evaluation of a computer-aided detection system for prostate can-
cer
Chapters 6 and 7 discuss the development and evaluation of a completely automated computer-
aided detection system for prostate cancer on MRI. Although several research groups have
investigated the use of CAD systems for prostate MRI, the system presented in this paper is
only the second completely automated system incorporating both a detection and a charac-
terization stage. Furthermore, the performance of the system presented in this thesis is beer
than the performances currently presented in literature. One caveat is that the performance
measures have not been obtained on the same data set, which means there is room for a future
’Grand Challenge’.
e building blocks of the system are quite typical for CAD systems and consist of a seg-
mentation of the organ of interest, extraction of voxel features, voxel classiﬁcation, candidate
detection, candidate segmentation and ﬁnally candidate classiﬁcation. e two-stage approach
to the system allows us to in the ﬁrst stage detect all suspicious areas and in the second stage
classify these areas, resulting in diﬀerent and easier tasks for each of the stages. Chapter 6
also shows that the second stage of the system signiﬁcantly improves the performance.
Although performance of the complete system is good, it is currently not as good as the
radiologist, although at high speciﬁcity there is no signiﬁcant diﬀerence. ere are still some
components which could be improved. e algorithm we used for the segmentation of the
prostate obtained 7th place out of the 11 participating algorithms in the PROMISE12-challenge.
Although the prostate segmentations themselves are quite reasonable, this means we are not
currently using the optimal segmentation strategy, causing us to miss some cancers (around
3%). In the challenge active shape based segmentation approaches seemed to outperform atlas
approaches. erefore, replacing our atlas based strategy with a more successful active shape
based strategy would be worthwhile. However, implementing such an algorithm is not trivial,
and can be the focus of an entire PhD thesis by itself.
Standardization of MR image acquisition is diﬃcult, even within a single institution. Vari-
ability between patients, scanners, and protocols make it challenging to create CAD systems
which can quantitatively assess MRI. We already incorporate a way to standardize the T2-
weighted images in our CAD system, however, also the supposedly quantitative parameters
like the ADC diﬀer substantially across diﬀerent protocols. Furthermore, imaging artifacts,
signal-to-noise ratio and lack of resolution can be problematic issues.
Another area of improvement is spatial alignment of the diﬀerent multi-parametric MR
images. Although the diﬀerent MR images are implicitly registered because they are acquired
sequentially (and thus within the same coordinate frame) patient and bowel movement can
cause problems. In practice there were only a few cases in our database where there is sub-
stantial misregistration within the prostate itself. Co-registration of multiple distinct MR pa-
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rameters is no trivial task and algorithm evaluation diﬃcult. One approach could be to ﬁrst
register all the within-parameter images (b-values in DWI, time points in DCE and axial, sagit-
tal and coronal T2-weighted acquisitions) and subsequently perform the between-parameter
registration. For evaluation we could potentially use the performance of our CAD system as
a surrogate marker for registration success.
Incorporation of new features like bi-exponential diﬀusion models or spectroscopy might
also further improve performance. Additionally, the usefulness of texture features on T2-
weighted imaging has not yet been investigated thoroughly. More algorithmic approaches to
feature discovery like sparse coders might be useful in discovering improved texture descrip-
tors.
In chapter 7 the CAD system was prospectively evaluated on a consecutive set of patients.
We used logistic regression to create a model which combines the radiologist and the CAD
system independently. We showed the potential of the CAD system to improve the assessment
of the radiologist and found a large correlation between CAD system likelihoods and cancer
grade.
Evaluating the CAD system in this way allows us to obtain results that are closer to clinical
practice than typical observer studies, as there was no patient selection and the radiologists
reported prospectively without knowledge of the outcome. However, this evaluation has its
own drawbacks. We only use locations that were actually biopsied and as such the locations
which were given a low score by the radiologist are not assessed by the CAD system. In the
more controlled seing of an observer study we could have used patients with subsequent
prostatectomy to obtain ground truth for the entire prostate. Furthermore, observer studies
would have allowed us to assess diﬀerent usage scenarios of the CAD system (interactive,
before/aer radiologist scoring) instead of the independent combination that was used now.
CAD systems can theoretically be used as independent readers, either as a ﬁrst reader or a
second reader. As a ﬁrst reader they could be used as a triage test, e.g. by leing them operate
at very high sensitivity (e.g. 99%) and moderate speciﬁcity (e.g. 40%). is would reduce the
amount of cases that need to be read by a radiologist substantially. e ﬁrst reader strategy for
CAD systems is especially useful in a screening seing, where there are many more healthy
men than men with prostate cancer. Currently, several groups are investigating the use of
pre-biopsy MRI, i.e. MRI aer only an initial PSA test. If such data would become available it
would be of great interest to investigate our current CAD system as a ﬁrst reader.
Last, the data used in this thesis to evaluate the CAD system all originated from a single
center, although it does consist of multi-scanner, multi-protocol data. e evaluation onmulti-
center data would be a logical next step to assess the generalization performance of the CAD
system.
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Epilogue
Rising healthcare costs will be the major healthcare problem in the coming decades. As the
the average age in the Netherlands (and the world) continuous to rise, more people will put a
strain on the healthcare system. Especially for prostate cancer, for which incidence is highly
correlated to age, oﬀering suitable diagnosis and treatment to everyone will become more and
more diﬃcult. To add insult to injury the current diagnostic pathway for the diagnosis of
prostate cancer is invasive, inaccurate, and causes a signiﬁcant amount of patient morbidity.
is currently makes it infeasible to perform screening for prostate cancer, which is unfortu-
nate as early detection of aggressive prostate cancer could lead to earlier (and usually cheaper
and less radical) treatment with beer outcome for the patient.
With rising healthcare costs MRI might not seem like an ideal solution for the detection
and diagnosis of prostate cancer as it is commonly viewed as an expensive modality. How-
ever, a recent study by de Rooij et al.64 has already shown that even in their proposed seing
(including a full multi-parametric MRI and an MR-guided biopsy) cost of MRI is almost the
same as the cost of PSA and TRUS-guided biopsies. e cost per quality-of-life-year is even
lower, mostly because of the reduced number of side eﬀects when using MRI. e main reason
for not performing MRI instead of TRUS-guided biopsies is the availability of MRI and the lack
of experienced radiologists.
is thesis does not try to answer the issue of MRI availability. However, some general
comments can be made. In the Netherlands, the availability of MRI is quite high, with 10.8 MR
scanners per 1.000.000 inhabitants, resulting in approximately 180 MR scanners (Brancher-
apport Nederlandse Vereniging van Ziekenhuizen 2012). In the Dutch population around
1.000.000 men would need to be screened according to the suggestions in Schröder et al.21.
Performing, for example, a biennial screening of this group using PSA upfront and subse-
quent MRI (with a PSA threshold of 1, giving us a sensitivity aer PSA of 92% for aggressive
cancer) would result in 3 - 4 scan per day, per scanner. Using a PSA threshold of 4 (sensitivity
for aggressive cancer 40%) would result in 1 scan per day, per scanner. Although this still
seems like a lot, it might be feasible when the multi-parametric MRI protocol is modiﬁed a bit.
For screening only acquiring T2-weighted imaging and diﬀusion-weighted imaging might be
enough to achieve good sensitivity and speciﬁcity and would reduce MRI acquisition time,
cost and the dependence on contrast agent. With the current protocol acquiring a sagial and
axial T2-weighted image in addition to a diﬀusion-weighted series including 3 b-values can be
performed within 10 minutes. Additionally, new techniques like compressed sensing might
revolutionize acquisition speed of MRI in the near future.
e lack of experienced radiologists to read prostate MRI can be partly mediated by train-
ing, but still the volume and time required to read all acquired MRIs, perhaps in a double
reading seing like in mammography screening, would put a large strain on the radiological
144 General discussion
community. is is one of the main problems this thesis tries to address. e current imple-
mentation of CAD systems mostly focuses on being an aid to the radiologist, but the potential
of computerized tools is not restricted to that. eir use as independent readers may have a
larger impact in the long run. is does not mean that the radiologists will be out of a job; it
will give them more time so they can focus on the patients that actually need their expertise.
To give an example, in the screening seing as suggested in the previous paragraph (PSA >
1), around 250000 MRIs are made each year, of which 85% will be normal. ese are not the
cases the clinician wants to spend a lot of their time on. If we can design a computerized sys-
tem which can, at a very high sensitivity, get rid of a substantial percentage of normal cases
that would already result in improved eﬃciency. In the case of prostate MRI, it might make
screening using MRI much more feasible. In this thesis we could not yet evaluate the CAD
system in this way because we do not yet have MRI screening data, however this would be the
ultimate goal.
Of course there are also some ethical considerations to screening for prostate cancer: every
screening program has to ﬁnd a balance between costs and beneﬁts. e current diagnostic
pathway already has shown the potential beneﬁts (reduction of prostate cancer mortality), but
at too high a cost, mostly in terms of over-diagnosis and over-treatment. e PSA/MRI path-
waymight oﬀer similar beneﬁts, but the straightforward implementation (all MRIs reported by
clinicians) puts too big a strain on the radiological community. Although there are still many
unanswered question about how to best use computer aids in screening (both from a practical
and a legislative point of view), it does have the potential to make PSA/MRI-based screening
for prostate cancer a reality. For me the biggest gain is the fact that we can reduce cancer
mortality and simultaneously provide healthy men with a clear yes/no-answer regarding the
presence of prostate cancer, reducing anxiety and morbidity relative to the current situation.
Maybe the days of patients suﬀering through more than 45 biopsy needles will then ﬁnally be
behind us.
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De focus van deze thesis was het ontwikkelen van een computer-ondersteund detectiesys-
teem (CAD-systeem) voor het vinden van kanker in prostaat MRI. De benodigde bouwstenen
hiervoor zijn het segmenteren van relevante structuren (hoofdstuk 2 en 3), het ontdekken van
kenmerken van kanker en benigne ziektepatronen (hoofdstuk 4 en 5), het ontwikkelen van het
CAD-systeem (hoofdstuk 6) en de prospectieve evaluatie van het systeem (hoofdstuk 7).
In hoofdstuk 2 werd de organisatie van een internationale wedstrijd voor prostaatsegmen-
tatie op MRI besproken. Deze wedstrijd werd georganiseerd om een eerlijke en betekenis-
volle evaluatie van segmentatiealgoritmen mogelijk te maken. Het ontwerp van de wedstrijd
hield onder andere in dat er multi-instelling, multi-fabrikant en multi-protocol data verzameld
moest worden. Daarnaast moest er gebruik worden gemaakt van evaluatiemethodieken die
een duidelijk onderscheid tussen algoritmen lieten zien op basis van accuratesse. De wedstrijd
bestond uit een online component en een live component, die laatste werd georganiseerd tij-
dens eenworkshop op deMICCAI2012-conferentie in Nice, Frankrijk. In totaal 11 teams deden
mee in deze initiële fase, met ieder unieke algoritmen. De algoritmen bestonden onder andere
uit active-shapemodellen en multi-atlas-registratiemethodieken. De resultaten laten zien dat
de twee beste algoritmes signiﬁcant beter zijn dan alle andere algoritmes buiten de top drie.
Daarbij hadden zij ook een eﬃciënte implementatie met een segmentatietijd van 8 minuten en
3 seconden per casus. Gemiddeld gezien waren active-shapemodellen beter dan demulti-atlas-
registratiemethoden, zowel in prestaties als in rekentijd. Alhoewel de gemiddelde prestaties
goed tot uitstekend waren en het Imorphics-algoritme beter presteerde dan de onervaren be-
oordelaar hebben we ook laten zien dat combinaties van algoritmen tot verdere verbetering
zou kunnen leiden. Dit laat zien dat de optimale prestatie in prostaatsegmentatie nog niet
gehaald is.
Segmentatie van de prostaatzones is een relatief nieuw onderzoeksveld en de initiële re-
sultaten verkregen via het gebruik van een patroonherkenningsaanpak werden getoond in
hoofdstuk 3. Automatische verdeling van de prostaat in de centrale klier en de perifere zone is
een zeer bruikbaar gereedschap voor computer-ondersteunde detectie van prostaatkanker om-
dat de prevalentie en de karakteristieken van kanker in beiden zones substantieel verschillen.
De patroonherkenningsaanpak gebruikt drie typen kenmerken om de twee zones uit elkaar
te houden: anatomie, intensiteit en textuur. Deze methode werd vergeleken met een multi-
atlas-registratietechniek die gebruik maakte van 48 multi-parametrische prostaatstudies. Drie
beoordelaars werden ingezet om de inter-beoordelaarvariabiliteit af te schaen en we vergelij-
ken de resultaten met de beste resultaten uit de literatuur. We verkregen een gemiddelde Dice
coeﬃciënt van 0.89 voor de centrale klier en 0.75 voor de perifere zone, vergeleken met 0.87 en
0.76 in de literatuur. Samenvaend, de patroonherkenningsaanpak die anatomie, intensiteit
en textuur gebruikt gee goede resultaten in de zonale segmentatie van de prostaat.
Kenmerken die onderscheidend zijn voor verschillende benigne ziekten en prostaatkanker
werden beschreven in hoofdstuk 4. De aanwezigheid van benigne ziekten in de prostaat is
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verwarrend voor het diagnosticeren van prostaatkanker. De meest voorkomende typen zijn
benigne prostatische hyperplasie (BPH), atroﬁe, ontsteking en prostatische, intra-epithele ne-
oplasie (PIN). Om vast te stellen wat de beeldkenmerken zijn van deze klassen gebruiken we
fusie van MRI en histopathologie en computer-geëxtraheerde kenmerken in combinatie met
classiﬁcatie. De prostatectomie en de preoperatieve, multi-parametrische MRI van 70 patiën-
ten werden geïncludeerd in deze studie. Intensiteit, textuur en farmacokinetische kenmerken
werden geëxtraheerd voor ieder van de benigne klassen en prostaatkanker. Kenmerkselectie
werd uitgevoerd voor elke classiﬁcatietaak om te bepalen wat de vijf belangrijkste kenmer-
ken waren voor ieder van de benigne klassen. In totaal 92 PIN-, 64 atroﬁe-, 120 ontstekings-
en 73 BPH-laesies werden geannoteerd en daarbij nog 128 prostaatkankerlaesies. Voor elke
classiﬁcatietaak was het meest belangrijke kenmerk verschillend ten opzichte van de andere
taken en elke benigne klasse had verschillende unieke kenmerken. Daarbij verbeterde de op-
pervlakte onder de ’receiver-operating characteristic’ (ROC) curve signiﬁcant voor elke taak
vergeleken met een monolithische classiﬁcatie (waarbij alle benigne ziekten als een enkele
klasse beschouwd werden).
In hoofdstuk 5 tesen we of we het potentieel van de ’apparent diﬀusion coeﬃcient’ (ADC)
voor het bepalen van kankeragressiviteit kunnen verbeteren door expliciet de inter-patiënt va-
riabiliteit in de normale perifere zone mee te nemen. Intra- en inter-patiënt variatie van de
ADCwaarden in de perifere zone werden vastgesteld door middel van herhaaldemetingen van
de ADC in de normale perifere zone in een retrospectieve cohort van 10 patiënten met drie
verschillende MRI sessie op 3 Tesla. Het eﬀect van deze intra- en inter-patiënt variabiliteit op
het bepalen van kankeragressiviteit werd bepaald in een tweede cohort van 51 patiënten met
prostaatkanker die een MRI ondergingen voor de prostatectomie. Logistische regressie werd
gebruikt om te bepalen of het toevoegen van normale ADC waarde de voorspelling van kan-
keragressiviteit zou kunnen verbeteren. Het eﬀect op de diagnostische prestaties werd bepaald
door middel van ROC-analyse. De herhaalde-metingen-ANOVA liet zien dat de inter-patiënt
variatie signiﬁcant hoger is dan de metingvariatie. Analyse van de tumor-ADC-waarden liet
een oppervlakte onder de ROC curve zien van 0.91, na het toevoegen van de normale ADC-
waarden verbeterde deze signiﬁcant naar 0.96.
De ontwikkeling van het twee-stadia computer-ondersteund detectiesysteemwerd bespro-
ken in hoofdstuk 6. In het eerste stadiumworden initiële kandidaten gedetecteerd door het ge-
bruik van prostaatsegmentatie, voxelkenmerken, classiﬁcatie en lokale-maximadetectie. Het
tweede stadium bestaat uit segmentatie van de kandidaten en het verkrijgen van een kanker-
waarschijnlijkheid door middel van classiﬁcatie. Kenmerken die gebruikt werden zijn onder
andere beeldintensiteit, farmacokinetisch gedrag en symmetrie. In beiden stadia wordt een
Random-Forestclassiﬁcatie gebruikt om kankerwaarschijnlijkheden te berekenen. Het sys-
teem is geëvalueerd op een grote continue cohort van 347 patiënten met MR-geleide biopten
als de referentiestandaard. Deze set bevae 165 patiënten met prostaatkanker en 182 zon-
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der prostaatkanker. De evaluatie werd gedaan door laesie-gebasseerde ’free-response receiver
operating characteristic’ (FROC-)analyse en patiënt-gebasseerde ROC-analyse. Het systeem
werd ook vergeleken met de prospectieve klinische prestaties van de radioloog. Resultaten la-
ten zien dat bij een sensitiviteit van 0.45, 0.75 en 0.89 er 0.1, 1 en 10 foutpositieven per normale
casus zijn. Daarbij laat de patiënt-gebasseerde ROC analyse zien dat bij hoge speciﬁciteit het
systeem niet signiﬁcant verschilt van de radioloog.
In hoofdstuk 7 onderzochtenwe de onaankelijke combinatie van het systeem en de radio-
loog. Het doel is het potentieel van het systeem te ontdekkenmet betrekking tot het reduceren
van het aantal biopten en bepalen van kankeragressiviteit. We hebben hiervoorMRI-studies en
MR-geleide bioptuitkomsten van een continue set van 130 patiënten tussen 1 januari en 1 sep-
tember 2013 gebruikt. Logistische regressie werd toegepast om de radioloog en het systeem te
combineren. Daarna werd bootstrapping ingezet om de mogelijke verbetering in sensitiviteit
en speciﬁciteit te bepalen van de systeem/radioloog combinatie ten opzichte van de radioloog
alleen. Spearman’s rangcorrelatiecoëﬃciënt werd gebruikt om de correlatie tussen de CAD-
waarschijnlijkheid en kankergraad te bepalen. Van alle biopten waren er 68% positief voor
kanker en de rest negatief. Bij het detecteren van gemiddeld-tot-hoog-gradige kankers kun-
nen we een signiﬁcant betere sensitiviteit bereiken bij een score van PIRADS 4 (0.93 naar 0.98).
Daarnaast werd er een signiﬁcante correlatie gevonden voor de waarschijnlijkheidsuitkom-
sten van de systeem/radioloogcombinatie en kankergraad, met een rangcorrelatiecoëﬃciënt
van 0.696.
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